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1 Introduction 
1.1  A short history of leprosy in Northern Europe 
Leprosy is one of the oldest infectious human diseases (Donoghue 2013; Monot et al. 2005; Zias 
2002). Leprosy sufferers often displayed serious disfiguration that led to strong social reactions 
such as marginalization and isolation of the diseased individual (Roberts & Manchester 1996). As 
a consequence, the depiction and discussion of the disease has been a part of ancient cultures for 
millennia (Singh & Cole 2011; Roberts & Manchester 1996). 
Leprosy is thought to have originated in Africa before the Pleistocene era (Schuenemann et al. 
2013; Roberts & Manchester 1996; Monot et al. 2005) and to have been brought into Europe 
when the armies of Alexander the Great returned from India in 327-326 BC (Dols 1979; Roberts & 
Manchester 1996). The first convincing evidence for leprosy in Northern Europe appears in 
written sources around 600 BC (Zias 2002; Kjellström 2012; Trautman 1984). However, on most 
occasions, the detail within historical records is insufficient to confirm the presence of the disease 
(Roberts & Manchester 1996). The first osteological evidence of leprosy in Europe dates from 5th 
century England, France and Sweden (Reader 1974; Kjellström 2012; Blondiaux 2002). 
 
Figure 1: History of leprosy in Northern Europe 
Intensity of the colour reflects the prevalence of the disease. As the first evidence of a disease 
does not necessarily relate to its actual first case and as there might also have been 
unreported cases which persisted after the official eradication date, the extremities of the 
coloured bars are blurred. 
The 11th to 15th century medieval period saw the highest prevalence of the disease (Boldsen 
2005a; Boldsen 2009b). In some communities in Denmark, it is thought that virtually 100% of the 
population was infected (Boldsen 2005b; Boldsen & Mollerup 2006; Boldsen 2009b). Leprosy 
remained endemic in Europe until it almost disappeared during the 16th century (Figure 1) 
(Lietman et al. 1997; Britton & Lockwood 2004; Bates & Stead 1993). Interestingly, between the 
15th and the 16th centuries, the prevalence of leprosy decreased without the use of modern 
medication (Stone et al. 2009; Manchester 1984). At the same time in which leprosy disappeared, 
the number of tuberculosis (TB) cases skyrocketed (Aufderheide & Rodriguez-Martin 1998; Bates 
 
1
 2 
 
& Stead 1993), despite the fact that TB was present in Europe long before the Middle-Ages (Singh 
& Cole 2011; Matheson et al. 2009; Stone et al. 2009; Nuorala 2004; Hulse 1972; Hershkovitz et 
al. 2008; Palfi et al. 1999; Mays & Taylor 2003; Faerman & Jankauskas 2000). Indeed, TB kept a 
low frequency until the 16th century (Trautman 1984), but rose to cause half of all human deaths 
during the following few centuries (Gagneux 2012). 
The observed switch in disease prevalence around the 16th century is rather surprising. Indeed, 
the respective prevalence of leprosy and tuberculosis depend on the same environmental factors: 
population density and health status. Therefore, both should have kept rising during the late 
medieval period, as the proportion of people living in restrained low-income urban areas was 
steadily increasing (Hunter & Thomas 1984; Stone et al. 2009; Lenski & May 1994; Anderson & 
May 1982; Scheuer 1992). So far, the reasons behind the disappearance of leprosy from medieval 
Northern Europe are not fully understood, although several hypotheses have been proposed. 
Unfortunately, our understanding of the causes is still in a state at which none of the scenarios 
proposed seems more likely than any other. 
Until present, the majority of researchers thought that the virulence of leprosy might have 
decreased over the time as it co-evolved with humans, as has been shown for other pathogens 
(Stone et al. 2009; Heesterbeek et al. 2015; Anderson & May 1982; May & Anderson 1983; Dubos 
1980). Indeed, selection pressure would favour mildly virulent leprosy bacteria, as the infected 
host would live longer with the disease, thereby extending the possibilities of spreading the 
bacteria to new hosts. In contrast, highly virulent leprosy bacteria might kill their host before 
having the opportunity to spread (Anderson & May 1982; May & Anderson 1983; Lenski & May 
1994). However, the recent sequencing of a medieval M. leprae genome has shown striking 
genetic conservation during the last 1000 years (Schuenemann et al. 2013; Han & Silva 2014). The 
fact that there is no major genetic variation between the ancient and modern seems to point 
towards a stability in the virulence of the pathogen, thereby suggesting another cause for the 
decrease in the prevalence of leprosy in the late Middle-Ages. 
It has also been suggested that the early segregation of leprosy sufferers might have helped to 
limit the spread of the infection and participated in the decline of leprosy (Scheuer 1992; Boldsen 
2007). However, recent studies have proven this hypothesis very unlikely, since leprosy displays a 
very long incubation period during which the affected individual is almost asymptomatic (see part 
1.2.1) and is, nonetheless, highly contagious (G. A. Clark et al. 1987; Manchester 1984). Currently 
under investigation is the idea that a change in the human genome could have reduced 
susceptibility to leprosy (Fine 1982). Indeed, as with many infectious diseases, the fitness of the 
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individuals affected is reduced, a fact which eventually leads to the selection of more resistant 
individuals. In fact, some human genetic variations have been shown to be linked to leprosy 
resistance (Fine 1982; Fine 1981). It has also been suggested that the early segregation of leprosy 
sufferers might have artificially helped the genetic selection process (Scheuer 1992). 
The most supported hypothesis is based on the observation that the modern-day bacillus 
Calmette-Guérin (BCG) vaccination against tuberculosis also provides partial protection against 
leprosy (Scheuer 1992; Chaussinand 1953; Fine 1984). Indeed, the main immune response to 
infection with either tuberculosis or leprosy is cell-mediated acquired immunity (Jopling & 
McDougall 1988; Ridley & Jopling 1966; Lurie 1955) in which the parasite species is recognised, 
ingested and digested by macrophages (Scheuer 1992). It has been shown that the cell-mediated 
response is not completely specific (Aufderheide & Rodriguez-Martin 1998; Scheuer 1992; 
Chaussinand 1953) and that M. tuberculosis hosts can be immune to other infections  (Mackaness 
1968). As a consequence, the growing exposure to TB at the end of the Middle-Ages could have 
provided increased resistance to leprosy (Scheuer 1992; G. A. Clark et al. 1987; Manchester 
1984). Only very few ancient cases of co-infections have been documented, a fact which is 
surprising given that leprosy and TB were endemic in Northern Europe during the same period 
(Donoghue et al. 2005; Roberts & Manchester 1996). This suggests that individuals infected with 
TB could, indeed, have been partially immune to leprosy (Boldsen 2007; Chaussinand 1953; 
Lietman et al. 1997). In addition, TB is more contagious and virulent than leprosy (Gagneux 2012; 
Han & Silva 2014; Walther & Ewald 2004). Therefore, individuals infected with TB were more 
likely to die before infection by leprosy could develop into a chronic disease and lead to bone 
lesions (Stone et al. 2009). Finally, the late medieval period saw the rapid development of cattle 
breeding and trade in Northern Europe (Scheuer 1992; Boldsen 2009b). Cattle are hosts to M. 
bovis, a close relative of M. tuberculosis. The former has been proven to also infect humans 
(O’Reilly & Daborn 1995; Stone et al. 2009). The increased exposure to bovine TB through contact 
with cattle and the consumption of meat and dairy products from infected animals could have 
participated in the progressive immunisation of the population against leprosy (K. A. Clark et al. 
1987; Monot et al. 2005). The hypotheses listed above are not mutually exclusive; it is likely that 
several or all of them played a role in the decrease of the prevalence of leprosy in favour of TB 
around the 16th century. 
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1.2 Aetiology of leprosy 
1.2.1 The clinical symptoms of leprosy and its transmission mechanisms 
The transmission of leprosy is thought to be principally airborne as transmitted via infected 
aerosols (Rodrigues & Lockwood 2011; Bryceson & Pfaltzgraff 1990; Sharma et al. 2015; Scheuer 
1992; Jopling & McDougall 1988). The incubation time of leprosy ranges between 2-20 years 
depending on the infected person’s immune status and the extent of his or her exposure to the 
pathogen (WHO 2016; Jopling & McDougall 1988; Fine 1982). 
The facial peripheral nervous system is the first invaded by the bacteria (Jopling & McDougall 
1988; WHO 2016; Scheuer 1992) an event which lead to the "rhino-maxillary syndrome" as well 
as the depigmented skin patches which have been so vividly described (Stieglmeier et al. 2014). 
The advent of the rhino-maxillary syndrome causes the anterior nasal spine and margins to 
disappear progressively, giving the nose a typical “sunken” appearance (Andersen & Manchester 
1992; Andersen et al. 1994). In severe cases, the upper maxilla undergoes resorption and the 
front teeth are partially lost (Misch et al. 2010; Möller-Christensen 1978; Andersen et al. 1994; 
Boldsen 2009b). The infection can spread to the limbs (thereby causing permanent nerve 
damage) which is often accompanied by osteomyelitis under an overlying skin infection (Desikan 
& Job 1968). Because leprosy bacteria show a strong affinity to the Schwann cells around nerves 
(Han & Silva 2014; Stieglmeier et al. 2014; Kaplan & Cohn 1986; Scheuer 1992; Bloom & Godal 
1983; Scollard et al. 2006), infected individuals experience a decrease in the sensation of pain in 
the extremities (Stieglmeier et al. 2014) which can, in turn, lead to a loss of phalanges due to 
injury and infection. 
The spectrum of clinical symptoms related to leprosy depends greatly on how efficiently the host 
immune system restrains the pathogen (Ridley & Jopling 1966; Degang et al. 2014; Kaplan & Cohn 
1986; Bloom & Mehra 1984; Scollard et al. 2006). Therefore, not all infected individuals will 
present the same symptomatic features. Consequently, the percentage of individuals who 
developed bone lesions in medieval times is estimated at only 5% (Roberts & Manchester 1996). 
Table 1 describes the main types of leprosy according to the Ridley-Jopling scale (Ridley & Jopling 
1966; Degang et al. 2014) along with the newly-discovered diffuse lepromatous leprosy (DLL) 
(Han et al. 2009; Han et al. 2008) and their characteristics in terms of pathogen load (the number 
of bacteria living in the body) and host resistance (see Table 1). Most leprosy sufferers fall 
between LL and TL in the borderline leprosy type (BL) and demonstrate mixed characteristics. BL 
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is described as an unstable state that can develop into acute LL or chronic TT. In between those 
extremes are borderline conditions which display mixed features. These will not be detailed here, 
as they are unlikely to be properly diagnosable by osteological observation alone (see section 
1.2.5 Comparison with Mycobacterium tuberculosis). For further reading on the subject, see 
section 8 References (Stieglmeier et al. 2014; Ridley & Jopling 1966). 
The recently described DLL (Han et al. 2008; Han et al. 2009) represents an extreme form of 
leprosy. Until recently, it has only been observed in a small number of patients and has yet to be 
fully investigated. It is clinically characterised by systemic sub-cutaneous swelling as well as the 
formation of numerous large ulcerative skin lesions (Han et al. 2008). 
Table 1: Different types of leprosy with regard to the immune status of the individual 
Due to the very recent discovery of M. lepromatosis, descriptions of the symptoms are still 
incomplete (ND). 
 
 
Diffuse lepromatous 
leprosy (DLL) 
(Han et al. 2008; Han et 
al. 2009; Han et al. 2015) 
Lepromatous 
leprosy (LL) 
Tuberculoid 
leprosy (TT) 
Pathogen load 
(Britton & Lockwood 2004; Ridley & 
Jopling 1966; Jopling & McDougall 
1988) 
High High Low 
WHO Classification Multibacillary Multibacillary Paubacillary 
Causative agent 
 
 
M. lepromatosis M. leprae 
M. lepromatosis 
M. leprae 
Bone changes ND Severe Mild to none 
Skin/nerve lesions 
(Stieglmeier et al. 2014) 
Numerous Numerous 
Symmetric 
Rare 
Skeletal involvement 
(Roberts & Manchester 1996; 
Blondiaux 2002) 
 
ND Usually 
symmetrical 
Unilateral 
Cell-mediated immunity 
(McMurray 1996; Britton & 
Lockwood 2004) 
Low response Low response High response 
Humoral antibody response 
(McMurray 1996; Stieglmeier et al. 
2014; Britton & Lockwood 2004) 
High High Low 
Infectivity 
(Manchester 1984) 
ND High Low 
Immune evasion 
(Britton & Lockwood 2004; 
McMurray 1996) 
No No High 
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As living conditions and the health status of the population were poor in the Middle-Ages, the 
clinical presentation spectrum of leprosy is thought to have shifted towards the LL form 
(Andersen et al. 1994). This has been widely discussed (Boldsen 2001; Boldsen 2007; Stone et al. 
2009; Roberts & Manchester 1996; Manchester 1984), as bone lesion frequency was higher in the 
past than it is today. 
 
1.2.2 Causative agents of leprosy 
To this day, two causative agents of leprosy are known. The first one, Mycobacterium leprae (M. 
leprae), was first described at the end of the 19th century by the physician G. A. Hansen 
(Stieglmeier et al. 2014; Monot et al. 2005). More recently, a second causative bacterium, named 
Mycobacterium lepromatosis (M. lepromatosis) was discovered (Han et al. 2009). Both M. leprae 
and M. lepromatosis are human pathogens, although singular M. leprae infections have been 
described in animals such as chimpanzees (Alford et al. 1996; Valverde et al. 1998). In the 
southern United States, nine-banded armadillos have been shown to be naturally susceptible to 
M. leprae, forming the only known zoonotic reservoir for human leprosy (Sharma et al. 2015; 
Truman et al. 2011; Loughry et al. 2009). 
M. leprae and M. lepromatosis are rod-shaped bacteria with exceptionally long generation times 
(Singh & Cole 2011; Han et al. 2008). Both species belong to the Mycobacterium genus as 
described by Lehman and Neumann in 1896 (Stieglmeier et al. 2014; McMurray 1996). Therefore, 
they display many of the biological features which are specific to Mycobacterium described 
below. 
M. leprae and M. lepromatosis cells are non-motile rods 1-8µm long and 0.2-0.5µm in diameter 
that can form clusters (Stieglmeier et al. 2014; McMurray 1996; Scollard et al. 2006; Draper 1983; 
Cowdry 1978). Both species have a characteristic thick and highly hydrophobic cell wall rich in 
mycolic acids and peptidoglycans (Draper 1983; Daffe & Draper 1998; Draper et al. 1987). 
Although they are Gram positive bacteria, their cell wall prevents discoloration by acids during 
staining for observation (Scheuer 1992; Draper 1983) (Figure 2). 
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Figure 2: Morphology of M. leprae 
A. M. leprae stained via the Fite-Faraco method appears as red, rod-shaped organisms 
(magnification 800X). B. M. leprae under the scanning electron microscope, (magnification 
12,000X). C. Internal features of M. leprae are observed in this ultrathin section of the bacilli 
under a transmission electron microscope (magnification 29,000X) (Scollard et al. 2006). 
Moreover, M. leprae and M. lepromatosis are obligate intracellular pathogens. Thus, they fail to 
grow on artificial media (Han & Silva 2014; Han et al. 2009; Stieglmeier et al. 2014; Scollard et al. 
2006). Although they have recently been successfully cultivated in armadillos and the foot pads of 
mice (Singh et al. 2015; Singh & Cole 2011; Kirchheimer & Storrs 1971), the efficiency of the 
cultivation approach is strongly hindered by the extremely long doubling time required by the 
bacteria (Singh & Cole 2011; Han et al. 2008) (see Figure 2). Indeed, the division cycle of M. leprae 
lasts more than 20 days and is the longest amongst Mycobacteria (Britton & Lockwood 2004). For 
these reasons, phenotypic studies of the pathogens remain extremely rare. Consequently, the 
knowledge available today about the biology and drug-resistance of leprosy is mainly provided by 
genomic investigations performed directly on pathogen DNA isolated from human patients. 
 
1.2.3 Basic infection mechanisms 
Upon infection, M. leprae bacteria settle first in the intracellular milieu around Schwann cells and 
exhibit a particular preference for the extremities of the body due to its low optimal growth 
temperature (about 33°C) (Scollard et al. 2006; Britton & Lockwood 2004). There, it is quickly 
recognized and ingested by macrophages, its primary host cells. In tuberculoid leprosy (TT) 
infections, the macrophages digest the pathogen and present pathogen-specific antigens to T-
cells. Subsequently, numerous T-cells are recruited to limit the spread of the infection, forming 
the characteristic granulomas observed in patients with TT (Scollard et al. 2006). As a 
consequence, only a few well-defined skin lesions are present, almost no antibodies are secreted 
and the pathogen load stays low (Britton & Lockwood 2004). On the other side, during the 
development of lepromatous leprosy (LL), the bacteria are not digested by the macrophages and 
spread extensively. Subsequently, the pathogen load is high and numerous skin patches appear. 
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Leprosy is the only bacterial disease which affects peripheral nerves (Scollard et al. 2006). 
Although this unique feature is likely related to the bacterium’s capacity to bind to a protein of 
the basal lamina of Schwann cells, the molecular mechanisms leading to the invasion of the nerve 
are not fully understood (Britton & Lockwood 2004). On the M. leprae membrane, PGL-1 and a 
21kDa protein have been shown to be involved in the uptake of the bacterium by Schwann cells 
when they interact with the host cell’s laminin receptor (Britton & Lockwood 2004; Shimoji et al. 
1999; Ng et al. 2000). How those protein interactions lead to the bacterium invading the host cell 
remains unclear (Britton & Lockwood 2004; Scollard et al. 2006). Afterwards, the bacterium 
slowly replicates inside the Schwann cell. Eventually, the host cell presents mycobacterial 
antigens to specific T-cells, triggering a strong chronic immune response (Spierings et al. 2001; 
Britton & Lockwood 2004). As a consequence, the nerve is damaged at two levels: the infected 
Schwann cells are specifically killed by CD4+ T-cells and the inflammation leads to further damage 
due to swelling inside the nerves. 
 
1.2.4 Genetics and evolution of Mycobacterium leprae and lepromatosis 
M. leprae and M. lepromatosis display the smallest of the Mycobacteriagenomes (See Table 2) 
(Han et al. 2015; Han et al. 2009; Singh & Cole 2011). This is thought to relate to their strict 
obligate parasite nature (Han et al. 2015; Han et al. 2009; Singh & Cole 2011). In addition, their 
GC content is significantly reduced compared to other Mycobacteria (Han et al. 2009; Clark-
Curtiss et al. 1985; Imaeda et al. 1982; Gross & Wayne 1970; Wayne & Gross 1968). GC content in 
genomes has been shown to be dependent on the percentage of coding sequences (Pozzoli et al. 
2008), with coding sequences being higher in guanine and cytosine than non-coding regions. In 
the case of M. leprae and lepromatosis, the reduced GC content is consistent with the reduced 
gene content (Table 2). 
The M. lepromatosis genome has not yet been completely sequenced. The current M. 
lepromatosis genome drafts only differ from the M. leprae genome by 9.1%, placing it as a 
separate (yet very close) relative species (Han & Silva 2014; Han et al. 2008; Vera-Cabrera et al. 
2011; Singh et al. 2015; Jessamine et al. 2012). Over the last few years, M. lepromatosis has been 
isolated from leprosy patients in Mexico, Canada and Singapore, suggesting that it might be as 
widely spread and as ancient as M. leprae (Han & Silva 2014; Monot et al. 2009; Han et al. 2009; 
Singh et al. 2015). Genomic comparisons between the M. lepromatosis isolates and various 
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Mycobacterium genomes also support an ancient origin for the species (Han et al. 2009; Han & 
Silva 2014; Singh et al. 2015). 
Almost half of the two bacteria genomes are composed of pseudogenes, indicating a strong 
reductive evolution resulting from one massive gene inactivation event within the last 20Myr 
(Gomez-Valero et al. 2007; Singh & Cole 2011) (see Figure 2). Indeed, during the adaptation to a 
parasitic lifestyle, genes non-essential to infection and parasitism are submitted to low selection 
pressure (Cole et al. 2001; Gomez-Valero et al. 2007). As a consequence, the accumulation of 
substitutions, insertions or deletions might deactivate complete groups of genes (Cole et al. 2001; 
Monot et al. 2005; Belda et al. 2010; Gil et al. 2008; Toh et al. 2006; Delmotte et al. 2006). Those 
deactivated genes would see their GC content drop, which would be consistent with the low GC 
percentage in M. leprae and lepromatosis genomes. Non-functional DNA was eventually lost, 
reducing the size of the genome (Gomez-Valero et al. 2007; Silva et al. 2001; Mira et al. 2001). 
 
Table 2: Genomic and biological features of Mycobacterium leprae, lepromatosis and two TB-
causing relatives 
For comparison, data for the related species M. tuberculosis and M. bovis are displayed on 
the right. Because M. lepromatosis has been discovered only recently, its information is 
incomplete. 
 M. leprae M. lepromatosis M. tuberculosis M. bovis 
References (Monot et al. 
2009; Singh & 
Cole 2011) 
(Singh et al. 
2015; Han & Silva 
2014) 
(Cole et al. 
2001; Scollard 
et al. 2006) 
(Michel et al. 
2010; Wirth 
et al. 2008) 
Genome size 3.27 Mb 3.21 Mb 4.41 Mb 4.35 Mb 
G+C content 57.8 % 57.9 % 65.6 % 65.6 % 
Genes 2,770 2,777 4,008 4,001 
Pseudogenes 1,115 (41 %) 1,334 (47 %) 30 (<1 %) 33 (<1 %) 
Growth on artificial 
media 
No No Yes Yes 
Generation time >20 days >20 days 15-20 hours 16-20 hours 
Main host Human Human Human Cattle 
Pathogenicity in humans Yes Yes Yes Yes 
Phenotype severity High Extreme High Mild 
Bone lesions frequency 
(Holloway et al. 2011; 
Roberts & Manchester 
1996) 
5 %  ND 3-7 % 30-50 % 
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No M. leprae- or M. lepromatosis-specific plasmids have been described so far, although typical 
bacterial plasmids have been found in most Mycobacteria(Meyers 1995). Plasmids are commonly 
found in most bacterial pathogens, as they increase the capacity to adapt to changes in the 
environment and have been shown to often carry genes involved in pathogenicity or drug-
resistance (Wang et al. 2016). During the reductive evolution process, M. leprae and lepromatosis 
might have lost their plasmids. Han et al. (Han & Silva 2014) constructed a phylogenetic tree of 
several Mycobacterium species using the sequences of the conserved rpoB protein gene. They 
showed that M. leprae and M. lepromatosis diverged from their last common ancestor ~10Myr 
ago, around the end of the reductive evolution process (Figure 3). 
From those results (Anastasiou & Mitchell 2013; Han & Silva 2014), it can be assumed that the 
evolution of leprosy bacteria started when their last common ancestor (a parasite which targeted 
early human ancestors) underwent reductive evolution. It is thought that around the time that 
this genome reduction ended, M. leprae and M. lepromatosis became separate species by passing 
through an evolutionary bottleneck which lead to their high clonal stability. 
 
 
Figure 3: Phylogenetic tree of several Mycobacterium species 
This Maximum-Likelihood tree is based on the amino acid sequences of rpoB proteins (Han & 
Silva 2014). The numbers to the left of each node are bootstrap values for 1000 replications. 
The length of the branches is proportional to the number of substitutions. 
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Monot and colleagues (Monot et al. 2005) have compared modern M. leprae genomes and 
grouped them into four genetic types defined by three single nucleotide polymorphisms (SNPs). 
More recently, the typing of leprosy strains has been refined to 16 genotypes (defined by 84 SNPs 
and InDels) which show more than 99% identity (Monot et al. 2009; Monot et al. 2005; Singh & 
Cole 2011). The study of the modern geographical distribution of those types and subtypes 
showed that the spread of leprosy followed human dispersals (Monot et al. 2009). Currently, M. 
leprae SNP types 2 and 3 are the only ones present in Europe. The geographical repartition of the 
various leprosy types suggests that leprosy was brought to Europe in successive events from an 
east African ancestor which resembled the present-day SNP type 2. From one of the earliest 
events, leprosy ancestral SNP type 2 evolved into SNP type 2 and 3 (Singh & Cole 2011; Monot et 
al. 2009) (Figure 4). 
 
Figure 4: Geographical distribution of M. leprae SNP types 
Pillars are located on the country of origin of the M. leprae sample and are colour coded 
according to the scheme for the 16 SNP subtypes (Monot et al. 2009). The thickness of the 
pillar corresponds to the number of samples (1-5, thin; 6-29, intermediate; >30, broad). The 
grey arrows indicate human migration routes, with the estimated time of migration shown in 
years. The red dots indicate the location of the Silk Road in the first century, and * denotes 
results obtained from aDNA. 
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1.2.5 Comparison with Mycobacterium tuberculosis 
Bacteria of the Mycobacterium Tuberculosis Complex (MTBC) are close cousin species of M. 
leprae and M. lepromatosis (see Figure 3). MTBC members cause tuberculosis (TB) in various 
animals (Stone et al. 2009; Manchester 1984). The two most common causes of TB in humans are 
M. tuberculosis and M. bovis (O’Reilly & Daborn 1995; Donoghue 2009; Fine 1984). Bacteria of the 
MTBC also display most of the Mycobacterium-specific biological features, as do leprosy-causing 
bacteria. One major discrepancy between leprosy-causative agents and MTBC members lies in 
their generation time. Indeed, MTBC species’ duplication time is counted in hours, whereas M. 
leprae and M. lepromatosis need up to 20 days to duplicate (Monot et al. 2009; Scollard et al. 
2006). Moreover, TB agents display larger genomes with almost no pseudogenes (see Table 2). 
This is considered consistent with their broader host range as well as their capacity to grow on 
artificial media, since the genes necessary to their own function were likely preserved during 
evolution. Only one M. tuberculosis plasmid (pTYGi9) has been published so far (NCBI, accession 
number NC_025025.1). Genetically, M. leprae and M. tuberculosis are about 50% identical, 
despite the fact that the M. tuberculosis genome is more than 1Mb bigger (Cole et al. 2001; 
Scollard et al. 2006; Imaeda et al. 1982; Gross & Wayne 1970). In general, Mycobacteria species 
show a high degree of genetic similarity (Gross & Wayne 1970; Imaeda et al. 1982; Stone et al. 
2009) which can make them difficult to differentiate through molecular biology. 
 
1.2.6 Osteological diagnosis of leprosy in ancient remains 
The bone lesions specific to leprosy which develop during the course of the disease are often the 
only evidence which is preserved by which ancient leprosy sufferers can be osteologically 
identified (Boldsen 2007; Andersen et al. 1994; Andersen & Manchester 1992). The main parts of 
the skeleton involved in the development of leprosy are the facial bones as well as the small 
bones of the hands and feet (See Figure 5), (Boldsen 2007; Andersen & Manchester 1992; 
Andersen et al. 1994). This manifests on the anterior cranium in the rounding of the edges of the 
nasal aperture and the complete or partial disappearance of the nasal spine and vomer (Boldsen 
2007). The upper maxilla shows evidence of bone resorption which is sometimes accompanied by 
the absence of the upper front teeth (Boldsen 2007). The hands and feet often display shortened 
small bones as well as terminal phalanges which are often partially absent (Boldsen 2007). Due to 
the restriction of bone lesions (especially facial deformations) chiefly to the LL form of leprosy, it 
is especially difficult to accurately diagnose other forms of the disease. Although TT leprosy can 
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sometimes be successfully diagnosed if the limb bones are present, borderline forms are 
extremely difficult to identify. 
 
Figure 5: Diagnostic bone lesions for leprosy described in the literature 
Extensive description of the lesions can be found in the work of J. Boldsen (Boldsen 2007) as 
well as photographic examples. This figure only shows the six features used during the 
diagnosis of the samples collected for this study. 
 
An osteological diagnosis has several drawbacks. The bone features are evaluated and graded by 
eye and the observations are then used as a whole to establish a diagnosis (Boldsen 2007). Since 
the beginnings of paleopathology, experts have tried to establish standard gradation scales for 
each type of lesion according to its location and severity. Nevertheless, the reliability of the 
diagnosis is heavily dependent on the observer’s experience. Moreover, the preservation state of 
the remains highly influences the diagnosis’ quality, as any missing bone reduces the amount of 
information available. Another disadvantage originates from the aetiology of leprosy itself, since 
the percentage of affected individuals who develop bone lesions is relatively low. Although the 
development of bone lesions might have been more frequent in medieval times (Boldsen 2009a; 
Boldsen 2001), the percentage of medieval remains showing bone lesions is bound to not be an 
accurate representation of the actual number of persons who suffered from leprosy during that 
time period. Therefore, palaeopathological observations are still mainly used to identify the 
remains of leprosy sufferers and to roughly estimate the variations in leprosy prevalence over 
time rather than as a means to declare individuals free of the disease. 
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1.3 Ancient DNA studies of mycobacterial infections 
1.3.1 The limitations of studies based on modern-day leprosy 
Research on modern leprosy has yielded numerous publications about the epidemiology, 
immunology and aetiology of the disease (Scollard et al. 2006; Britton & Lockwood 2004). Those 
studies, however, are all based on either M. leprae strains that faced (and survived) modern 
medication for the last 70 years or patients who had benefitted from modern-day diagnosis 
methods and health care. Although they have helped unravel the history and the evolution of the 
disease since it first came in contact with humans (Singh et al. 2015; Singh & Cole 2011; Monot et 
al. 2005; Monot et al. 2009; Cole et al. 2001), those studies can only be partially used to 
understand the disease and its impact on human societies before the medical progress of the 
early 1900s. Indeed, differences in the development of the disease have been noticed (Boldsen 
2001; Stone et al. 2009) and suggest that host-pathogen interactions in the past were more 
complex than those described by modern-day data alone. 
 
1.3.2 Preservation of mycobacterial DNA molecules in ancient remains 
Ancient remains of living organisms can still contain the endogenous DNA (Hagelberg & Clegg 
1991; Pääbo 1989; Higuchi et al. 1984) of the deceased organism as well as that of any 
microorganism which lived in the animal at its time of death (Pääbo et al. 2004). The preservation 
of ancient DNA (aDNA) molecules in a deceased organism depends on many environmental 
factors, including temperature, humidity and oxygen levels (Poinar et al. 2008; Pääbo et al. 2004). 
Since the mid-1980s, methods for the study of DNA have been progressively adapted to the 
characteristics of aDNA (Pääbo 1989; Higuchi et al. 1984; Pääbo 1985; Pääbo et al. 2004; Shapiro 
& Hofreiter 2012). Under certain conditions, it is possible to extract and analyze endogenous DNA 
from long-dead organisms as well as the DNA of the pathogens that might have infected them 
(Cooper & Waynet 1998). When preserved, aDNA is generally present in minimal amounts (Pääbo 
et al. 2004) and is accompanied by much larger amounts of exogenous microbial DNA (Hoss et al. 
1996; Noonan 2005). Moreover, DNA molecules spontaneously degrade in the absence of repair 
mechanisms inside a living cell (Lindahl 1993). In consequence, aDNA is chemically modified 
compared to modern DNA. In fact, aDNA molecules are typically short (rarely longer than 150bp) 
and display an increased occurrence of Guanine (G) and Thymine (T) at the 3’-end and 5’-end of 
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the fragments, respectively, due to deamination of the purine bases (Lamers et al. 2009; 
Overballe-Petersen et al. 2012; Briggs et al. 2007; Brotherton et al. 2007). 
Mycobacterium species present biological characteristics that enhance the preservation of their 
DNA in ancient remains. They have a tropism for bone structure cells and display a robust lipid-
rich cell wall. The strong hydrophobic nature of this cell wall protects the Mycobacterium DNA 
from hydrolytic damage (Haas et al. 2000; Donoghue et al. 2004; Donoghue 2011; Donoghue et 
al. 2015). In addition, Mycobacterium genomes display high G+C contents, a feature that has been 
shown to increase DNA stability over time (Donoghue 2013). As a result, in aDNA extracts from 
human remains, Mycobacterium DNA fragments can sometimes be longer and less degraded than 
human DNA (Schuenemann et al. 2013; Mendum et al. 2014). 
 
1.3.3 PCR investigations of ancient leprosy cases 
The Polymerase Chain Reaction (PCR) was invented in 1984 and allows for the amplification of a 
specific DNA target fragment of known sequence. It was almost immediately adapted for the 
aDNA research field, leading to the first amplification of aDNA molecules which was reported the 
very same year (Higuchi et al. 1984; Pääbo 1985). The first analysis of ancient Mycobacterium 
DNA was performed in 1993 (Spigelman & Lemma 1993) and consisted of the PCR amplification of 
a M. tuberculosis 123bp-long fragment from the IS6110 insertion element. The first DNA 
amplification from ancient leprosy sequences was reported soon thereafter (Rafi et al. 1994). 
Sanger sequencing technology enables researchers to read the sequences produced during the 
PCR by using the PCR primers as sequencing primers. Since then, PCR has become a powerful tool 
for detecting and studying the aDNA of pathogens in archaeological samples (Matheson et al. 
2009; Donoghue et al. 2001; Maricic et al. 2010; Fletcher et al. 2003). 
Recently, PCR methods have allowed for the identification of cases of co-infection between 
leprosy and tuberculosis (Donoghue et al. 2005). In addition, PCR amplifications are commonly 
used by aDNA laboratories to genotype the isolated strains and to establish their place in the 
phylogeny of the Mycobacterium genus (Mendum et al. 2014; Taylor et al. 2013). However, the 
PCR approach is hindered by the possibility of contamination as the close similarity between 
Mycobacterium species can lead to non-specific amplifications (Stone et al. 2009). Several 
published results have been debated a posteriori due to missing negative controls or insufficient 
description of the measures taken to avoid contamination (Lindahl 1997; Hofreiter 2008; Barnes 
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& Thomas 2006; Cooper & Waynet 1998; Stone et al. 2009; Willerslev & Cooper 2005; Wilbur et 
al. 2009). Indeed, the very principle of PCR increases the risk of contamination as the molecular 
degradation of ancient DNA tends to reduce the amplification yield of authentic PCR products 
compared to non-degraded contaminating DNA fragments (Willerslev & Cooper 2005; Cooper & 
Waynet 1998; Hofreiter 2008). 
1.3.4 Next-generation sequencing studies of ancient Mycobacterium genomes 
Over the last decades, the development of Next-Generation Sequencing (NGS) has considerably 
increased the throughput of DNA sequencing while also allowing for the discovery of new ways of 
handling aDNA molecular specificities. NGS involves the ligation of all DNA molecules from an 
extract to known artificial adapters to create a DNA library (see Methods 3.2.2). That library can 
then easily be amplified and sequenced as a whole, avoiding the need to target known DNA 
sequences. Creating libraries also increases the life expectancy of DNA fragments (by protecting 
them at each end, excluding any interaction with a host genome and removing the need of clone 
cultivation) and enables the fragments to be re-amplified virtually endlessly (Kircher et al. 2012; 
Meyer & Kircher 2010). The library also preserves the misincorporated bases in the aDNA 
fragments, thereby establishing a new way to rule out modern contamination (Sawyer et al. 2012; 
Overballe-Petersen et al. 2012). Moreover, libraries can be identified using molecular barcodes to 
multiplex DNA sequencing reactions to reduce sequencing costs and to decrease the risks of 
contamination. To compensate for aDNA degradation, libraries can be prepared using an enzyme 
that replaces misincorporated Uraciles bases by Cytosines (Hofreiter et al. 2001), a great 
advantage in the field of aDNA. This “UDG treatment” greatly reduces the number of wrongly-
sequenced Thymines and, consequently, the rate of false C->T polymorphisms observed in 
comparison with the reference sequence (Hofreiter et al. 2001; Shapiro & Hofreiter 2012; Lamers 
et al. 2009). 
The basic “shotgun” approach consists of sequencing an aDNA library prepared directly from a 
whole aDNA extract. It is often used in the initial evaluation of the aDNA extract contents in terms 
of diversity and the proportions of species present. For the same reason, it is also a common 
metagenomics method for ancient samples. As the shotgun approach relies on the breadth of the 
reference genome databases available to match the DNA fragments, a large majority of the aDNA 
reads obtained cannot be attributed to any specific species and are classified as unknown (Krause 
2010; Schuenemann et al. 2013). Typically, only 1-2 % of the reads actually belong to a species of 
interest. 
16
 17 
 
Using NGS, new cases of M. tuberculosis and M. leprae infections have been confirmed (Mendum 
et al. 2014; Schuenemann et al. 2013; Müller et al. 2014; Kay et al. 2015). However, publications 
reporting the use of NGS to study ancient Mycobacteria infections are still scarce. Whole-genome 
drafts from ancient M. leprae strains were successfully assembled for the first time in 2013 
(Schuenemann et al. 2013). Interestingly, in one sample, the ancient M. leprae DNA molecules 
were so well-preserved in the sample that no enrichment was necessary to perform de-novo 
assembly. To date, there is no record of successful ancient Mycobacteria Next-Generation 
Sequencing projects performed on more than a dozen individuals; most of them report the 
recovery of only a handful of partial ancient mycobacterial genomes. 
 
1.3.5 Authenticity of the Mycobacterium genomes recovered 
Numerous Mycobacteria species are free-living organisms that can subsist in the environment 
(Han & Silva 2014; Anastasiou & Mitchell 2013; Bouwman et al. 2012; Wilbur et al. 2009). 
Therefore, in an ancient DNA extract, the mycobacterial genetic material which is found can come 
either from mycobacterial infections which took place during the life of the person under 
investigation or mycobacterial colonization of the corpse following burial. Moreover, modern 
mycobacterial contamination can occur if the ancient remains are not kept and handled correctly 
(Yang & Watt 2005; Walther & Ewald 2004; Knapp et al. 2012; Krause 2010). In consequence, the 
authenticity of the ancient genomes recovered has to be carefully established. Contamination 
with modern DNA is commonly avoided by performing all aDNA pre-PCR work in dedicated 
facilities in which contamination levels are controlled by using blanks. Contamination of the 
endogenous DNA by the environment before excavation has to be assessed after sequencing by 
searching for DNA sequences specific to the endogenous or environmental species of interest. In 
addition, all settings have to be adjusted to minimise aspecific mapping during data processing. 
The precautions taken to avoid contamination and to check for the authenticity of the results in 
each part of this study will be detailed in the corresponding methods section (see part 4.1.1). 
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1.5 Research questions and objectives 
So far, most ancient M. leprae DNA studies have been based on a few isolated cases from 
different periods and locations. The overall aim of this project is to investigate the genomic 
diversity of M. leprae from a defined geographic area and period (Germany and Denmark 
between 1000-1560 AD). The aims can be subdivided into several specific objectives: 
a. Collecting samples from human skeletal remains which date from 11th – 16th-century 
Northern Europe which demonstrate bone lesions suggestive of leprosy. In addition, samples 
with tuberculosis lesions will be included as a means of investigating possible co-infections. 
b. Screening the remains for M. leprae and M. tuberculosis DNA using PCR to identify samples 
with good M. leprae DNA preservation and to identify possible M. tuberculosis co-infection 
cases. 
c. Next-Generation Sequencing of the confirmed leprosy cases from a and b: pooled shotgun 
sequencing will be performed to identify the best samples for re-sequencing. 
d. Confirming potential M. tuberculosis co-infection cases using the Next-Generation Sequencing 
data obtained in c. 
e. Identifying M. leprae genetic variations to construct an M. leprae phylogeny. 
f. Investigating the possible effects of the variations using in-silico prediction tools. 
g. Interpreting the data obtained in the historical and biomedical context to obtain a more 
detailed picture of the history and evolution of M. leprae in Northern Europe. 
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2 Material and Methods 
2.1 Sample collection and dating 
2.1.1 Description of the cemeteries and human remains 
 
Figure 6: Geographical origin of the sample sets 
In total, 140 samples were collected from three locations. 
 
The first sample cohort was excavated in 1980/81 in St. Jørgen (Odense, Denmark) from an urban 
leprosarium cemetery that was in use between 1270 and 1560 (Boldsen 2007). Approximately 
1544 graves were discovered in this cemetery (Boldsen 2005b). The diagnosis of the disease was 
confirmed by distinct lesions on the bones of the individuals concerned (Boldsen 2007; Boldsen & 
Mollerup 2006). From this cemetery, a subset of 34 samples was randomly selected for this study 
(see Supplementary Table 1: ). 
The second sample set comes from the Rathausmarkt cemetery (Schleswig, Germany) which was 
in use from 1000 to 1250 (Boldsen 2009a). The cemetery excavation in the 90s (Lüdtke 1997; 
Boldsen et al. 2013; Grupe 1997) uncovered 223 individuals. The anthropological evaluation was 
conducted by J. Boldsen, S. Weise and colleagues (Lüdtke 1997; Grupe 1997; Boldsen 2009a) and 
identified 120 individuals with leprosy- or tuberculosis-related lesions. Of those 120 individuals, 
79 were further investigated within this study (see Supplementary Table 2). 
 
21
 22 
 
The third sample collection was taken from material recovered from Ribe (Denmark). This 
cemetery was in use between 1250 and 1400 and was excavated in 1993. Although the analysis of 
the skeletal material is not yet complete (ongoing work is being undertaken by D. Pedersen and J. 
Boldsen, ADBOU, Denmark), the first 27 individuals diagnosed with either leprosy or tuberculosis 
were sampled for inclusion within this ancient DNA study (see Supplementary Table 3). 
 
2.1.2 Radiocarbon dating 
Radiocarbon dating was performed on those samples which showed promising results in the first 
sequencing phase. Indeed, the previously-cited date estimations for the cemeteries provided by 
the archaeologists were based on their observations of the changes in the arm position of the 
deceased over time. This is not sufficiently accurate for the purposes of phylogenetic analysis. The 
chosen samples were sent to the Curt-Engelhorn Archäometrie gGmbH laboratories where the 
collagen was extracted and prepared for radiocarbon dating on a mini-radiocarbon dating system. 
 
2.2 Minimizing contamination by modern DNA 
In fulfilment of the guidelines relative to contamination control in aDNA studies (Yang & Watt 
2005; Pilli et al. 2013; Knapp et al. 2012), all surfaces and reusable utensils were extensively 
cleaned with bleach before and after work. In addition, UV lights were used to improve the 
decontamination process whenever possible. Moreover, negative controls were regularly used for 
each step involving non-indexed DNA molecules. Finally, the access of both persons and objects 
was strictly restricted in the laboratory to a one-direction route from the pre-PCR rooms to post-
PCR rooms. 
The pre-PCR facilities are located at the Universitätsklinikum Schleswig Holstein (UKSH, Kiel) 
campus and consist of three rooms used sequentially for sample preparation, DNA extraction and 
library preparation and PCR set-up. No modern DNA work or PCRs have ever been carried out in 
those rooms. In addition, this study is the first to extract and study Mycobacterium DNA in those 
rooms. Proper laboratory clothing was worn in the pre-PCR facilities, namely (and in the order of 
suit-up): a surgical mask, hairnet, sterile surgical latex gloves, hooded laboratory overall, latex 
boots and a second pair of gloves (which were changed as often as was necessary). 
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The PCR room was located in an independent building on the UKSH campus. As for the pre-PCR 
rooms, no leprosy studies (either modern or ancient) were conducted previous to this project. 
This room was used to run the screening and indexing PCRs (for which the reaction mixes had 
previously been prepared in the dedicated pre-PCR rooms) and to process the indexing PCR 
products (purification, amplification). 
The sequencing facilities are located at the Zentrum für Molekulare Biowissenschaften (ZMB) on 
the main campus of Kiel University. Two sequencing platforms dedicated to Sanger sequencing 
and next-generation sequencing respectively took care of the technical work involved in DNA 
sequencing after thorough DNA preparation according to their requirements. 
 
2.3 Selection of the remains and identification of putative leprosy cases 
2.3.1 Pre-selection according to established archaeological data 
Putative leprosy cases in each cemetery were carefully selected according to the work of expert 
palaeopathologists (Lüdtke 1997; Grupe 1997; Boldsen 2009a). For the leprosarium cemetery 
subset, samples with unspecific diagnoses were also added to the study (see Supplementary Table 
1: ). This choice was due to the fact that the prevalence of leprosy was high when the St. Jørgen 
leprosy hospital was open, in addition to the reliable diagnosis of leprosy in medieval times (Stone 
et al. 2009). Moreover, given the proximity between leprosy sufferers in the hospital, the poor 
understanding of the transmission of the disease prevalent at the time and the absence of 
modern medication or cleaning methods, it is likely that even a healthy person who spent time in 
the hospital would eventually have become infected. 
Cemeteries were chosen according to location and time period. Indeed, the study was 
geographically restricted to Northern Germany and Denmark for organisational reasons. In order 
to effectuate a thorough investigation, it was also important to gather individuals from before, 
during and after the recorded decrease in the prevalence of leprosy in the region. Moreover, 
individuals showing bone lesions suggestive of tuberculosis were also sampled from each 
cemetery in order to gather information on M. tuberculosis which, again, is considered likely to 
have played a role in the disappearance of medieval leprosy from Europe. 
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2.3.2 Sample collection 
Following the selection of the individuals to be sampled, one tooth from each skeleton was 
collected in person (in order to choose a non-broken tooth with the best preservation state 
possible). During the extraction of the teeth, the author was wearing gloves. Immediately 
thereafter, the teeth were stored in labelled individual DNA-free sample bags to prevent further 
contamination with modern human DNA. This method allowed the materials to be transported 
directly (rather than having to rely upon the post with the accordant danger that the material be 
exposed to X-rays). The documentation of the sampled teeth was conducted alongside the 
persons in charge of the various collections and was in accordance with their recommendations. 
The teeth were identified and pictures were taken whenever necessary. 
 
2.3.3 Sample cleaning and pre-processing 
All collected samples were given a unique lab ID (see Supplementary material for the lists) and 
were cleaned for 5min with 15mL of bleach before being rinsed three times with 50mL of bi-
distillated DNA-free water. Whenever possible, samples were cut before cleaning and only about 
500mg of material was prepared for extraction. After drying overnight at 37°C, the samples were 
ground for 20s at maximum speed using a ball mill homogenizer. Each sample was individually 
removed from its container and placed in a metal mill egg under a DNA-free hood. The metal eggs 
were thoroughly cleaned with soap and dried with pure ethanol between each sample. Under the 
hood, powder from each sample was recovered from its metal egg and weighed and stored in a 
2mL DNA-free LoBind Eppendorf tube. Between 90 and 120mg of material was put into a new 
clean 2mL Eppendorf tube for DNA extraction. When not immediately in use, the powder tubes 
were stored at -20°C. 
 
2.3.4 DNA isolation 
The powder was decalcified and the collagen digested as follows (see Figure 7): Each aliquot of 
tooth powder was suspended in 500μL of EDTA (pH8, 0.5M) and 10μL of Proteinase K 
(0.25mg/mL). The tubes with the suspensions were hermetically sealed with Parafilm and left in 
the dark overnight at 37°C. A thermomixer was used to regulate the temperature while also 
preventing the powder from settling down. On the following day, another 20μL of Proteinase K 
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(0.25mg/mL) was added to each tube and the suspension was incubated on the thermomixer at 
56°C for 120-150 min in the dark. Prior to DNA purification, the remaining solid particles were 
collected at the bottom of the tube by centrifugation for 3min at maximum speed. Two hundred 
microlitres (200μL) of the supernatant were then pipetted into a new clean tube for DNA 
isolation. The remaining material from the digestion step was stored at -20°C for possible re-
extraction. 
 
Figure 7: Schematic representation of the DNA extraction from ancient remains 
The specificity of aDNA extraction from bones lies in the necessity of first dissolving the bone 
and collagen matrices. 
 
The DNA purification was performed using a magnetic bead approach on an EZ1 DNA Investigator 
robot from Qiagen with a DNA Investigator Extraction Kit from the same supplier. Built-in options 
were set to “Trace” (minute amounts of DNA) with elution in a 50μL TE buffer. The extracts were 
stored at -20°C. One extraction blank (EB) for each run of the EZ1 robot was added prior to the 
digestion step, adding up to approximately one blank per five samples. 
 
2.3.5 PCR screening for human and pathogen DNA 
PCR screening was performed to identify samples containing M. leprae and M. tuberculosis DNA. 
In addition, a screening for human mitochondrial DNA (mtDNA) was conducted as a means to 
estimate the state of DNA preservation. Indeed, most human cells contain multiple copies of the 
mtDNA molecule compared to nuclear DNA. MtDNA is, thus, more likely to be present in ancient 
remains and its amplification can be a good way to discriminate samples with extremely degraded 
DNA from those samples with aDNA preservation sufficient for further analyses. Each PCR was 
repeated by a student assistant (Y. Burmeister) to ensure the reproducibility of the results. The 
PCR reactions were set up in 25μL using Immolase DNA polymerase (Bioline) according to the 
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supplier’s recommendations. The master mix was composed of 1X Bioline Immobuffer (Bioline), 
200μM 2.5mM dNTP mix (Bioline), 1.5mM 50mM MgCl2 (Bioline), 4% DMSO, 0.4μM of each 
primer and 2U Immolase DNA polymerase (Bioline). For the pathogen DNA PCRs, 5μL of template 
was used. For the mtDNA PCRs, the amount of template was reduced to 1μL. Several PCR blanks 
(PB) were added for each primer pair by replacing the template by the corresponding volume of 
the DNA-free water used in the master mix setup. 
 
Table 3: PCR oligonucleotides, specificities and expected PCR product lengths 
The oligonucleotide sequences and publication references are available in Supplementary 
Table 4. 
The PCR runs consisted of a 10min activation steps at 94°C, followed by 40 cycles of DNA 
denaturation (94°C for 30s), primer annealing (for which the temperatures are described in Table 
3) for 30s and elongation (72°C for 30s). A final elongation step at 72°C for 10min completed the 
run. The PCR products were kept at 4°C if used within the following 24 hours. Otherwise, they 
were stored at -20°C. 
The results of the PCRs were visualized at the Sanger Sequencing platform at the IKMB by 
electrophoresis using the Qiaxcel DNA electrophoresis robot together with the QX DNA Size 
Marker 25–500bp v2.0. PCR products which presented a single clear band of the expected size 
were labelled as positive (+), products with no clear band were labelled as negative (-) and 
products which presented many bands were labelled as non-specific (nsp). All PCR products 
displaying bands were sequenced by the Sanger Sequencing platform of the IKMB and the 
corresponding chromatograms were compared with the expected target sequence. Target 
sequences for each of the primer pairs can be found in Supplementary Table 5. In case the 
Target 
organism 
Target region Primer pair Annealing 
temperature 
(°C) 
Product 
length 
(bp) 
Human mtDNA 15975-16158 mt1 60 183 
16106-16256 
 
mt2 60 150 
M. leprae RLEP repetitive element LP1 - LP2 52 130 
176239-176336 
 
LP11 - LP12 52 98 
M. tuberculosis IS6110  Insertion Sequence IS3 - IS4 58 92 
IS6110  Insertion Sequence lns1 - Ins2 68 264 
IS6100 Insertion Sequence P1-P2 68 123 
IS6110  Insertion Sequence Tb-A - Tb-B 61 123 
IS6110  Insertion Sequence Tb-C - Tb-D 60 95 
IS1081 Insertion sequence F-F2 - R-R3 60 113 
IS1081 Insertion sequence IS1081-F2 - IS1081-F3 58 135 
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sequenced DNA did not match the expected sequence, a nucleotide BLAST was performed to 
identify possible contamination sources (see section 3.5.1 The mapping of PCR screening 
sequences against their genomic references). 
 
2.4 Next-Generation Sequencing 
2.4.1 A short description of the Next-Generation Sequencing workflow 
The library preparation protocol is adapted from published methods (Kircher et al. 2012; Meyer & 
Kircher 2010). Briefly, all aDNA molecules from an extract are ligated to known artificial adapters 
(IS1, IS2 and IS3 from Figure 8) to create a library. That library is then identified using a unique 
combination of two molecular barcodes and amplified with primers which target the adapters. 
For the full list of kits, reagents, instruments and suppliers, see 12.1 Supplementary material. Two 
different libraries were prepared for each sample: one treated to remove Uraciles (UDG-treated) 
and one without treatment (NT) to preserve the damage patterns. 
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Figure 8: Overview of Next-Generation Sequencing library preparation 
Although it would later be improved (Kircher et al. 2012), this diagram as well as the first 
description of the method dates from 2010 (Meyer & Kircher 2010). 
 
To check for possible contamination, a minimum of one library negative control (LNC) per run was 
included for each set of libraries prepared. Moreover, the EB from the extraction step were 
identically processed and converted into libraries (LEB). Finally, all libraries (including LNCs and 
LEBs) were first shotgun sequenced in pools before a re-sequencing of those samples which 
showed promising results. The Next-Generation Sequencing platform performed the quality 
controls of the indexed libraries after amplification and the sequencing and the demultiplexing 
according to the sample barcodes. 
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2.4.2 Illumina sequencing library preparation 
Ancient DNA extracts were converted into DNA libraries as follows: Overhanging 5’- and 3’ -ends 
were removed to allow the ligation of P5 and P7 adapters to both ends of the ancient DNA 
fragments. Then, the adapters were filled in using Bsm Polymerase. 
The blunt-end repair for non-UDG treated libraries was performed in a 50μL reaction mix 
containing 20μL of aDNA extract, 1X NEB Buffer 2, 300mM dNTPs mix, 0.8mg/mL BSA, 1mM ATP, 
20U T4 Polynucleotide Kinase and 1U T4 Polymerase. The solution was incubated for 30min at 
room temperature (RT). For UDG-treated libraries, the reaction mix contained (aside from the 
aDNA extract) 1X NEB Buffer 2, 300mM dNTPs mix, 0.1mg/mL BSA, 1mM ATP, 20U T4 
Polynucleotide Kinase and 3U USER Enzyme. A first three hour incubation step at 37°C was 
performed before adding 1U T4 Polymerase to the mix and following up with the normal 30min 
incubation at RT. MinElute purification into 18μL 1x TE Buffer was immediately conducted as 
described in the manufacturer’s procedures (See 12.2 Supplementary methods). The library 
Adapter Mix was prepared according to the published protocol (Meyer & Kircher 2010). The 
ligation of the adapters was conducted by adding 21μL of a mix containing 1X Quick Ligase Buffer 
and 2.5μM Adapter Mix to the 18μL purified blunt-ended DNA molecules. 1μL of Quick Ligase was 
added at the end to prevent the formation of adapter chimeras. The reactions were incubated for 
20min at RT and MinElute purification into 20μL 1x TE Buffer was immediately conducted, as 
described in the manufacturer’s procedures. Finally, the fill-in step was conducted in a 40μL 
reaction containing the 20μL purified ligated DNA, 1X Thermopol Buffer, 125nM dNTPs mix and 
16U Bsm Polymerase. Libraries were incubated for 20min at 37°C for the fill-in reaction to take 
place, followed by a 20min deactivation step at 80°C. The libraries were then stored at -20°C until 
the indexing PCR. 
 
2.4.3 Library indexing, amplification and quality assessment 
The indexing PCR of the libraries consisted of 5’- and 3’- tailed primers containing both a 6nt-long 
molecular barcode and general Illumina sequencing adapters (Kircher et al. 2012; Meyer & 
Kircher 2010). Specifically, 10μL of each library was added to a 40 μL mix containing 1X AccuPrime 
Reaction Mix, 0.3μM of each primer and 2U of AccuPrime Pfx Polymerase. For each library, a 
unique combination of two indexing primers was chosen and the reaction was performed four 
times to index the complete volume of library while avoiding possible PCR inhibition. The PCR 
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reaction itself consisted of a 10min activation step at 95°C, followed by nine cycles of 15s 
denaturation at 95°C, 30s annealing at 68°C and 32min extension at 68°C. The number of cycles 
was kept low to prevent the synthesis of adaptor chimeras when reaching the PCR plateau phase. 
MinElute purification of all 4 PCR products into a single 50μL 1x TE Buffer aliquot was immediately 
conducted as described in the manufacturer’s procedure (see 12.2 Supplementary methods). 
When not amplified on the same day, indexed libraries were stored at -20°C. 
Amplification of the indexed libraries took place in four parallel 50μL PCR reactions containing 5μL 
of template indexed library DNA, 1X AccuPrime Reaction Mix, 0.4μL of standard Illumina primers 
IS5 and IS6 and 20U/μL AccuPrime Pfx Polymerase. The IS5 and IS6 oligonucleotides target the 
common part of the indexing primers and, thus, are used to amplify all indexed library DNA 
fragments as a whole. MinElute purification of all four PCR products into a single 50μL 1x TE 
Buffer aliquot was immediately conducted as described in the manufacturer’s procedures. When 
not quantified on the same day, amplified indexed libraries were stored at -20°C. 
Quantification and quality control of the amplified indexed libraries, LNCs and LEBs was 
performed at the ZMB on Agilent DNA1000 bioanalyzer or Qiagen TapeStation according to the 
manufacturers’ protocol. The DNA concentration in the amplified indexed library was estimated 
and library quality was checked in two different ways. First, as aDNA fragments are usually very 
short, this results in the presence of DNA constructs which are shorter than 300bp in the indexed 
library. Any concentration of longer molecules, therefore, is likely to be a result of contamination. 
The second verification concerns the presence of adapter chimeras. Narrow peaks of 
concentration for DNA fragments below 170bp usually originate from library and/or indexing 
adapter chimeras and are not related to contamination (Kircher et al. 2012; Meyer & Kircher 
2010). Adapter chimeras are artificial DNA fragments produced during the library preparation and 
indexing when the relative proportion of adapters to insert DNA is too high in a reaction mix 
(Kircher et al. 2012; Meyer & Kircher 2010). Chimeras present little risk for the sequencing of 
blanks on a Illumina HiSeq, because the cluster generation step requires DNA fragments to be 
longer in order to properly form bridges (Kircher et al. 2012; Meyer & Kircher 2010). Amplified 
indexed libraries showing low concentrations were consequently re-amplified using the same PCR 
protocol, in order to obtain enough material for subsequent sequencing. 
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2.4.4 Pooled shotgun sequencing 
For sequencing, pools of indexed libraries were designed to contain eight samples, each identified 
with a unique pair of sequencing indices. In addition, the forward and reverse indices were 
present only once in each pool to minimize the risks of cross-talk during sequencing and the 
percentages of each base in the indices were checked to avoid over-representation of one of the 
bases and the saturation of the sequencer’s camera. The technicians in the ZMB then prepared 
the pools with equimolar amounts of the eight samples. Non-UDG treated libraries and UDG-
treated libraries were sequenced separately on different Illumina Hi-Seq 2000 sequencing lanes in 
Single Flow Cell mode with 2x100bp read length. One flow cell under those conditions can yield 
up to 2 billion single-end reads. Consequently, one lane is expected to yield up to 250 million 
paired-end reads. Therefore, each of the eight samples sequenced on a lane is expected to yield 
up to about 25 million paired-end reads.  
 
2.4.5 Re-sequencing 
After a first analysis of the pooled sequencing run datasets, some samples showed high library 
complexity rates and only partial coverage for the M. leprae genome, suggesting that the re-
sequencing of larger amounts of sequencing libraries would yield a larger number of informative 
reads mapping to the M. leprae genomes. For those samples (see section 4.4), the UDG-treated 
libraries were re-sequenced to increase the coverage and read depth on the reference genomes 
and to allow for a more reliable analysis of the recovered pathogen genome. Indeed, deeper 
sequencing decreases the proportion of artifactual sequence variants and the number and size of 
gaps in the draft genomes. The re-sequencing was run with virtually one Illumina Hi-Seq 2000 
lane per sample. In reality, to maintain the cluster generation and sequencing quality, each 
sample was sequenced four times on 1/4th of a lane. The four datasets generated were then 
pooled together after demultiplexing. 
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2.4.6 Additional datasets 
Several samples originally collected for this study were later included in other projects and 
sequenced using different strategies. Most frequently, the same libraries generated for this study 
were enriched for human DNA (by L. Möbus in the context of her Master thesis and by L. Böhme 
as part of her PhD) As enrichment approaches are rarely fully specific and selective, numerous 
sequencing reads from those enriched libraries did not match the target species but could still be 
used to study other organisms. Consequently, sequencing datasets generated for side-projects 
were merged with the ones obtained during this study to maximise the number of informative 
reads which mapped to the genomes of the pathogens of interest. 
 
2.5 Preliminary data analysis 
2.5.1 The mapping of PCR screening sequences against their genomic references 
In the M. leprae TN and the M. tuberculosis H37Rv references genomes, the sequence of each 
expected PCR product was extracted (Supplementary Table 5). All PCR products displaying bands 
were Sanger sequenced at the IKMB. DNA fragments were sequenced from both ends; forward 
and reverse reads were merged using the Geneious software and aligned to the corresponding 
target sequence. All chromatograms and alignments were manually checked to identify base 
calling or alignment errors. In case the sequenced DNA did not match the expected sequence, a 
nucleotide BLAST was performed to identify possible contamination sources (Altschul et al. 1990). 
Settings were set to “Optimize for more dissimilar sequences (discontiguous megablast)”. All 
other settings were left as default. 
 
2.5.2 Pathogen reference genomes and Next-Generation Sequencing target sequences 
One reference genome per genome was downloaded from the NCBI databank. The full list of 
reference genomes with accession numbers is available in Table 4. In those cases in which several 
reference genomes were available for a species, the most commonly used or most recent 
assemblies were chosen. In addition to M. leprae TN, M. lepromatosis FJ924, M. tuberculosis 
H37Rv and M. bovis AF2122/97, all other mycobacterial reference genomes were included in the 
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dataset, along with the more distant relative Y. pestis (C092). Indeed, Y. pestis is the human 
pathogen which caused the Black Death. It shares some limited genetic similarity with 
mycobacterial genomes and is archaeologically unlikely to have been present in the samples 
under study. It was chosen, therefore, as an outgroup to evaluate the baseline cross-species' non-
specific mapping. 
 
Table 4: List of reference sequences, strains and NCBI accession numbers 
Species Reference strain RefSeq accession number (NCBI) 
Mycobacterium abscessus ATCC 19977 NC_010397.1 
Mycobacterium africanum GM041182 NC_015758.1 
Mycobacterium avium  paratuberculosis K-10 NC_002944.2 
Mycobacterium bovis AF2122/97 NC_002945.3 
Mycobacterium canettii CIPT 140010059 NC_015848.1 
Mycobacterium leprae TN NC_002677.1 
Mycobacterium lepromatosis FJ924 NZ_LAWX01000032.1 
Mycobacterium marinum M NC_010612.1 
Mycobacterium smegmatis MC2 155 NC_008596.1 
Mycobacterium tuberculosis H37Rv NC_000962.3 
Yersinia pestis C092 NC_003143.1 
 
Due to the high levels of genetic conservation between the members of the Mycobacteria genus, 
a large number of reads could be expected to map to any Mycobacteria genome and prevent the 
accurate determination of the infective species in the samples under study. To reduce the 
percentage of non-species-specific reads mapping, “target” genomic regions characteristic of a 
species were extracted from each reference genome to facilitate the species identification step. 
To this end, the bacterial reference sequences were aligned to each other using the Progressive 
MAUVE algorithm with default settings. The genomic multiple alignment was used to evaluate the 
sequence conservation levels between the mycobacterial reference species and their distant Y. 
pestis relative. 
Finally, regions present in only one of the genomes were consequently identified and extracted 
from the alignment backbone file using AWK. Those species-specific regions were then ordered to 
identify the two longest ones for M. leprae, M. lepromatosis, M. bovis and M. tuberculosis. 
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2.5.3 Pre-processing of reads 
The demultiplexing of the reads according the adapter barcodes was performed by the NGS 
sequencing platform (M. Schilhabel). The resulting raw files were saved in the FastQ format and 
were subsequently copied through FTP to the aDNA group working directories on the 
Rechenzentrum clusters. The raw reads were processed using the EAGER (Efficient Algorithms for 
Ancient Human Genome Reconstruction (Peltzer et al. 2016)) pipeline which incorporates 
published bioinformatic softwares into a user-friendly framework optimized for aDNA analysis. 
The softwares are implemented in the form of modules that can be called and set up 
independently through a graphical user interface (GUI). The pipeline allows each module to be 
performed one after the other by automatically converting or preparing the output files from one 
step to fit input files requirements for the next step. The pipeline is described in more detail in 
12.2 Supplementary methods. To start with, all sequencing results were analysed using FastQC to 
evaluate the quality of the sequencing run and to identify possible problems during library 
preparation. Module 2 from the EAGER pipeline was used to call for the FastQC software. The 
quality controls were performed with default settings used for the evaluation of modern DNA 
sequencing runs. As a result, warnings or errors were necessarily interpreted with regards to 
aDNA molecular specificities. 
Raw sequencing reads needed to be prepared for mapping against the chosen reference 
genomes. All Illumina sequencing runs were performed as paired-end, creating two raw read files 
for each sample: a forward FastQ file and reverse FastQ file. Therefore, forward and reverse read 
files had to be merged to improve the mapping step. Moreover, since aDNA fragments are usually 
short, it is common to find adapter sequences at the end of the sequenced reads. If not removed, 
those adapter sequences might impair the rest of the analysis. The clipping of adaptors, the 
merging of the forward and reverse reads as well as a subsequent quality filtering step were 
performed by Module 3 from EAGER. 
 
2.5.4 Species identification 
For each UDG-treated library, the sequencing reads from the pooled samples were mapped 
against four mycobacterial reference genomes (M. leprae, M. lepromatosis, M. tuberculosis and 
M. bovis) as well as against the Y. pestis reference. The reads which mapped to each reference 
with low quality were then filtered out and PCR duplicates were removed. The analysis was 
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performed on the two libraries available for each sample (normal and UDG treated). For the non-
UDG treated mapping reads, the coverage statistics were calculated for the whole reference as 
well as for the reference-specific regions. Indeed, if the reads are authentic DNA fragments from 
the organism, the coverage and read depth on the whole genome and on the target region should 
be consistent or increased. If the target region shows a significantly lower coverage, this would 
suggest that a large part of the reads actually originated from another (related) organism. For 
comparison, the sequencing reads from the same datasets were mapped against the human 
mtDNA reference to provide an estimate for the recovery of human aDNA. 
2.5.5 Ancient DNA authentication using damage patterns 
Ancient DNA typically displays short fragment lengths and increased occurrence of G and T 
towards the 3’-end and 5’-end of the DNA strand, respectively (Briggs et al. 2007; Pääbo 1989; 
Overballe-Petersen et al. 2012; Brotherton et al. 2007; Lamers et al. 2009). Those characteristic 
modifications depend not only on the age of the DNA molecules but also on numerous other 
environmental factors, such as climate or burial conditions. Therefore; the study of the DNA 
fragments’ molecular characteristics (damage patterns) can differentiate between a young DNA 
sample (below 20yo) and an ancient DNA sample, although the molecular age of the sample 
cannot be used as a proxy for the estimation of the actual age of a sample (Sawyer et al. 2012; 
Overballe-Petersen et al. 2012; Seguin-Orlando et al. 2015). 
Damage patterns are computed directly from NGS data obtained from non-UDG treated 
sequencing libraries (Molak & Ho 2011; Krause 2010; Ginolhac et al. 2011; Sawyer et al. 2012). 
The length distribution of the mapping reads as well as the frequencies of misincorporated bases 
can be calculated for a specific reference sequence (Briggs et al. 2007; Ginolhac et al. 2011; 
Jonsson et al. 2013). In this study, Module 9 from the EAGER pipeline (mapDamage2.0, see 12.2 
Supplementary methods) (Ginolhac et al. 2011; Jonsson et al. 2013) was used to determine the 
damage patterns for all sequenced samples. Damage patterns were analyzed for each sample 
with every reference used for mapping. The frequencies of misincorporation over the first (3’-
end) and last (5’-end) base of the fragments for each reference were compared to published data 
to determine the authenticity of the results and the reliability of the validation method. Fragment 
length distributions were used as complementary information to estimate the preservation of the 
molecules of interest. 
35
 36 
 
 
Figure 9: Example of misincorporation patterns in ancient DNA 
A) C to T misincorporation frequency in samples from various ages. B) G to A misincorporation 
frequency in samples from various ages. HGDP cell line DNA was used as a modern control 
(Skoglund et al. 2014). MapDamage results possess a similar layout; a sample highly 
contaminated with modern sequences will show no increase in misincorporation frequency 
toward the ends of the reads. 
 
 
2.5.6 Statistical tests 
Wherever possible, basic statistical tests were performed on the results to guage the significance 
of the variations observed in the data distribution. Therefore, the null hypothesis is the identity 
between distributions. All tests described below and the graphical representations of the results 
were performed using Microsoft Excel as well as the software R (R Core Team 2008). Depending 
on the results, the proper Student/ Wilcoxon test was chosen to test for distribution variation 
significance. 
 
2.6 Mycobacterial plasmid analyses 
All the UDG-treated reads were mapped against the reference sequences of major mycobacterial 
plasmids. This was performed to see if a mycobacterial plasmid could be found associated with M. 
leprae in the medieval DNA samples. The list of reference sequences is available in Table 5. The 
coverage statistics were then compared between the genome of the modern species carrying the 
plasmid, the plasmid itself and the ancient M. leprae. The mapping of the sequencing reads to the 
reference sequences was performed using the Bowtie pipeline. 
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Table 5: Names and accession numbers of the plasmid reference sequences 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Only mycobacterial plasmids clearly documented as part of a Mycobacterium genome were 
taken into account. Several plasmids from unknown mycobacterial origin were not selected for 
this study, as it would have been virtually impossible to rule out contamination. 
 
2.7 Human DNA analyses 
All the merged sequencing reads were mapped against the human GRCh38 mitochondrial DNA 
(mtDNA) sequence (NC_012920.1), X and Y chromosomes (NC_000023.11 and NC_000024.10, 
respectively) using the EAGER pipeline as well as modules alpha (α) to delta (δ) (see 12.2 
Supplementary methods). 
Those sequencing reads mapping to the human genome were mainly used to confirm the age of 
the remains through the use of damage patterns (see section 2.5). In addition, the number of 
reads mapping to chromosomes X and Y were analysed to confirm the anthropological sexing of 
the remains. 
Species Plasmid name Accession number (NCBI) 
M. tuberculosis pTYGi9 NC_025025.1 
M. avium pMAH135 NZ_AP012556.1 
pVT2 NC_005016.1 
M. chubuense pMYCCH01 NC_018022.1 
pMYCCH02 NC_018023.1 
M. celatum pCLP NC_004963.1 
M. kansasii pMK12478 NC_022654.1 
M. smegmatis pMYCSM01 NC_019957.1 
pMYCSM02 NC_019958.1 
pMYCSM03 NC_019959.1 
M. marinum pMM23 NC_010604.1 
pMUM003 NC_019018.1 
pRAW NZ_HG917973.1 
M. yongonense pMyong1 NC_020275.1 
pMyong2 NC_020276.1 
M. gilvum pMFLV01 NC_009339.1 
pMFLV02 NC_009340.1 
pMFLV03 NC_009341.1 
pMSPYR101 NC_014811.1 
pMSPYR102 NC_014812.1 
M. lilfandi pMUM002 NC_011355.1 
M. ulcerans pMUM001 NC_005916.1 
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A female individual displays two copies of the X chromosome, while a male individual one copy of 
the X and one copy of the Y chromosome. Therefore, comparing the coverage statistics on the X 
and Y chromosomes should provide a good proxy for sex determination. The mapping statistics 
against the X and Y chromosomes were compared and the X/Y coverage ratio was used as a proxy 
for sex typing (see 12.2 Supplementary methods). The results were compared with the sex-typing 
results as completed by osteological observation (data from the collaboration partners, see 12.11 
List of samples) or forensic STR typing (data from L. Böhme as part of her PhD). 
 
2.8 Mycobacterium leprae data analysis 
2.8.1 Assembly of the ancient genomes 
All the reads available for each UDG-treated library originating from separate sequencing runs 
were pooled in order to maximise the recovery of the targeted ancient sequences. The final 
genome assemblies for the ancient Mycobacteria genomes were performed for each of the 
collected datasets by Dr. M. Nutsua. To improve the mapping results, the raw reads were mapped 
against the M. leprae TN reference genome using an in-house approach similar to EAGER with the 
caveat that BWA was replaced by Bowtie (Dr. M. Nutsua, see 12.1 Supplementary material). 
Indeed, BWA as available through EAGER only allows for a fixed number of mismatches between 
the read and the reference. Therefore, it is difficult to set a stringent mismatch cut-off for 
datasets with reads of various lengths. Bowtie allows the number of mismatches to be set as a 
percentage of the read length, which optimises the mapping of long reads while decreasing the 
risk of aspecific mapping of small reads. The mapping assemblies were generated from the read 
alignment files as described in Schuenemann et al., 2013. The Genome Analysis Toolkit (GATK) 
(McKenna et al. 2010; Van der Auwera et al. 2013) was used to call reference bases and variants 
from the mapping (module UnifiedGenotyper) according to three possibilities: 
1) Call quality ≥ 50 & read depth ≥ 5 & fraction of mapping reads with the variant ≥90%: the SNP 
was called. 
2) Call quality ≥ 50 & read depth ≥ 5 but fraction of mapping reads with the variant <90%: the 
reference base was called. 
3) Neither 1) or 2) criteria are reached: the base was called as unknown (“N”). 
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2.8.2 Single nucleotide polymorphism typing of ancient M. leprae genomes 
GATK UnifiedGenotyper was used to call all M. leprae genomic positions confidently covered 
(EMIT_ALL_CONFIDENT_SITES option) after removing the PCR duplicates from the mapped reads 
BAM file. All positions not listed in the output VCF file were subsequently considered as not 
covered (NC). Finally, a filter was applied to remove all positions with quality scores under 50. 
Therefore, the final variant list discriminates between positions with a variant, positions without 
variant (reference base) and positions which were not covered (or of insufficient quality). 
 
Figure 10: Single nucleotide polymorphism-typing for Mycobacterium leprae 
Using the first three SNPs shown on the chart, the a strain is first typed into one of the four 
SNP types (1–4) and then subtyped using the three or four markers shown at right/SNP type to 
give 16 subtypes (A–P). SNPs shown in blue are the same as those used for typing into types 1, 
2, 3 & 4 (at left). InDel: Insertion-deletion; SNP: Single nucleotide polymorphism. From (Singh 
& Cole 2011). 
 
Genomic positions involved in M. leprae genotyping were isolated from the filtered VCF files using 
a grep-based script prepared by the author for that specific purpose (Monot et al. 2005; Monot et 
al. 2009; Singh & Cole 2011). SNP types were inferred via two different approaches. First, the 
number of variants consistent with each genotype was calculated. The type with the highest 
number of consistent variants was established as the most likely SNP type (Monot et al, 2005). 
The second approach resembles an inference method (Sing et al, 2011). Only discriminating 
39
 40 
 
positions were sought after; the SNP type was established without confirming the alleles of the 
other positions (see Figure 10). 
 
2.8.3 Phylogenetic analyses  
Phylogenetic trees were built as described in previous publications (Schuenemann et al. 2013; 
Mendum et al. 2014) with the help and support of Dr. M. Nutsua. The approach utilized made use 
of regions that were covered in all the genomes used in order to identify positions where 
variations could be found and to calculate the position of each genome on a phylogenetic tree. A 
multiple genome alignment of the six high-coverage ancient M. leprae sequences recovered in 
this study was constructed. In addition, the sequences from the study by V. Schünemann and 
colleagues were added to further refine the resolution of the trees (four M. leprae reference 
genomes, seven modern strains and five ancient strains). One of those previously published 
strains originated from the St. Jørgen cemetery, a site which was also sampled as part of the 
present study. Two whole genome multiple alignment softwares were used for comparison 
purposes: the progressiveMauve algorithm (Darling et al. 2010) and the MAFFT program (Katoh & 
Standley 2013). 
From the multiple alignments, Mauve’s SNP calling function was used to generate a table of all 
alignment columns where at least one of the strains contained a SNP. The concatenation of these 
alignment columns was then used as input for MEGA5 (Tamura et al. 2011) to construct 
Maximum Parsimony, Neighbour-Joining (Saitou & Nei 1987) and Maximum Likelihood trees 
(Schuenemann et al. 2013). To obtain rooted trees for all three reconstruction methods, M. avium 
104 (NC_008595.1) was included as the out-group. Bootstrap values (Felsenstein 1985) were 
inferred from 500 replicates. The MP tree was obtained using the Close-Neighbour-Interchange 
algorithm (Nei & Kumar 2000) as described in Schuenemann et al., 2013. To assess the best 
model to be used for the evolutionary distances used for the Neighbour-Joining tree and the 
evolutionary model used for the Maximum Likelihood tree, the author and M. Nutsua used 
Mega's model test and chose the results with the highest BIC value. For both alignments (with 
and without the outgroup sequence), the Tamura 3-parameter model (Tamura 1992) and uniform 
rate proved the best model for all sites. All positions with less than 90% site coverage were 
eliminated (see Schuenemann et al. 2013 for more details about the method). The MAFFT 
alignment as well as the tree constructions were realized by Dr. M. Nutsua. 
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Regardless of the alignment software used, the inherent inconvenience of the method is that low-
coverage samples must be discarded in order to maintain a sufficient number of informative SNPs 
within the multiple alignment of the genomes. With ancient DNA, this inconvenience becomes a 
major hurdle, especially as DNA preservation is often not good enough to permit the recovery of 
genomes with high coverage. To avoid losing too much information by discarding all the low-
coverage genomes, a method was developed to allow for the placement of as many of the low-
coverage genomes into the previously-constructed phylogenetic trees as is possible. First, 
progressiveMAUVE was used to generate a multiple alignment of all the ancient genomes 
recovered in this study. Then, based on the genetic distances between the M. leprae isolates and 
the pre-determined location of the high-coverage genomes within the tree topology, the low-
coverage genomes were assigned to the branch of the two closest high-coverage genomes. The 
assignment was considered significant when identical between the two high-coverage anchors 
used. After assigning a low-coverage genome to a branch, all ancient and modern strains 
belonging to that branch were re-aligned in order to produce a branch-specific list of variants. 
Finally, this list was used as described above to construct branch-specific trees and to place the 
low-coverage genomes. 
 
2.8.4 Evaluation of the effects of the variations observed 
All SNPs occurring in at least one strain as identified with GATK (see section 2.8.3 Phylogenetic 
analyses) were analysed with respect to their effect on annotated genes. The SNPS were 
annotated using the software snpEff (Schuenemann et al. 2013; Cingolani et al. 2012). An 
annotation database of the M. leprae TN genome was constructed from the NCBI genomic 
reference. The up/ downstream region size parameter for reporting SNPs that are located 
upstream or downstream of protein-coding genes was set to 100 nts. Default parameters were 
used for all other settings. The results were compiled into a table containing information for each 
SNP regarding its effect on the genes in the strains in which the SNP occurs. The SNP distribution 
was plotted to evaluate the density of SNPs along the genome and to identify possible variations 
hotspots or conserved regions. Moreover, the types, effects and annotations of the SNPs were 
analysed in correlation with each other to highlight possible in-depth SNP analysis approaches. 
Due to the impossibility of growing M. leprae as a culture, in vivo phenotypic studies confirming 
the in silico annotations are rare. Therefore, most of the predicted gene functions are based on 
comparisons with M. tuberculosis and numerous genes remain annotated as hypothetical 
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proteins whose functions are unknown. Variants for which there is enough information available 
to perform in silico evaluation of the variant effects were selected by filtering out the effects with 
the following annotations: 
 Intergenic, Upstream, Downstream: The understanding of M. leprae intergenic regions is 
insufficient at present to estimate the effects of the intergenic variants on the expression of 
other genes. 
 Hypothetical protein & pseudogene: The information available, if any, does not provide 
sufficient background knowledge of the transcripts. 
 Stable RNAs: The variants in annotated stable RNAs were removed so that the study could 
focus on protein variants. 
 Variants present on only one genome: This filtering step was performed to focus the study 
on common variants. 
 
2.8.5 Case-study: detailed polymorphism effect estimation 
Three genes were selected for in-depth analysis of the possible effects of the observed variants 
on their function. The selection was performed as follows. First, the functional profile of each 
gene was completed with GO annotations, the evolutionary rate amongst Mycobacteria and the 
number of InterPro domains. Then, genes with synonymous variants or unknown GO cellular 
components were filtered out. Finally, the variants were sorted according to protein length, 
number of InterPro Domains and evolutionary rates in order to select the longest protein gene, 
the gene with the highest number of InterPro domains and the best conserved gene, respectively. 
Several aspects of the protein properties and functions were studied and the possible effects of 
their variants analysed by comparison with the reference sequence. For the purpose of this 
comparison, the protein with the amino acid reference was called the reference type (RT). First, 
the proteins’ general chemical properties (pI, mW, aliphatic index, average hydrophobicty) were 
calculated using several online tools available through the SIB bioinformatics resource portal 
ExPasy (see list in 12.2.4 Bioinformatic pipeline descriptions). Then, the ProtScale tool of the same 
platform was used to compute the polarity, hydrophobicity and buried residue profiles of each 
protein, RT and variants to investigate the local impact of the amino acid change. In addition, the 
secondary structure of the protein was predicted using three different prediction tools (see list in 
12.2 Supplementary methods) with and without amino acid change to evaluate the influence of 
the variant on the formation of helices and sheets. Finally, the amino acid change loci were 
identified within the protein-annotated regions using the UniprotKB and NCBI protein database to 
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investigate the active regions that might be influenced by the variants. Using the UniprotKB built-
in Clustal Omega protein alignment server, the reference protein sequence was aligned to all the 
other available proteins with 100% similarity from UniRef (Bateman et al. 2015; Suzek et al. 2015; 
Sievers et al. 2011). In cases when the 100% cluster only contained the reference sequence, the 
similarity threshold was decreased to 90% (dnA and glcB). Then the protein sequence with 
variants was added to the alignment in order to investigate the influence of the variant on 
conserved patterns. 
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3 Results 
3.1 PCR screening for human and pathogen DNA 
All extraction and PCR negative controls gave no PCR products for the primer pairs used. Most 
cemeteries showed quite good human mtDNA preservation, with at least 30% of the samples 
yielding the expected PCR products. In comparison, no sample yielded positive results for M. 
tuberculosis DNA, a result which will be discussed in more detail below. The number of samples 
which showed positive results for M. leprae DNA was null for all but a single cemetery (St. Jørgen, 
Denmark). The preservation level for M. leprae at St. Jørgen cemetery was as high as for human 
mtDNA; almost all samples which were positive for mtDNA also yielded M. leprae DNA (see 12.3 
Supplementary results for further detail). 
Table 6: PCR screening results summarized by cemetery 
A sample is considered positive when the PCR products of the expected length and sequence 
were obtained with at least two different primer pairs. Detailed results per sample and primer 
pairs as well as the sequences obtained with each PCR are available in Supplementary Table 5. 
 
The alignments of the sequenced M. leprae and human mtDNA PCR products to the target 
reference sequences showed results consistent with the electrophoresis observations (see Figure 
11). For M. tuberculosis, several aspecific amplifications yielded multiple products of highly 
various lengths (see Figure 12). A total of seven different primer pairs were tested, each with two 
annealing temperatures. The same phenomenon was observed with all different primer pairs and 
with no consistent correlation to the sample, PCR setup or reagent batch used. Sequencing and 
BLAST search of the sequences showed hits in numerous bacterial species, consequently 
preventing the identification of common contamination sources. Although no sample could be 
clearly identified as tuberculosis positive, three samples showed consistent PCR products in two 
of the PCRs tested. 
Site 
Number of 
samples 
PCR screening results 
Number of leprosy 
positives 
Number of 
tuberculosis 
positives 
Number of 
human mtDNA 
positives 
St. Jørgen 34 16 0? 32 
Dagmargården 27 0 0? 20 
Rathausmarkt 79 0 0 25 
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Figure 11: Example of leprosy PCR result 
A) Gel electrophoresis of the PCR products: the length is consistent with the expected product. 
B) BLAST results when using the product sequence as query to search the complete genomes 
database: the first hit is M. leprae. C) Pairwise alignment of the PCR product sequence and the 
reference genome target. 
 
 
Figure 12: Example of tuberculosis PCR result 
Gel electrophoresis of the PCR products. For ease of visibility, pictures were cut and blanks 
displayed on a lower line. Many aspecific products are observed, while no band shows a size 
consistent with the expected product. 
 
 
Target 1 
Reference TGTCGGCGTGGTCAATGTGGCCGCACCTGAACAGGCACGTCCCCGTGCACGGTATAACTATTCGCACCTGATGTTATCCCTTGCACCAT 
KH130050 TGTCGGCGTGGTCAATGTGGCCGCACCTGAACAGGCACGTCCCCGTGCACGGTATAACTATTCGCACCTGATGTTATCCCTTGCACCA 
Target 2 
Reference TAGAACAAATAGGGTGGTTCTGCTTCTATTGCACCGACCAACAGTAGGAATGGTCTGA 
KH130050 TAGAACAAATAGGGTGGKTCTGCTTCTATTGCACCGACCAACAGTAGGAATGGTCTGA 
A B
C
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3.2 Illumina sequencing library concentration and quality 
All the indexed libraries were quantified on the Agilent bioanalyzer or the Qiagen TapeStation at 
the ZMB to evaluate not only the DNA quantity but also the general library quality before Illumina 
sequencing. Library blanks and extraction blanks were also quantified and showed no evidence of 
contamination. In addition, the concentration plots were checked for length distribution and the 
peaks which would indicate the presence of adapter chimeras. These results are summarized in 
Supplementary Table 7. The figures below are examples of the quantification plots for a sample 
and a blank. The peak in concentration for the sample is clearly below 300bp-fragments. The 
sample shows only few adapter chimeras (the peak is around 100bp). The blank shows no DNA 
apart from the lower and upper ladder bands and some adapter chimeras. 
 
 
Figure 13: Example of quantification plots for a sample and a blank 
UP: Sample SJG978 UDG-treated library. DOWN: UDG-treated library from extraction blank. 
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3.3 Preliminary analyses findings 
3.3.1 Comparison of the reference genomes 
The results of the Mauve multiple alignments of the Mycobacteria genomes were used to 
produce the genetic conservation distance matrix shown in Table 7. 
Table 7: Genome conservation distance matrix between the Mycobacterium genomes 
This matrix was obtained after multiple alignment of the genomes using Mauve. The colour 
formatting indicates the percentage of genomic conservation: from yellow (lowest) to green 
(highest). 
 
The similarity between the Mycobacteria genomes under study is high, especially between M. 
leprae and M. lepromatosis and between the members of the Mycobacterium tuberculosis 
complex. M. leprae showed at least 38% genetic similarity with all the other species as well as 
16% with the completely unrelated Y. pestis bacterium. While this result does not take genome 
sizes into account nor represent the actual relatedness of the species, it highlights the need to 
identify species-specific genomic regions that can be used to rule out artifactual M. leprae 
identification due to the presence of other Mycobacteria species. 
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Genome 
sizes 
(Mb) 
M. lepromatosis  0.70 0.43 0.43 0.43 0.43 0.42 0.39 0.43 0.40 3.22 
M. leprae   0.44 0.44 0.44 0.44 0.43 0.38 0.44 0.41 3.27 
M. bovis    0.99 0.98 0.96 0.70 0.57 0.68 0.65 4.35 
M. africanum     0.99 0.96 0.70 0.57 0.68 0.65 4.39 
M. tuberculosis      0.96 0.70 0.57 0.68 0.65 4.41 
M. canettii       0.69 0.57 0.67 0.64 4.48 
M. avium        0.62 0.72 0.74 4.83 
M. abscessus         0.60 0.64 5.07 
M. marinum          0.69 6.64 
M. smegmatis           6.99 
Y. pestis 0.16 0.16 0.17 0.17 0.17 0.17 0.16 0.09 0.20 0.18 4.65 
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Supplementary Figure 2-5 show the synteny in parts of the genomes for which species-specific 
regions (targets) were found using the multiple alignment file. No contradiction between the 
alignment backbone and the display was observed, apart from the M. lepromatosis genomic 
targets. Indeed, because this genome is still formed of non-ordered contigs, the target positions 
had to be first recalculated as positions per contig. 
Table 8: Chosen genomic regions used as specific target for each species 
 
3.3.2 Quality control of the sequencing data with FastQC 
An extensive list of the FastQC results is provided in Supplementary Table 8. The most commonly 
observed failure report originated from the K-mer content control. Specifically, K-mer enrichment 
plots show several sharp peaks at the beginning of the sequences, suggesting the presence of a 
small amount of short and over-amplified DNA fragments. The second most common failure 
report was issued by the adapter content control, which indicated that part of the Illumina 
adapters were sequenced due to the fact that a large part of the sequencing reads were shorter 
than the maximal read length. 
Most of the sequencing runs also triggered warnings during the control for GC percentage per 
sequence. The distribution of the average GC% amongst all sequences showed deviations from a 
normal distribution mainly on the left flank (the presence of a low, broad peak around 35-40bp) 
and at the ~60% maxima (the number of reads with ~60% GC is higher than the expected mono-
modal distribution). The warning concerning the per-base sequence content was often reported 
as well. The G and C frequencies are in disequilibrium compared to the A and T frequencies (~30% 
and ~20%, respectively). Interestingly, UDG-treated libraries and non-UDG-treated libraries 
trigger the warning in a similar manner. Almost half of the runs triggered warnings for the per tile 
sequence quality. This warning is issued when a tile on the flowcell sequences a given read 
position whose quality is significantly lower than average. All the heatmaps provided by FastQC 
 Genomic target 1 Genomic target 2 
 Start End Length (bp) Start End Length (bp) 
M. lepromatosis 3: 1 3:4950 4949 39:10452 39:14651 4199 
M. leprae 1306215 1313716 7501 202661 209677 7016 
M. bovis 1766079 1773879 7800 1764633 1765779 1146 
M. tuberculosis 2969989 2980970 10981 1779267 1787933 8666 
Y. pestis 1277307 1976310 699003 4371904 4611816 239912 
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showed variations limited to only a couple of cycles or a few number of basepairs in the reads. 
This variation was observed regularly for the last cycles at the end of a sequencing run. In 
addition, FastQC files originating from one sequencing lane displayed similar heatmaps patterns. 
Some samples triggered the warning for the sequence quality per base and the corresponding 
quality whisker boxplots systematically showed a decreased quality very early in the read 
(decrease happening around 25-35bp). A few samples issued warnings for over-represented 
sequences. All of those samples showed an over-representation of sequences that could be 
attributed to the primers used during the indexing or amplification PCRs. Finally, one sample 
triggered the sequence duplication levels warning, indicating low levels of sequence diversity in 
the corresponding library (KH130040 UDG-treated). 
 
3.3.3 Ancient DNA authentication 
During a study, the first indication of contamination danger often comes when the blanks show 
traces of DNA. In this project, there were several blanks used at various steps in the analyses. The 
first blank used was to control against possible contamination during the extraction process. It 
was carried along into the later assays and did not show signs of contamination. When used 
during the PCR screening the extraction blanks were clean, as were the proper PCR blanks (see 
section 3.1 PCR screening for human and pathogen DNA). When converted to sequencing libraries 
and sequenced, the extraction blanks stayed clear of contamination, as did the library blanks (see 
section 3.2 Illumina sequencing library concentration and quality). All told, these results indicate 
that the sequences were not contaminated with modern DNA during the laboratory procedures 
and that the DNA recovered did, in fact, come from the ancient remains. 
However, the use of blanks is not sufficient to authenticate DNA sequences as ancient, as remains 
could have been contaminated prior to their collection for a project. One characteristic of ancient 
DNA is the accumulation of deaminated bases at the end of the DNA fragments (see section 
1.4.2). The frequency of the deamination of Cytosines and Guanines at the ends of the sequenced 
fragments can be calculated from the non-UDG treated datasets and used to rule out 
contamination with modern DNA. This analysis was performed for the human mitochondrial DNA 
as well as for the M. leprae DNA using the mapDamage2.0 software (Jonsson et al. 2013; Ginolhac 
et al. 2011) as implemented in EAGER (Peltzer et al. 2016). An example of the mapDamage output 
is provided in Figure 14. 
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Figure 14: Example of mapDamage output 
Sample SJG 507, UP: Misincorporation frequencies on the 5’-end (left) and 3’-end (right), 
DOWN: Read length distribution 
The Figure 15 gathers the 1st base deamination frequency at the 5’ and 3’ end of the DNA 
fragments for each sample. The 5’-end C to T and 3’-end G to A misincorporation frequencies 
calculated were significantly higher for the reads which mapped to human mtDNA than for the 
reads which mapped to the M. leprae reference genome, suggesting that ancient M. leprae DNA 
is better preserved than its human DNA counterpart. In addition, the human mtDNA reads 
showed a lower 5’-end C to T misincorporation frequency for almost all the samples. This 
discrepancy between the two ends of the sequenced reads was not observed for the M. leprae 
reads. For both M. leprae and human reads, the increased misincorporation frequencies at the 
end of the DNA fragments was sufficient to rule out being in the presence of modern human or 
mycobacterial DNA. Nevertheless, in the case of M. leprae reads, a thorough study of the 
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literature was necessary to explain the lower degradation of the DNA and to authenticate the 
results (see discussion below). 
Figure 15: 1
st
 base deamination frequency at the 5’ (C to T) and 3’ (G to A) ends 
 
Frequencies for SJG 404 are not reported because the number of non-UDG reads which 
mapped to each species was too low for mapDamage to perform reliably. 
 
The fragment length distribution for the reads mapping to the human mtDNA reference revealed 
that more than 99% of the reads were shorter than 120bp (see Figure 16). In comparison, more 
than 99% of the reads were shorter than 90bp for the reads mapping to the M. leprae reference 
(see Figure 17). This would seem to indicate that, this time, the ancient human mtDNA was better 
preserved than its M. leprae counterpart. Both maximal read lengths stayed in the range of what 
could be expected of ancient DNA fragments, suggesting, once again, that contamination did not 
bias the sequencing results. The apparent inconsistency between the less damaged patterns but 
shorter reads in M. leprae probably only reflects the duality of DNA molecular degradation 
processes, as is discussed below. 
 
mtDNA 5‘ 
mtDNA 3‘ 
M. leprae 5‘ 
M. leprae 3‘ 
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Figure 16: Fragment length distribution for the ancient human mtDNA reads 
The length distribution for SJG 404 was not reported because the number of non-UDG reads 
which mapped to each species was too low for mapDamage to perform reliably. 
 
 
 
Figure 17: Fragment length distribution for the M. leprae aDNA reads 
The length distribution for SJG 404 was not reported because the number of non-UDG reads 
which mapped to each species was too low for mapDamage to perform reliably. 
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3.3.4 Species identification 
Species identification was performed on the datasets with eight samples per sequencing lane. The 
reads were first mapped against the human mtDNA. The results of this mapping step for the UDG-
treated libraries are displayed in Table 9. The results for the non-UDG treated libraries are 
available in Supplementary Table 11. 
 
Table 9: Human mtDNA reference coverage and read depth 
 
Overall, the human mtDNA was well-preserved in all samples sequenced, with the percentage of 
the mtDNA reference genome covered ranging from 69.99% to 99.99%. The UDG-treated reads 
were then mapped against five pathogen reference genomes to identify the pathogens that were 
likely to be present in the remains (see Table 10). The same procedure was applied to the non-
UDG-treated sequencing reads, the results of which are displayed in 12.3 Supplementary results. 
The M. leprae reference genome showed the percentage of mapping reads with the highest 
coverage (with up to 99.99% of the reference covered). All three other Mycobacteria species also 
showed up to 55%, 5.80% and 5.74% for M. lepromatosis, M. bovis and M. tuberculosis, 
respectively. The coverage percentages for the distant cousin Y. pestis were significantly lower (no 
more than 0.57% of the reference genome was covered). 
 
Sample 
Number of raw 
reads (millions) 
Reads mapping 
(%) 
Reference 1X 
covered 
(%) 
Reference 4X 
covered 
(%) 
SJG 022 7.1 0.02 98.42 73.09 
SJG 131 17.6 0.01 99.56 82.27 
SJG 149 8.0 0.01 97.46 71.52 
SJG 189 6.4 0.03 69.99 71.52 
SJG 289 17.1 0.01 99.79 92.32 
SJG 404 21.6 0.01 99.23 80.99 
SJG 427 28.9 0.01 99.92 99.19 
SJG 472 9.7 0.02 99.44 92.14 
SJG 507 19.6 0.01 99.96 99.95 
SJG 533 28.4 0.03 99.97 99.94 
SJG 611 27.2 0.01 99.78 95.18 
SJG 658 38.8 0.01 99.79 92.32 
SJG 722 25.0 0.02 99.91 99.79 
SJG 749 22.8 0.04 99.99 99.91 
SJG 978 22.3 0.01 99.57 88.30 
SJG 1137 9.6 0.01 98.32 66.32 
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As expected, there seems to be a certain proportion of reads which mapped aspecifically, as the 
samples showing the best M. leprae coverage were also the ones with highest coverage for all the 
other species (including Y. pestis). The coverage statistics calculated for the two species-specific 
target regions for each species are displayed in Table 11. The coverage on the M. bovis-specific 
targets was always lower compared to the whole genome, which agrees with the very low 
coverage observed for this species in Table 10 and suggests that the bacterium was not present in 
our samples. 
The coverage on the M. leprae-specific target was either consistent or higher compared to the 
whole reference genome. The slight decrease observed in some samples might be caused by 
variations in the read repartition along the reference (some regions being spontaneously better 
covered than others) and does not seem to have been caused by the presence of reads from 
another related species. The issue will be discussed further below. The coverage statistics for M. 
lepromatosis have to be considered with caution as the reference genome is not yet complete 
and only consists of several non-ordered contigs. However, there is a clear trend towards a lower 
coverage on the target regions, suggesting that the reads seen in the whole-genome mapping are 
likely cross-species mapping from M. leprae reads. 
Interestingly, although none of the sequenced samples were positive for M. tuberculosis DNA 
during the PCR screening phase of this project, five samples display significantly higher coverage 
on the target regions compared to the whole M. tuberculosis genome (Table 11). The coverage 
statistics for the distant relative of Y. pestis are shown in Supplementary Table 12. Some samples 
also showed slightly better coverage on the regions possessed by Y. pestis and not the 
mycobacterial species. Since the coverage stayed extremely low, it is likely that those reads are 
cross-mapping reads from closely related species. Indeed, the target regions were only designed 
to discriminate between reads which mapped to both mycobacterial genomes and the Y. pestis 
reference and could not rule out the presence of DNA fragments with a shared similarity with Y. 
pestis but not Mycobacteria. 
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3.3.5 Radiocarbon dating 
Table 12: Radiocarbon and calibrated age of the dated samples 
 
3.3.6 Mycobacterial plasmid results 
Of the 22 plasmid reference sequences tested, 17 yielded virtually no mapping reads (data not 
shown). The five plasmids with mapping sequencing reads (pTYGi9, pMYCCH01, pMYCSM01, 
pMYCSM03 and pMSPYR101) all showed a coverage and read depth which was too low for their 
presence to be clearly assessed in order to rule out unspecific mapping (data not shown). 
 
 
 
 
 
 
 
 
 
Sample 
MAMS lab 
ID 14C age (±24) 
Calibrated age 
(INTCAL13 & SwissCal1.0) Collagen content (%) 
SJG 404 26162 780 cal AD 1226-1268 4.1 
SJG 427 26163 835 cal AD 1177-1250 3.6 
SJG 472 26164 756 cal AD 1252-1280 3.6 
SJG 507 26165 856 cal AD 1170-1214 1.8 
SJG 533 26166 892 cal AD 1051-1206 3.8 
SJG 722 26167 722 cal AD 1269-1285 2.1 
SJG 749 26168 763 cal AD 1230-1277 2.0 
SJG 978 26169 672 cal AD 1283-1381 6.5 
SJG 1137 26170 675 cal AD 1282-1380 6.5 
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3.3.7 Re-sequencing 
Eight (8) samples were chosen for re-sequencing (SJG 404, SJG 427, SJG 472, SJG 507, SJG 658, 
SJG 722, SJG 978 and SJG 1137). The reads from the re-sequencing runs were analysed using the 
BOWTIE pipeline described above. The results are shown in Table 13. The eight (8) samples 
showed minimum 4X per base coverage on at least 32% of the M. leprae reference genomes. 
Although all the re-sequenced DNA samples also yielded virtually complete human mtDNA 
sequences, several samples with high mtDNA recovery yielded only fractions of the M. leprae 
genome. 
 
Table 13: Human mtDNA and M. leprae DNA reference coverage and read depth for the UDG-
treated libraries 
 
 
 
 
 
 
Samples 
human mtDNA M. leprae 
Read length 
(bp) 
Reference covered Read length 
(bp) 
Reference covered 
1X 4X 1X 4X 
SJG 404 74 (57-100) 1.0000 0.9996 88 (61-102) 1.0000 0.9979 
SJG 427 85 (63-105) 1.0000 0.9998 101 (80-115) 1.0000 1.0000 
SJG 472 74 (58-97) 1.0000 0.9996 75 (55-101) 0.9966 0.9060 
SJG 507 82 (60-103) 1.0000 1.0000 95 (66-106) 1.0000 1.0000 
SJG 658 77 (58-102) 1.0000 1.0000 68 (48-98) 0.5462 0.1894 
SJG 722 74 (55-100) 1.0000 0.9999 84 (58-121) 1.0000 0.9999 
SJG 978 85 (65-104) 0.9998 0.9976 92 (65-101) 0.9867 0.8081 
SJG 1137 81 (62-105) 1.0000 0.9999 77 (53-109) 0.8732 0.3175 
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3.4 Human DNA results 
3.4.1 Combined datasets mapping statistics  
The pooled reads from the first sequencing runs, the re-sequencing runs and the additional 
datasets were analyzed using the previously-mentioned BOWTIE pipeline. The results are shown 
in Table 14. All the high-coverage samples also yielded virtually complete human mtDNA 
sequences, however several samples with high mtDNA recovery yielded only fractions of the M. 
leprae genome. This will be discussed in greater detail below. 
Table 14: Coverage and read depth statistics for the human mitochondrial DNA 
 
 
 
 
 
Samples 
human mtDNA 
# Reads mapping 
Read length 
(bp) 
Reference covered 
1X 4X 
SJG 022 3228 83 (64-109) 0.9998 0.9858 
SJG 131 2157 83 (63-105) 0.9976 0.9708 
SJG 149 5397 76 (60-98) 0.9992 0.9937 
SJG 189 13671 77 (60-99) 0.9996 0.9972 
SJG 289 3186 86 (65-110) 0.9990 0.9935 
SJG 404 11497 74 (57-100) 1.0000 0.9996 
SJG 427 22126 85 (63-105) 1.0000 0.9998 
SJG 472 29163 74 (58-97) 1.0000 0.9996 
SJG 507 98655 82 (60-103) 1.0000 1.0000 
SJG 533 19914 84 (64-110) 1.0000 0.9997 
SJG 611 1938 67 (53-88) 0.9966 0.8982 
SJG 658 42832 77 (58-102) 1.0000 1.0000 
SJG 722 3449 74 (55-100) 1.0000 0.9999 
SJG 749 15347 81 (59-107) 1.0000 0.9996 
SJG 978 13755 85 (65-104) 0.9998 0.9976 
SJG 1137 13331 81 (62-105) 1.0000 0.9999 
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3.4.2 Sex typing based on X and Y chromosome coverage 
Table 15 shows the results obtained by the X and Y mapping statistics sex typing proxy. Some 
samples only showed low coverage on the X and Y chromosomes. As the Y/X ratio is highly 
coverage-dependent, those samples were not typed and are listed below as undetermined. Two 
samples showed a Y to X ratio inconsistent with their osteologically-determined sex. This will be 
discussed further below. 
Table 15: Results of the human sex typing 
 
 
 
 
 
 
 
 
 
 
 
Those individuals described as “Und.” had inconclusive results due to low coverage on the 
sexual chromosomes. Inconsistencies with the osteological sexing provided by the 
archaeologist collaborators are highlighted in red. 
 
3.5 Mycobacterial plasmid results 
The pooled reads from the first sequencing runs, the re-sequencing runs and the additional 
datasets were analysed using the BOWTIE pipeline as has already been described. The mapping 
was repeated following the same methodolgy as had been completed in the first run against the 
reference sequences of the five (5) plasmids which previously showed reads which had mapped 
(pTYGi9, pMYCCH01, pMYCSM01, pMYCSM03 and pMSPYR101). Although mapping coverage and 
read depth did improve after re-sequencing, the coverage statistics stayed too low to be 
conclusive regarding the presence of a plasmid. No plasmid showed a coverage higher than about 
2% of the reference (data not shown). 
Sample Sex typing from NGS data Osteological sex 
SJG 022 Und. F 
SJG 131 F F 
SJG 149 Und. F 
SJG 189 Und. F 
SJG 289 M Und. 
SJG 404 M M 
SJG 427 F F 
SJG 472 F F 
SJG 507 F F 
SJG 533 Und. F 
SJG 611 M M 
SJG 658 M M 
SJG 722 F M 
SJG 749 F F 
SJG 978 M F 
SJG 1137 F F 
61
 62 
 
3.6 M. leprae genome findings 
3.6.1 Combined datasets' mapping statistics 
The pooled reads from the first sequencing runs, the re-sequencing runs and the additional 
datasets were analyzed using the BOWTIE pipeline which has already been mentioned. The 
results are summarized in Table 16. 
Table 16: Combined datasets’ coverage statitstics for M. leprae 
 
In addition, the mapping to M. tuberculosis (whole reference and target regions, see 
Supplementary Table 13) showed no increase in the coverage statistics on the target regions, 
thereby confirming the likely absence of any co-infection cases from the sequenced samples. 
 
Samples 
M. leprae 
# Reads mapping 
Read length 
(bp) 
Reference covered 
1X 4X 
SJG 022 15870 91 (63-116) 0.3190 0.0086 
SJG 131 10875 80 (56-102) 0.2104 0.0022 
SJG 149 5349 79 (54-101) 0.0616 0.0070 
SJG 189 77462 82 (59-111) 0.6970 0.2055 
SJG 289 5233 65 (47-96) 0.0765 0.0008 
SJG 404 566204 88 (61-102) 0.9999 0.9979 
SJG 427 11623054 101 (80-115) 1.0000 1.0000 
SJG 472 362963 75 (55-101) 0.9966 0.9060 
SJG 507 35561167 95 (66-106) 1.0000 1.0000 
SJG 533 933382 98 (68-125) 0.9999 0.9998 
SJG 611 6258 63 (46-92) 0.1102 0.0007 
SJG 658 103592 68 (48-98) 0.5462 0.1894 
SJG 722 1135985 84 (58-121) 1.0000 0.9999 
SJG 749 4111522 94 (65-119) 1.0000 1.0000 
SJG 978 1308555 92 (65-101) 0.9867 0.8081 
SJG 1137 125425 77 (53-109) 0.8732 0.3175 
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3.6.2 Single nucleotide polymorphism analysis of the ancient M. leprae genomes 
Genomic positions involved in M. leprae genotyping are listed in 12.3 Supplementary results for 
all the recovered ancient M. leprae genomes. Table 17 shows the various strains observed in the 
ancient M. leprae isolates. The genotyping method based on all the variants published in Monot 
et al. seems less reliable and less sensitive than the inference-like approach described by Singh et 
al. Irrespective of the method, it was not possible to determine the SNP type for the low-coverage 
genomes. The reasons behind this issue will be discussed below. 
 
Table 17: Leprosy genotypes observed in this study 
Sample Most likely SNP type 
according to Monot et al (2005) 
SNP type 
according to Singh et al (2011) 
SJG 022 Und. nd 
SJG 131 Und. 1d 
SJG 149 Und. nd 
SJG 189 Und. Und. 
SJG 289 Und. nd 
SJG 404 Und. 3I 
SJG 427 Und. 3I 
SJG 472 3I 3I 
SJG 507 3I 3K 
SJG 533 Und. Und. 
SJG 611   
SJG 658 Und. 1d 
SJG 722 3I 3I 
SJG 749 2F 2F 
SJG 978 Und. 2F 
SJG 1137 Und. 3I 
Genotyping was done according to Monot et al, 2005 and Sing et al, 2011. The lower-case 
letters indicate a genotype determined with low confidence. The sample highlighted in red 
showed different results depending on the method used. 
 
3.6.3 Phylogenetic analyses 
The phylogenetic trees calculated using several multiple alignment and construction methods 
showed a consistent grouping of the samples into the four SNP-types (see 12.3 Supplementary 
results). Figure 18 below shows a representative example of the tree obtained. All high-coverage 
ancient strains were found to cluster according to their SNP-types. Sample SJG 533 (which gave 
inconclusive SNP typing results) clustered with the 3I strains. Sample SJG 507 fell into the recently 
described Branch 0, which confirms the SNP typing results obtained via the Singh approach. 
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Figure 18: Phylogeny of M. leprae including six new high-coverage genomes. 
Maximum Likelihood rooted tree constructed from the MAFFT multiple alignment. The node 
labels indicate the bootstrap values after 500 replications. The six new genomes are indicated 
with blue dots on the branch tips. Ancient genomes are shown in orange, modern ones in 
black. The name “RefSeq” is used to identify the four modern reference sequences. The scale 
represents the average substitution rate. 
 
Amongst the ten low-coverage genomes, five were consistently assigned to Branch 3I (SJG 1137, 
SJG 189, SJG 472 and SJG 611) and Branch 2F (SJG 658). For the remaining five low-coverage 
genomes, it was not possible to confidently assign the sequence to one branch. Branch 3I and 
Branch 2F of the M. leprae partial tree constructions showed that the low-coverage genomes 
clustered within the branch (Figure 19). The clustering patterns observed were consistent with 
the global phylogeny which was previously constructed. Moreover, the genetic distance observed 
between members of the 3I Branch is higher than those between members of the 2F Branch, 
which is consistent with the trend observed on the global tree. 
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Figure 19: Partial genetic distance trees for Branch 3. UP: Branch 3I, DOWN: Branch 2F. 
HC indicates the high-coverage genomes, LC the low coverage isolates. M. leprae TN was used 
as an outgroup to root the tree. 
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3.6.4 Variant annotation 
The variant lists created with higher-stringency criteria were submitted to the SNPeff annotation 
software. Table 18 provides an overview of the number of variants per sample. The number of 
variants is highly variable between the samples, which is due to the differences in the coverage of 
M. leprae (as has previously been observed) and explains the range of variant rates displayed. 
Table 18: SNPeff results overview statistics 
 
In addition, SNPeff also provides an overview of the types of variants and their locations (Table 
19). It is notable that SNPeff has only annotated SNPs. Moreover, most of the variants are located 
upstream or downstream from annotated genes; only a few are located inside exons, in a splice 
site or inside a non-gene transcript region. This is coherent with the expected location of variants 
in bacteria, since non-coding regions are submitted to a lowest selection pressure and, therefore, 
tend to accumulate mutations. The low number of SNPs found in intergenic regions might be 
related to the short length of those regions in a genome as small as M. leprae. 
 
 
 
 
Sample 
Total number of effects 
found Number of variants 
Variant rate on the M. 
leprae reference 
SJG 022 102 14 1/233,443 
SJG 131 155 19 1/172,010 
SJG 149 125 17 1/192,247 
SJG 189 193 29 1/112,696 
SJG 289 165 20 1/163,410 
SJG 404 1,229 188 1/17,384 
SJG 427 1,234 189 1/17,292 
SJG 472 1,145 174 1/18,782 
SJG 507 1,613 268 1/12,194 
SJG 533 761 124 1/26,356 
SJG 611 119 14 1/233,44 
SJG 658 676 97 1/33,692 
SJG 722 1,252 192 1/17,021 
SJG 749 638 107 1/30,543 
SJG 978 1,363 196 1/16,674 
SJG 1137 775 114 1/28,668 
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Table 19: M. leprae variants per type and location 
 
The proportion of SNPs in each location is similar between all the samples, as is the genomic 
distribution of the variants (data not shown). The SNP distributions consistently showed a striking 
peak in variant frequency between 1,300,000 and 1,400,000 (see Figure 20). This region might be 
the location of a variable element, as is discussed below. 
 
Figure 20: Example of SNP distribution along the M. leprae genome (SJG 472) 
 
Finally, SNPeff provides an overview of the effects of the variants (Table 20). This overview is 
useful to estimate the proportion of SNPs, where an important effect might be expected for each 
sample. 
 
 
Sample 
Types of variants Location of the effects 
SNP INS DEL Other Downstr. Exon Intergenic Splice 
site 
Transcript Upstr. 
SJG 022 14 0 0 0 49 11 2 0 1 39 
SJG 131 19 0 0 0 78 19 0 0 0 58 
SJG 149 17 0 0 0 66 16 1 0 0 42 
SJG 189 29 0 0 0 85 18 1 0 10 79 
SJG 289 20 0 0 0 82 20 0 0 0 63 
SJG 404 188 0 0 0 527 118 28 1 41 514 
SJG 427 189 0 0 0 543 124 25 1 39 502 
SJG 472 174 0 0 0 498 117 22 1 34 473 
SJG 507 268 0 0 0 676 98 75 0 94 670 
SJG 533 124 0 0 0 307 72 16 0 36 330 
SJG 611 14 0 0 0 61 14 0 0 0 44 
SJG 658 97 0 0 0 326 85 7 0 5 253 
SJG 722 192 0 0 0 553 130 23 1 38 507 
SJG 749 107 0 0 0 279 48 21 0 38 252 
SJG 978 196 0 0 0 629 155 17 0 24 538 
SJG 
1137 
114 0 0 0 358 87 8 1 18 303 
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Table 20: M. leprae variants effects by functional class and impact 
 
3.6.5 Possible effects of the variations observed 
Once the results from all the samples were merged, the collected list of SNP effects showed 696 
unique effects. Supplementary Figure 6 shows the distribution of the effects per type, impact, 
affected gene products and pathways before filtering. The filtering steps removed 648 effects as 
shown in Table 21. Most of the filtered variants were removed due to the fact that they were 
located in intergenic regions or because they were hypothetical protein genes or stable RNA 
genes. 
 
Table 21: Number of annotated effects during and after filtering 
 
 
 
 
  
Sample 
Functional class 
Impact 
Missense Silent None Low Moderate High Modifier 
SJG 022 1 2 99 2 1 0 99 
SJG 131 1 0 154 0 1 0 154 
SJG 149 3 0 122 0 3 0 122 
SJG 189 3 3 187 3 3 0 187 
SJG 289 1 0 164 0 1 0 164 
SJG 404 46 24 1,159 24 46 0 1,159 
SJG 427 44 24 1,166 24 44 0 1,166 
SJG 472 35 27 1,083 27 35 0 1,083 
SJG 507 65 32 1,516 32 64 1 1,516 
SJG 533 40 22 699 22 40 0 699 
SJG 611 0 0 119 0 0 0 119 
SJG 658 14 7 655 7 14 0 655 
SJG 722 38 29 1,185 29 38 0 1,185 
SJG 749 28 17 593 17 28 0 593 
SJG 978 36 23 1,304 23 36 0 1,304 
SJG 1137 19 13 743 13 19 0 743 
 Number of effects 
Before filtering 696 
After removal of intergenic variants 522 
After removal of hypothetical proteins and pseudogenes  304 
After removal of the stable RNAs 127 
After filtering of the variants observed in only one genome 48 
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Figure 21 below shows the distribution of the effects per type, impact, affected gene products 
and pathways. 
 
 
Figure 21: M. leprae variant distribution after filtering 
A) SNP distribution per annotated effect, B) SNP distribution per impact, C) SNP distribution 
per product functional category. 
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Table 22 highlights the most frequent amino acid changes after filtering. Finally,  
Figure 22 displays the number of genes and variants in each functional category. 
 
Table 22: Amino acid change observed after filtering 
The number of occurrences of each amino acid change is recorded in the corresponding cell. 
The colour intensity (from light to dark orange) highlights those changes which occur more 
often. 
 
 
Figure 22: Number of genes and variants of each type per functional category 
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3.6.6 Selection of variants of interest and detailed SNP effect estimation 
After the first filtering steps, only two possible variants of interest were found. One was a variant 
annotated as related to adaptation and virulence, the other a variant in a splice site. 
Unfortunately, both were missing critical protein contextual information and their effects could 
not be studied in detail. 
The three proteins selected for in-depth analysis are listed in Table 23 along with their 
annotations and GO profiles. The dnaA protein showed two different possible amino acid 
changes. Those two changes can be observed both simultaneously and separately in this study’s 
sample set. Therefore, the rest of the analyses were performed for the RT and the three possible 
variant combinations. The chemical properties of the proteins are shown in Table 24. None of the 
protein variants showed a pI, mW, hydrophobicity or aliphatic index variation suggestive of a 
major change in the protein solubility or activity. The same observation was made on the profiles 
computed using the protein sequences (Supplementary Figure 7-9). The secondary structure 
predictions are available in 12.3 Supplementary results. Although it is not possible to assess the 
effect of the variants on the proteins’ activity levels, it is noticeable that the glcB variant does not 
seem to affect the secondary structure, while the secondary structure is affected by the other 
variants. 
Figures 22-24 show the variant loci in their protein feature context. In dnaA and glcB, the variant 
loci were located in annotated conserved sites with known amino acid patterns. Similar results 
were obtained with the protein multiple alignment (Figures 25-26). The gyrA variant was outside 
of any conserved region (data not shown). The dnaA and glcB variants were located in conserved 
regions. The variants dnaA ser25gly and glcB leu591pro were also present in other species, while 
the dnaA gly295ser variant was only present in the sequences from the present study. 
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Figure 23 dnaA variant loci and protein features 
UP: locus 1: ser25gly, DOWN: locus2: gly295ser 
 
 
Figure 24: gyrA variant locus and protein features 
Amino acid change: leu379pro 
 
 
Figure 25: glcB variant locus and protein features 
Amino acid change lys591glu 
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Figure 26: dnaA variant loci inside their conserved amino acid sequence 
UP: locus 1, DOWN: locus 2 
 
 
Figure 27: glcB variant locus inside its conserved amino acid sequence 
Amino acid change lys591glu 
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4 Discussion 
4.1 Authenticity of the results 
4.1.1 aDNA good laboratory practices 
Several reviews have discussed the necessity of setting up rigorous guidelines for good ancient 
DNA work in order to increase the quality of the results and avoid false findings (Shapiro & 
Hofreiter 2012; Cooper & Poinar 2000). The guidelines involve 1) the use of a physically-isolated 
area for pre-PCR work, 2) the systematic implementation of negative controls, 3) the control of 
PCR results with regards to the expected product length and sequence, 4) the setting up of 
biological and technological replicates, 5) the control of PCR-based variant detection using 
cloning, 6) the setting up of independent replication in other research groups when studying 
human DNA and 7) the testing of the recovered DNA for characteristic ancient DNA damage 
patterns using Next-Generation Sequencing. 
The details of the measures taken within this study in relation to these guidelines are fully 
described in the corresponding methods section. In general, pre-PCR steps were carried out in a 
dedicated aDNA room exempt of any modern DNA work and were thoroughly maintained using 
cleaning procedures specifically intended to remove any and all DNA traces. Three types of 
negative controls were systematically used to assess contamination levels during the extraction, 
the PCRs and the library preparation. A separate scientist replicated all PCR-based assays and 
Next-Generation Sequencing datasets were checked for coherence between datasets of the same 
DNA extract. Adhesion to the guidelines specific to PCR or Next-Generation Sequencing are 
discussed below. Although independent replication of the results by another laboratory was not 
performed, all the results were compared to previously-published data from samples of similar 
historical context. As the study focusses on mycobacterial DNA, the risk of artifactual results due 
to human contamination is negligible. 
In addition to the guidelines, the choice of the reagents and PCR oligonucleotides were carefully 
thought through. Indeed, contamination can happen through the use of contaminated reagents 
and consumables. To avoid indirect contamination by the reagents, all the reagents were chosen 
for their DNA-free certifications. Moreover, all reagents able to sustain UV radiation and room 
temperatures were de-contaminated under UV light between each use. 
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Because it followed the guidelines for good ancient DNA practices, this study places itself in the 
best situation to yield reliable results. 
4.1.2 PCR results 
Because of the molecular degradation of aDNA fragments, the polymerases used to perform PCRs 
inherently show a higher amplification rate for non-degraded contaminant DNA fragments 
(Willerslev & Cooper 2005; Cooper & Waynet 1998; Hofreiter 2008). Consequently, PCR is 
strongly sensitive to contamination and many aDNA PCR results have been heavily debated after 
publication due to missing negative controls or insufficient description of the measures taken to 
avoid contamination (Lindahl 1997; Hofreiter 2008; Barnes & Thomas 2006; Cooper & Waynet 
1998; Stone et al. 2009; Willerslev & Cooper 2005; Wilbur et al. 2009). 
Three criteria are essential to authenticate ancient DNA PCR results: negative controls must show 
no amplification, the PCR product length must be consistent with the expected product size and 
the PCR product sequence must match the reference sequence. 
In a typical PCR amplification from an aDNA extract, contamination might arise from the 
extraction step or from the PCR set-up step. Here, two types of blanks were used to monitor the 
contamination levels at the end of the analysis: Extraction blanks and PCR blanks. If 
contamination happens during the extraction procedure, only the extraction blank should return 
positive. If both blank types return positive, this would reveal contamination during PCR setup. A 
PCR blank that shows contamination while the extraction blank remains clear could be a sign for 
cross-contamination between the reaction tubes during the PCR procedure. 
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Figure 28: Sources of PCR contamination and measures taken to estimate its level 
The extraction and PCR blank were created during the extraction and library blank, 
respectively, by replacing the volume of DNA solution with molecular-grade water. Blanks 
were then checked twice, once for the presence of amplification products, and (if necessary) a 
second time for the origin of the amplified sequence. 
 
In this study, all extraction and PCR negative controls gave no PCR products for the primer pairs 
used. Moreover, apart from the case of M. tuberculosis (which will be discussed further below) all 
the PCR products obtained showed lengths and sequences consistent with the target sequences. 
Therefore, with regards to PCR contamination control procedures and checkpoints, this study 
fulfils the authenticity criteria discussed in the literature and the presented results are reliable. 
 
 
 
79
 80 
 
4.1.3 Next-Generation Sequencing results 
 
Figure 29: NGS sources of contamination and measures taken to avoid it 
In addition to the PCR negative controls, several contamination control steps were taken 
during the NGS procedure. A library blank was added to each sample set. All the libraries were 
checked for concentration. Finally all the sequences were examined for degradation patterns 
characteristic of ancient DNA fragments.  
 
The contamination or cross-contamination of samples is considered negligible after the indexing 
of the Illumina sequencing libraries because only the DNA sequences flagged with the expected 
barcode for a specific sample will be retrieved after sequencing (Kircher et al. 2012; Meyer & 
Kircher 2010; Cooper & Poinar 2000). Therefore, only contamination which happens before the 
indexing step presents a risk for the authenticity of the results. The contamination of the results 
might come from either the laboratory work or the sample itself (Figure 29). In addition, the DNA 
recovered for a species might not be ancient (even if present in the remains before extraction). 
These last three issues will each be addressed individually in the following. 
The non-contamination of the DNA extracts by exogenous DNA was already assessed once during 
the PCR screening, as has been discussed previously. Library blanks help to assess the levels of 
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contamination during the library preparation and indexing procedures. The quality and quantity 
control of the extraction blank and library blanks after indexing of the Illumina sequencing 
libraries showed virtually empty libraries, sometimes presenting an adapter chimera peak around 
100bp. In the case of sequencing blanks, chimeras are actually to be expected since the library 
preparation and indexing procedure is applied to a “DNA extract” composed only of water and 
buffers. Chimeras present little risk for the sequencing of blanks on a Illumina HiSeq, because the 
cluster generation step requires DNA fragments to be longer in order to properly form bridges 
(Kircher et al. 2012; Meyer & Kircher 2010). The absence of modern contamination is confirmed 
by the second control using the extraction and library blanks after sequencing, when the blanks 
showed no contaminating DNA sequences once again. Some blanks yielded small amount of small 
reads which were too short to map specifically anywhere. The origin of those small reads is still 
unclear, although they were likely brought in by one (or several) of the enzyme kits, considering 
that enzymes are mass-produced in modified cell lines such as E. coli and that their purification 
process is often not well described by the suppliers. All in all, the extraction blanks and library 
blanks showed no evidence of contamination with modern DNA after the sampling of the 
remains. 
The endogenous DNA from the remains themselves might well carry contamination that dates 
from the time the skeleton spent buried or during its storage after excavation, or even from the 
osteological study of the remains. DNA molecules not processed and stored for molecular 
biological use will display the same features as “ancient DNA” after about 20 years (Mitchell et al. 
2005; Brotherton et al. 2007; Overballe-Petersen et al. 2012; Sawyer et al. 2012). Therefore, 
skeletons that spent time in storage are likely to yield large numbers of ancient-looking DNA 
molecules from various organisms. To authenticate the results of any ancient DNA study, it is 
important to also discuss the issue of pre-sampling contamination. This type of contamination is 
rarely a risk for studies which rely on a mapping approach to identify the DNA fragments 
belonging to the species of interest. In this study, a mapping strategy was applied to discriminate 
M. leprae DNA fragments and human mtDNA fragments from the rest of the sequenced DNA 
molecules and strict mapping criteria were chosen to minimize the risk of aspecific mapping. In 
addition, species-specific genomic regions were chosen in order to evaluate the sequence 
coverage and read depth with a minimal background mapping level. Therefore, the results 
presented are unlikely to be artefacts due to the presence of close relative species within the 
sample. 
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The last step for the authentication of aDNA results is to show that the recovered DNA molecules 
for the species under study present the spontaneous molecular degradation characteristics which 
are commonly referred to as “damage patterns”. As was described in the introduction, after the 
death of an organism, DNA molecules start to accumulate molecular modifications. Amongst 
those modifications are the deamination of the purine bases (Lamers et al. 2009; Overballe-
Petersen et al. 2012; Briggs et al. 2007; Brotherton et al. 2007) which leads to an increased 
occurrence of Guanine (G) and Thymine (T) at the 3’-end and 5’-end of the DNA molecule, 
respectively. This is accompanied by the apparition of single-strand breaks leading to a 
progressive fragmentation of the DNA molecule (Pääbo 1989; Hofreiter, Serre, et al. 2001; 
Willerslev & Cooper 2005). In consequence, the authentification of aDNA should not rely only on 
the damage patterns, but should instead be discussed in relation to fragment length distribution. 
In this study, two results were used to evaluate the length of the DNA fragments. The first of 
these was the quality control of the indexed sequencing libraries. The second was the insert 
length distribution provided by the software which also calculated the damage patterns. The first 
was only an approximation since the plot showed the length distribution of the insert plus both 
side library and indexing adapters. However, it also provided the first evaluation of the fragment 
lengths: given the length of the adapter constructs, the total length with aDNA insert should not 
exceed 300bp. The insert distribution length provided by the mapDamage 2.0 software gives a 
better estimate of the length of the fragments mapping the genome of the species under study. 
Moreover, as it is calculated from the exact same dataset as the one used to compute the 
misincorporation frequencies at the ends of the DNA fragments, both results can be directly 
compared. In all the datasets, the fragment length distribution observed was consistent with the 
ancient origin of the recovered genomes. 
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Figure 30: Correlation between aDNA length distribution and damage patterns 
G to A frequency on the first 3’ base of the fragments is displayed in red. UP: Data from the 
reads mapping to the M. leprae genome. DOWN: Data from the reads mapping to the human 
mtDNA. 
 
The damage patterns observed for the human mtDNA fragments ranged from 0.076 to 0.150 on 
the 5’ end (C->T) and 0.097 to 0.200 on the 3’ end (G->A), numbers that are consistent with 
previously published data (Schuenemann et al. 2013). The damage patterns observed for the M. 
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leprae DNA fragments ranged from 0.033 to 0.051 on the 5’ end and 0.030 to 0.052 on the 3’ end. 
Those numbers are also consistent with several previous medieval M. leprae studies 
(Schuenemann et al. 2013). Interestingly, for the human mtDNA, the 5’-end of the molecules 
always displayed higher misincorporation frequencies than the 3’-end, a phenomenon which has 
not often been observed within M. leprae data. A recent study published after the laboratory 
work of this project showed that the use of Accuprime polymerase to amplify indexed libraries 
tended to reduce the misincorporation frequency on the 5’-end of the DNA molecules (Seguin-
Orlando et al. 2015). The observation was made on ancient equid DNA and is consistent with the 
damage patterns shown by the human mtDNA sequences. It is curious that this bias seems almost 
negligible for the mycobacterial DNA. Several publications have suggested that M. leprae’s thick 
and highly hydrophobic cell wall enhances the preservation of its DNA after death (Schuenemann 
et al. 2013; Mendum et al. 2014). The data presented here supports this hypothesis, as the 
damage patterns were generally higher for the human mtDNA than for the M. leprae DNA. It is 
likely that this differential DNA preservation is, at least partly, also involved in the different 
behaviour of the DNA libraries when amplified with Accuprime. 
The mapDamage results showed an apparent conflict between the damage patterns and the 
length distributions. On one side, the damage pattern data suggests that M. leprae is better 
preserved than the human mtDNA (lower misincorporation frequencies at the end of the aDNA 
fragments). However, the distribution plots would instead suggest that the reverse were true: the 
human mtDNA was the best preserved as it presented longer DNA fragments. In fact, these 
results do not actually contradict each other. Indeed, although the DNA molecular degradation 
processes leading to misincorporations and strand breaks are independent, the apparition of a 
strand break in a DNA fragment creates new 3’ and 5’- ends which display lower misincorporation 
frequencies, decreasing the average misincorporation frequencies over all 5’ and 3’ fragment 
ends. Therefore, from two samples of the same age and deamination rate over time, the sample 
with the highest strand break rate over time will show lower damage patterns at the end of the 
DNA fragments (see Figure 31). 
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Figure 31: Influence of deamination and strand breaks on damage patterns 
The dataset from one of the samples from this study was used to simulate simple cases when 
the rates of deamination and strand break over time vary. To simplify the situation, this 
simulation considers deamination and strand breaks as the only degradation mechanisms and 
assumes that strand breaks would occur in the middle of aDNA fragments. 
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In summary, the results showed clean blanks before and after sequencing and damage patterns 
consistent with the medieval origins of the remains. The possibility of exogenous contamination 
of the samples is considered negligible after the indexing of the Illumina sequencing libraries 
because only the DNA sequences flagged with the expected barcode for a specific sample would 
be retrieved after sequencing (Kircher et al. 2012; Meyer & Kircher 2010; Cooper & Poinar 2000). 
Moreover, as a mapping strategy is used to reconstruct the mycobacterial genomes, the 
likelihood of endogenous contamination is strictly limited to DNA from close relatives of the 
species under study. Therefore, the Next-Generation Sequencing results from this study can also 
be considered reliable. 
 
4.1.4 Age of the samples 
Table 25: Comparison between radiocarbon dating and burial period 
Sample Calibrated radiocarbon 
age 
 
Burial period (arm 
position) 
SJG 404 cal AD 1226-1268 1000-1375 
SJG 427 cal AD 1177-1250 1000-1375 
SJG 472 cal AD 1252-1280 1000-1375 
SJG 507 cal AD 1170-1214 1000-1375 
SJG 533 cal AD 1051-1206 1000-1375 
SJG 722 cal AD 1269-1285 1000-1250 
SJG 749 cal AD 1230-1277 1000-1375 
SJG 978 cal AD 1283-1381 1000-1375 
SJG 1137 cal AD 1282-1380 1000-1250 
The burial period is an estimate of the sample age based on burial practice as determined by 
the archaeological collaborators within this project. Two of the samples which exhibited 
apparently inconsistent results are highlighted in orange. 
The radiocarbon dating results were consistent with the archaeological determination based on 
burial practices in all but two samples. Sample SJG 722 also showed sexing results inconsistent 
with the archaeological data. These two problematic areas for this sample are most likely linked 
and will be discussed later on. 
 
 
 
 
86
 87 
 
4.2 DNA preservation in the various cemeteries 
4.2.1 Human mitochondrial DNA preservation 
The human mtDNA PCRs were performed in order to estimate the human DNA preservation levels 
in the samples and to provide a baseline from which to interpret the results of the pathogen DNA 
PCRs. The St. Jørgen cemetery showed the highest number of human mtDNA PCR positives, 
suggesting that it is the best-preserved cemetery of this study. With almost 50% of the samples 
yielding mtDNA PCR products, it counts among the best-preserved of the cemeteries that have 
been used in ancient DNA studies to date. The two last large sample sets from Ribe and the 
Rathausmarkt showed lower human DNA preservation. The preservation of human mtDNA in the 
remains was apparently unrelated with the sex, age at death or historical age of the remains. 
 
4.2.2 M. tuberculosis DNA preservation 
The PCR results for M. tuberculosis yielded no clear tuberculosis positive. Several other attempts 
were performed as well as PCR optimisation and extensive troubleshooting, all without results. 
The PCR optimisation assays included the testing of two new annealing temperatures (+2°C and -
2°C compared to the published annealing temperatures) and the testing of two new template 
DNA input volumes (2μL and 10μL). The PCR troubleshooting included the testing of new 
oligonucleotides, new reagents and a different PCR machine. As the PCR setup was also tested 
successfully with modern M. tuberculosis DNA, the absence of results for the ancient samples 
suggests that either the bacterial DNA was not present in the samples (i.e. the individuals were 
not infected with tuberculosis), or that the M. tuberculosis DNA was present, albeit in amounts 
that were too small or that were too degraded to be successfully recovered with the protocols 
used in this study. 
For the three samples which showed partial M. tuberculosis DNA preservation, the presence of 
the pathogen seems uncorrelated with any of the archaeological information which is available.  
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4.2.3 M. leprae DNA preservation 
The number of samples which showed positive results for M. leprae DNA was null for all but one 
cemetery (St. Jørgen). The two other large sample sets yielded no positives for M. leprae DNA, 
which was rather surprising. Indeed, the samples were collected from individuals whose remains 
demonstrated leprosy lesions and who were collected from cemeteries whose use lives coincided 
with the period during which leprosy was highly prevalent in the region. However, DNA 
preservation is highly dependent on burial conditions and varies greatly not only from one 
cemetery to another but also from one species to the other. Therefore, the absence of a PCR 
positive for M. leprae DNA in the Ribe and Rathaus Markt cemeteries might simply be due to poor 
DNA preservation as a whole. This interpretation would be compatible with the lower 
preservation levels of human mtDNA within those two cemeteries as compared with that at St. 
Jørgen. 
The St. Jørgen cemetery preservation level for M. leprae was extremely high compared to that of 
other cemeteries previously studied (Schuenemann et al. 2013; Taylor et al. 2013). Indeed, almost 
50% of the samples showed positive M. leprae fragments. This number was not completely 
unexpected, as the individuals buried in the cemetery either were diagnosed with leprosy during 
their lifetime, or lived in close contact with infected people for a prolonged time. Moreover, a 
study published in 2013 had already showed very high M. leprae preservation in one St. Jørgen 
sample (Schuenemann et al. 2013), thereby suggesting that the burial environment at the site 
was favourable to the recovery of medieval mycobacterial DNA. Nevertheless, the number of 
samples which showed M. leprae DNA preservation goes far beyond current achievements in 
terms of positive leprosy molecular identifications from the same geographical origin. 
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Figure 32: PCR results in relation with the archaeological features. 
A) Proportion of PCR positives according to the archaeological sex of the samples. B) 
Proportion of PCR positive according to burial time period. C) Proportion of PCR positives 
according to palaeopathological status. D) Proportion of PCR positives according to whether 
or not the individuals presented rhinomaxillary lesions. E) Age at death distribution amongst 
the PCR positives and negatives. 
 
 
 
 
89
 90 
 
The number of samples yielding PCR positive results seems to be independent of the age at death 
of the sample and the sex of the individuals. In addition, the number of PCR positives does not 
seem to be correlated with the presence of leprosy-specific bone lesions (with or without 
rhinomaxillary lesions). This might be due to a sampling bias, as all the remains presented here 
originated from a leprosarium hospital cemetery. Although the number of samples does not allow 
for the quantification of the correlation between age at death and the proportion of PCR 
positives, there is a clear trend for individuals between 20 and 25 to yield PCR positive results for 
M. leprae. This cannot be explained only by a DNA preservation difference and would suggest a 
higher number of M. leprae cells in the organisms of the 20-25 year old individuals before their 
death. The development of leprosy towards its multibacillary form is linked to the type of immune 
response of the affected individual and is dependent on his or her life quality. Therefore, if 
confirmed, the higher pathogen load in medieval 20-25 year olds might indicate that individuals 
around that age tended to respond to the infection through antibody-mediated immunity, which 
has been shown to promote the immune evasion of M. leprae. 
 
4.3 Next-Generation Sequencing reads pre-processing 
4.3.1 Data quality 
The FastQC sequence quality controls returned numerous warnings. After careful examination, all 
the warnings likely originated from ancient DNA molecular characteristics (see Table 26). 
Therefore, it can be assumed that no major technical failure took place during the library 
preparation, indexing or sequencing. In addition to the preliminary FastQC control, several 
bioinformatics steps are designed to optimise the quality of the datasets for each sample before 
mapping the reads to the reference genomes. The first step is the trimming of the adapter 
sequences which are likely to be sequenced due to the short length of aDNA insert molecules. 
Those adapter sequences are removed to prevent errors during the mapping step and increase 
general mapping quality. After adapter trimming, the forward and reverse sequencing reads are 
mapped. This increases the length of the DNA sequences that will be used for the mapping step, 
therefore decreasing the risks of aspecific mapping. Moreover, merging raises the per base 
sequencing quality and decreases the number of sequencing errors by selecting the base with the 
best quality score in case of conflict between forward and reverse sequences. Finally, the merged 
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reads are trimmed if the sequencing quality drops towards the end of the read and filtered to 
remove the reads which are too short to be accurately mapped. 
Table 26: FastQC observed warnings and possible aDNA cause 
 
A rather large variability was observed between the raw numbers of reads available for each 
sample after sequencing, although the protocols were designed to input the samples in equimolar 
amounts. The causes of this variability are difficult to investigate. Pipetting uncertainty is likely 
involved, as well the cluster generation method which might be uneven when fragments of 
various lengths and GC contents are processed in parallel. 
 
4.3.2 Identification and analysis of human DNA reads 
Human mitochondrial DNA reads were identified by mapping the sequencing reads to the GRCh38 
mitochondrial DNA (mtDNA) reference sequence (NC_012920.1). The percentage of reads 
mapping to the human mtDNA also fits in the frame of previous studies involving samples from 
the same geographical and historical contexts (Schuenemann et al. 2013). The coverage and read 
depth over the human mtDNA were also in agreement with previous studies. 
Step Control for Possible explanation 
2 Per base sequence quality Ancient DNA short reads are likely to enhance the per base 
sequence quality drop towards the ends of the reads  3 Per tile sequence quality 
5 Per base sequence content The formation of the aDNA library and indexing are likely to 
lead to over-representation of adapter sequences within the 
sample 
6 Per base GC content The shotgun sequencing approach used means that the 
DNA sequence likely originates from several organisms with 
various GC contents. 
9 Sequence duplication levels aDNA library diversity is commonly reduced compared to 
modern DNA libraries; therefore, this warning is likely to be 
triggered by the presence of numerous PCR duplicates. 
10 Overrepresented sequences aDNA is not homogenously preserved in a genome; 
therefore, the reads from regions with high coverage are 
likely to seem over-represented 
11 Adapter content Ancient DNA inserts are usually shorter than the read 
lengths; therefore, the sequencing adapters are likely to be 
sequenced  
12 K-mer content aDNA is not homogenously preserved in a genome; 
therefore, the reads from regions with high coverage are 
likely to appear over-represented 
91
 92 
 
The sex typing proxy developed seems to have been reliable; eight out of 16 samples showed 
results which matched osteological sex. However, two samples showed an Y/X ratio inconsistent 
with their osteologically-determined sex. To control the results obtained with the Y/X ratio proxy, 
STR typing was performed (by Lisa Böhme for her PhD). For the two samples showing Y/X ratios 
incompatible with the osteological sexing, the STR analysis confirmed the Y/X ratio results (see 
Table 27). An investigation was undertaken with the archaeologists in charge of the sample 
collections in Odense to understand the origin of the contradiction. It was discovered that for 
those two samples, a loose tooth was collected from the numerous loose teeth labelled as 
belonging to this individual. In the case of very close graves, teeth might have been exchanged 
between individuals during the excavation, as it is very difficult to properly assess the origin of a 
tooth when the maxillae are not well preserved. Therefore, it is possible that the material used in 
samples SJG 722 and SJG 978 actually came from other individuals. For the remainder of this text, 
these two samples will be referred to as SJG 722* and SJG 978*. In the case of sample SJG 722, 
this differential between intended sample grave and actual sample grave also explains the 
discrepancy between the radiocarbon date and the archaeological estimate of the burial period 
which was discussed above. 
 
Table 27: Results and comparison of the various human aDNA analyses performed 
 
 
 
 
 
 
 
 
 
 
 
 
Columns marked with * indicate results not obtained personally. The label “Und.” denotes 
inconclusive results. Red cell shading highlights inconsistencies. 
 
Sample 
Sex typing 
NGS data STR typing* Osteology* 
SJG 022 Und. Und. F 
SJG 131 F Und. F 
SJG 149 Und. F F 
SJG 189 Und. F F 
SJG 289 M M Und. 
SJG 404 M M M 
SJG 427 F F F 
SJG 472 F F F 
SJG 507 F F F 
SJG 533 Und. F F 
SJG 611 M M M 
SJG 658 M M M 
SJG 722 F F M 
SJG 749 F Und. F 
SJG 978 M M F 
SJG 1137 F F F 
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4.3.3 Identification of M. leprae DNA reads 
Mycobacterium leprae DNA reads were identified by mapping the sequencing reads to the TN 
strain reference sequence. The percentage of raw sequencing reads mapping to the reference 
ranged from 0.01% to about 12%. Due to the close genetic similarity between the mycobacterial 
species, the presence of M. leprae was confirmed using the results of the mapping onto the two 
M. leprae-specific genomic targets. The overall coverage and read depth statistics were 
interpreted while taking into account the 38-44% of genetic identity observed during the 
preliminary analyses. The other references used as mapping comparisons all yielded similar low 
coverage and read depth. In addition, there was a clear positive correlation between the coverage 
of M. leprae and the coverage of the other species. In addition, the coverage statistic on the M. 
leprae-specific targets were similar or higher compared to the whole-genome data. Those results 
suggest that the reads which mapped to the other species were likely M. leprae DNA fragments 
which mapped aspecifically due to sequence similarity. 
The Next-Generation Sequencing results confirmed the presence of M. leprae in all the samples 
selected using the PCR screening. However, the levels of DNA recovery are highly variable. Some 
samples yielded only a low coverage over the M. leprae reference with a number of raw reads 
and a proportion of PCR duplicates which suggest low library complexity. Therefore, only seven 
samples were selected for re-sequencing. 
 
4.3.4 Testing for the presence of other infectious pathogens 
The mapping-to-targets approach was repeated with three other mycobacterial reference 
genomes (M. lepromatosis, M. tuberculosis and M. bovis) and Y. pestis. All four species might have 
been present during the time period studied. They represent, therefore, good co-infection 
candidates as well as good aspecific read mapping controls. The results of the mapping to the 
reference genomes all showed read mapping. The statistics of the mapping to the species-specific 
targets ruled out the presence of M. bovis or M. lepromatosis, as the coverage of the target was 
systematically significantly lower than the coverage of the whole reference genome. The mapping 
statistics for the Y. pestis target regions are slightly more difficult to interpret, as the target was 
only chosen to be present in Y. pestis but not in the mycobacterial genomes. Given the low 
coverage obtained, it is likely that the reads originated from another Yersinia species.  
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No evidence of M. tuberculosis infection was found after sequencing. This result is consistent with 
the absence of positive PCR for M. tuberculosis DNA in the first phase of this study. The coverage 
statistics for the M. tuberculosis reference showed increased coverage on the targets for five 
samples, which might be explained by the extremely high coverage of M. leprae. Indeed, after re-
sequencing, the M. tuberculosis coverage statistics on the targets no longer showed the increase 
which was previously observed. The absence of M. tuberculosis is rather surprising, since the 
three cemeteries studied were in use during the rise of tuberculosis in Northern Europe. It is an 
arduous task to determine whether the methods used were sufficiently sensitive. It has been 
suggested that M. tuberculosis DNA is more difficult to recover than DNA from its cousin M. 
leprae (Harkins et al. 2015; Taylor et al. 2013). Indeed, M. leprae possesses a thicker cell wall than 
M. tuberculosis (Donoghue 2013) with different mycolic acids. Therefore, M. tuberculosis DNA 
might be more susceptible to environmental factors promoting DNA degradation (such as 
humidity). In addition, the affinity of M. leprae for teeth is rather well documented, whereas 
there is no data on the affinity of M. tuberculosis for the oral cavity (Boldsen 2007). As a 
consequence, teeth might not be the best starting material to recover M. tuberculosis DNA from 
ancient tuberculosis sufferers. 
 
4.3.5 Relative abundance of human and mycobacterial DNA 
The percentage of reads obtained for the human mtDNA is consistent with the reference size as 
well as with previously-published aDNA results. However, the fraction of reads mapping to the M. 
leprae genome is extremely high for some samples. Only one previous study reports such a 
proportion of reads mapping to the M. leprae reference genome after shotgun sequencing and 
without enrichment (Schuenemann et al. 2013). In fact, the sample described in this previous 
study comes from the same cemetery, suggesting that this cemetery’s environment favorises high 
M. leprae DNA preservation. 
The results from the current study concur with the previous observations which place M. leprae 
as the organism with the best post-mortem DNA preservation in teeth DNA extracts. The M. 
leprae DNA fragments recovered are indeed present in high amounts and with lower signs of 
degradation than the mitochondrial DNA of the human host. The reasons for the difference in 
preservation are not yet fully understood, but there is an agreement around the likely 
involvement of M. leprae’s thick waxy coat composed of highly hydrophobic mycolic acids 
(Schuenemann et al. 2013). 
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4.3.6 Mycobacterial plasmids 
Only a few mycobacterial plasmid references were found to show sequencing read mapping 
(pTYGi9, pMYCCH01, pMYCSM01, pMYCSM03 and pMSPYR101). It was not possible, however, to 
rule out unspecific mapping or contamination. Indeed, not more than 2% of each reference was 
covered. Moreover, the number of mapping reads was too low to perform damage pattern 
computation. If the DNA fragments are of authentic ancient origin, the low number of reads 
might be a side-effect of the small length of the plasmid genomes. However, the methods used in 
this study are insufficient for further analysis. The results only suggest that the preservation of 
mycobacterial plasmid sequences seems possible. The sequencing of ancient mycobacterial 
plasmids has not yet been performed and plasmids are known to greatly influence virulence in 
bacterial pathogen species (Wang et al. 2016). Therefore, given the trends observed in this study, 
it seems both possible and pertinent that more resources should be brought to bear on the 
recovery of ancient mycobacterial plasmid sequences. Methods such as targeted enrichment 
captures might help to overcome the hurdle presented by the low number of mapping reads and 
confirm the results using damage patterns as well as phylogenetic downstream studies. 
 
4.4 Reconstruction and analysis of medieval M. leprae genomes 
4.4.1 Coverage and read depth of the M. leprae genome drafts 
 
Figure 33: M. leprae TN reference covered depending on the number of mapping reads 
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While the number of data points is not sufficient for quantitative analysis, the minimum number 
of reads mapping to recover a near-complete ancient M. leprae genome from samples from this 
cemetery would be about 4 million. Considering that only roughly 0.05-13 % of the raw reads map 
to the M. leprae reference in this dataset, the sequencing reads should be set up to provide 350-
400 million reads per sample. For most of the samples, however, this represents two sequencing 
lanes, which is still too expensive for most research groups. 
Eight (8) out of the 16 samples sequenced yielded very highly-covered genomes with up to a read 
depth of 600 X. While this is rather unexpected for aDNA studies, in the literature there is an 
example of a sample from this cemetery which yielded high amounts of M. leprae DNA 
(Schuenemann et al. 2013). The DNA preservation in those eight samples was sufficient to also 
perform de-novo assemblies of the ancient mycobacterial genomes (by J. Suzat for his master 
thesis, data not shown). 
 
4.4.2 Variant calling and effect prediction 
The effect distribution along the reference genome consistently showed a frequency peak 
between positions 1,300,000 and 1,400,000. The M. leprae genomic annotations showed the 
presence of three rRNA genes in this region (Figure 34). As rRNA sequences are highly variable 
regions, the observed peak in variant frequency is likely a consequence of the presence of those 
genes and is not an indication of a virulence-related variation hotspot. 
 
Figure 34: M. leprae annotation context between positions 1,300,000 and 1,400,000 
This region shows the highest frequency of variants, most likely because of the presence of the 
sequences coding for the rRNA 5S, 16S and 32S that are highly variable. 
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After the first filtering steps, only two variants of possible interest were found. One was a variant 
annotated as related to adaptation and virulence, the other a variant in a splice site. 
Unfortunately, both were missing critical protein contextual information and their effects could 
not be studied in detail. The three proteins eventually selected were cytoplasmic proteins. dnA 
and gyrA are proteins which interact with DNA and glcB is involved in malate metabolic pathways. 
M. leprae dnaA (ML0001) is a chromosomal replication initiator protein whose function and 
features have been determined through sequence homology (Cole et al. 2001). It plays an 
important role in the initiation and regulation of chromosomal replication (Bateman et al. 2015; 
Suzek et al. 2015) and possesses binding sites for DNA (dnaA-box), ATP and acidic phospholipids. 
In the sample set for this study, two variants were found in the protein sequence (ser25gly and 
gly295ser). No modification of the overall protein chemical properties could be noticed when one 
or both variants were present. However, the in-depth study of the variant loci and context 
showed that both are located in regions conserved amongst members of the dnaA protein family 
and are predicted to induce a change in the secondary protein structure. The second variant in 
particular is located in the ATP binding site and is predicted to locally modify an α-helix near one 
of the three binding site’s highly conserved amino acid motifs (Walker B). 
M. leprae gyrA (ML0006) is an ATP-dependent DNA gyrase subunit. The GyrA chain is responsible 
for the separation and rejoining of the two strands of DNA during the replication process. Its 
features and functions have been predicted using its homology with M. tuberculosis gyrA. It has 
been shown to possess a HOP domain as well as an Intein chain. In the samples analyzed for this 
study, one variant was found in the HOP domain (leu379pro) and is predicted to locally change 
the secondary structure of the protein by disrupting a long alpha-helix. It was, however, located 
outside of the main conserved motifs and is, therefore, considered unlikely to have major 
consequences on protein activity. 
M. leprae glcB (ML2029) is predicted to be homologous to M. tuberculosis malate synthase G and 
to take part in intermediary metabolism processes. One variant was found in the conserved 
region of glcB acetyl-coA binding site (lys591glu). This variant was predicted to have very little 
effect on the secondary structure of the protein. 
In all three studied cases, the amino acid change was predicted to have a local effect on the 
secondary structure of the protein and, in most of the cases, the variants were found inside 
conserved protein regions. However, our knowledge of the protein expression and activity in M. 
leprae is very limited (due to the impossibility of cultivating the bacterium). The only information 
available comes from in-silico predictions and comparisions with M. tuberculosis. Little is known 
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about the specificity of each protein’s cellular location, biochemical properties, structure and 
importance for M. leprae fitness or virulence. Therefore, it is impossible go any further than the 
protein’s primary and secondary structure when attempting to predict the effects of a variant. 
While it is impossible to clearly quantify the effect of the variants on the protein’s function and to 
assess their influence on M. leprae’s overall fitness and virulence, it was still possible to detail the 
variant effects up to secondary structure. Such an evaluation has never been previously 
attempted on variants originating from ancient mycobacterial genomes and could easily be scaled 
up to all the variants found in well-documented proteins. Moreover, while it was not the topic of 
this study, it is likely that protein modeling by homology could detail the consequences of the 
variants on the activity levels of the protein. However, to determine whether or not a variant 
might influence pathogen fitness and virulence, more biological background information is 
needed. 
 
4.4.3 Strain typing 
Table 28: SNP types of the recovered genomes 
 
 
 
 
 
 
 
 
 
 
The results from the various typing methods were consistent for most samples. In the few cases 
where there were discrepancies, the typing results from the Singh et al. approach were used, as 
this method is considered the most accurate (Singh & Cole 2011). Inconsistencies from the other 
Sample 
Most likely SNP type 
according to Monot et al 
(2005) 
SNP type 
according to Singh et al 
(2011) 
SJG 022 Und. Nd 
SJG 131 Und. 1d 
SJG 149 Und. Nd 
SJG 189 Und. Und. 
SJG 289 Und. Nd 
SJG 404 Und. 3I 
SJG 427 Und. 3I 
SJG 472 3I 3I 
SJG 507 3I 3K 
SJG 533 Und. Und. 
SJG 611   
SJG 658 Und. 1d 
SJG 722 3I 3I 
SJG 749 2F 2F 
SJG 978 Und. 2F 
SJG 1137 Und. 3I 
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methods are likely due to the low coverage of some recovered genomes or to the high genetic 
proximity between strains. No association could be observed between the M. leprae strains, the 
age of the samples and the osteological features. This observation, however, must be considered 
in relation to the low number of samples. Five (5) samples were typed as 3I, two (2) as 2F and one 
(1) as 3K. The implications of the presence of those strains is discussed below. 
 
4.5 Phylogenetic placement of M.leprae strains 
4.5.1 Consistency between the phylogenetic trees 
Three types of trees (Maximum-Likelihood, Maximum-Parsimony and Neighbour Joining) were 
constructed from two different whole-genome multiple alignments of the six new, highly-covered 
genomes and the previously-published ancient and modern genomes. All three types of tree 
showed consistent results insofar as each new sample clustered with previously-published strains 
of the same type. The overall phylogeny is also consistent with previously-published trees, with 
four major branches corresponding to groups 1 to 4. In addition, sample SJG 507 clusters in every 
tree with modern 3K strains, confirming the existence of the recently-described fourth branch (0). 
Only one inconsistency was noticed between the SNP typing results and the branching of the new 
train in the phylogeny (sample SGJ 533). Indeed, the M. leprae strain from SJG 533 clusters within 
Branch 3 with its closest neighbour being an ancient 3I strain from Denmark. Its strain typing, 
however, yielded inconsistent results insofar as the first SNP trio was different from the four 
possible combinations. Another apparent inconsistency was observed with the modern sequence 
s15 (type 3L). Depending on the trees, the 3L strain clusters either with 3K strains or with 3I 
strains. This phenomenon has been observed by the authors of the publication which mentioned 
s15 (Schuenemann et al. 2013). It is believed to be a result of to the high number of variants 
present in this strain compared to the others. Moreover, the 3L branch only has one 
representative while the others possess several representatives. Therefore, the uncertainty in the 
location of this strain might be a consequence of its under-representation. 
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4.5.2 Placement of the low-coverage genomes 
The approach which combined the branch assignment of the low-coverage genomes to a 
previously-built tree and partial tree reconstruction for each branch allowed adding five strains to 
the set of newly-described strains. The low-coverage strains typed fell into Branch 3I and Branch 
2F. Moreover, the proportion of 3I and 2F found in the low-coverage genomes seems to support 
the previously-observed dominance of 3I. Because of the principle of the branch assignment, no 
new strain can be discovered via this method. A straightforward follow-up would be to apply the 
same approach using all previously-published strains as anchors, thus enabling the assignment of 
low-coverage samples to branches other than 3I or 2F. However, the coverage of the previously-
published strains has been observed to be greatly variable, with several strains being themselves 
at very low coverage. In consequence, this follow-up was not implemented, as it would make little 
sense to use low-coverage genomes as anchors. It is likely that future research will provide more 
high-coverage genomes to increase the resolution of M. leprae’s phylogeny, allowing the use of 
more sequences as anchors for the kind of phylogenetic placement strategies which are currently 
being developed for M. tuberculosis (Kay et al. 2015). 
 
4.6 M. leprae in Northern Europe 
4.6.1 M. leprae in the medieval St. Jørgen leprosarium 
Table 29: SNP types of the recovered genomes and geographical context 
 
Sample SNP type 
Radiocarbon age 
(cal AD) 
Modern geographical 
association 
(Monot et al. 2009) 
Ancient geographical 
association 
(Mendum et al. 2014) 
SJG 189 3I  America & Europe Sweden, Denmark, UK 
SJG 611 3I  America & Europe Sweden, Denmark, UK 
SJG 658 2F  Middle East Sweden, Denmark, UK 
SJG 507 3K 1170-1214 Middle East & Asia Egypt, Hungary, Turkey 
SJG 533 3I  America & Europe Sweden, Denmark, UK 
SJG 427 3I 1177-1250 America & Europe Sweden, Denmark, UK 
SJG 404 3I 1226-1268 America & Europe Sweden, Denmark, UK 
SJG 749 2F 1230-1277 Middle East Sweden, Denmark, UK 
SJG 472 3I 1252-1280 America & Europe Sweden, Denmark, UK 
SJG 722 3I 1269-1285 America & Europe Sweden, Denmark, UK 
SJG 1137 3I 1282-1380 America & Europe Sweden, Denmark, UK 
SJG 978 2F 1283-1381 Middle East Sweden, Denmark, UK 
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The radiocarbon dating results suggest the possible co-existence of several M. leprae strains 
within the leprosarium (Table 29). Strains 3K and 3I in particular seem to have co-existed from the 
12th-14th centuries. Strain 2F seems to have also been present during and after the 13th century. In 
the absence of registers indicating the admission and death dates of leprosy sufferers, it is 
difficult to assess if the studied individuals were in contact with each other during their stay in the 
leprosarium. It is interesting to notice, however, that none of the individuals showed evidence of 
infection by several strains. Indeed, after arrival in the leprosarium, the leprosy sufferer would 
have been exposed to various strains of the pathogen for a prolonged period of time. During this 
exposure time, little is known regarding the spread of the strains. It has been suggested that the 
most contagious strain would spread to all patients, at the expense of less contagious ones. In a 
case in which several strains would present similar contagion capacity and virulence, a few co-
infection cases would still be expected. The results presented above do not seem to support this 
hypothesis. This might be explained by the long incubation time of leprosy. Indeed, stays in 
leprosariums have been reported to have lasted for several years before the death of the 
patients. As leprosy can take up to 20 years to develop, a leprosy patient would have been likely 
to die before the spread of a secondary infection. Nevertheless, the presence of various strains in 
the hospital in such a close time frame suggests two possible alternate explanations: the large 
geographical influence of the St. Jørgen leprosarium, and/or very rapid changes in the distribution 
of M. leprae strains between the 12th and the 14th centuries. 
The observation regarding the influence of St. Jørgen originates from the hypothesis that if all M. 
leprae strains were present homogeneously in southern Denmark without one strain 
overpowering the others, then infections with multiple strains should be found. The results of this 
study instead suggest that M. leprae strains might have had more localised distribution areas in 
which a single village may have been mainly affected by a specific strain. The major strain 
determination might have been related to the various living standards, levels of animal contact 
and/or integration into local village networks. The region of origin of the leprosy sufferers is 
difficult to determine using only the results of ancient DNA. In the case of the St. Jørgen 
cemetery, no leprosarium register was available as a historical source. Moreover, no isotopic 
studies have been performed to date. Mitochondrial DNA typing of the human genomes 
performed by colleagues showed no direct maternal relationship between the individuals, 
supporting the suggestion made using the M. leprae data. Therefore, the leprosy sufferers likely 
came not only from the nearby city of Odense, but also from remote villages.  
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The second hypothesis comes from the data suggesting that strain 2F was present only in the 
second part of the leprosarium’s active period as well as the impossibility of evaluating the 
contemporaneousness of the individuals studied here. If none of the recovered strains were 
present simultaneously, strains 3K, 3I and then, finally, 2F would have been present in the region 
between the 12th and 14th centuries. The succession of three strains in a 300 year time frame with 
the accepted M. leprae incubation period of 2-20 years would suggest that M. leprae strains were 
completely replaced in the region in less than 80 years, which equates to about two to three 
human generations. So far, there is not enough data available on the dynamics of M. leprae 
strains in medieval times to evaluate the plausibility of this calculation. It is worth noting, 
however, that the 80- year replacement time is not biologically impossible, especially given the 
efforts which were made to isolate leprosy sufferers within dedicated hospices. 
 
4.6.2 Medieval M. leprae genetic diversity in Northern Europe 
All the 16 ancient M. leprae genomes recovered varied from each other by at least one SNP 
(Supplementary Table 14) and clustered in various branches in the pathogen phylogeny. The St. 
Jørgen cemetery presents, therefore, the most genetically diverse collection of medieval M. 
leprae genomes from one locale studied to date. It also brings to light one genome typed as strain 
3K which had never previously been described in medieval Northern Europe. This suggests that 
the genetic diversity of M. leprae in southern 12th -14th century Denmark has likely been 
underestimated in the literature. In addition, not all individuals infected with the disease would 
have been sent to the leprosarium. Commonly, only persons who showed striking symptoms 
(such as disfiguration or the loss of fingers) were ostracized. Persons with mild symptoms were 
able to avoid marginalization by hiding those symptoms. Moreover, individuals who developed 
the more extreme forms of the disease might have died before being sent to specialized 
establishments. Therefore, the observed genetic diversity of M. leprae in the St. Jørgen individuals 
is itself likely an under-representation the overall genetic diversity of the pathogen in Northern 
Europe. While it is still impossible at present to accurately quantify the genetic diversity of 
medieval European M. leprae, it is likely to have been similar to the one observed today in 
countries where the disease is still endemic. 
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4.6.4 Spread of M. leprae strains into and out of Europe 
Strains 3I and 2F have been previously documented in medieval Northern Europe (Mendum et al. 
2014), although strain 3K has not yet been documented within that time frame. A few previous 
identifications of this strain in ancient remains exist, albeit in older samples (4th-5th century Egypt, 
7th century Hungary and 8th-9th century Turkey (Monot et al. 2009)). Its presence in 12th century 
Denmark highlights the wide distribution of the 3K strain in medieval times. Moreover, the 
ancient 3K clusters with modern-day 3K strains from China and New Caledonia. The branch 
containing 3K strains has been suggested as a separate branch (Branch 0) corresponding to a fifth 
M. leprae type (Schuenemann et al. 2013). These results seem to corroborate this hypothesis and 
support the very early branching point previously observed. Indeed, in this data, Branch 0 appears 
to be separate from the ancestral type 2 before its diversification into subtypes E, F, G and H. 
According to the evolutionary history of the pathogen as it is currently understood (see part 1.2), 
M. leprae type 3 likely derived from a type 2-related ancestor in Europe (Monot et al. 2009). 
Afterwards, type 3 strains probably evolved into 4 subtypes (I, J, K, and L) during the time in which 
they were spreading into Europe. Each of the four subtypes has been shown to be associated with 
human migrations out of Europe, with strain 3K being associated with eastward human 
migrations to Asia (Monot et al. 2009; Monot et al. 2005). The current geographical distribution of 
type 3K is consistent with this association, with the majority of 3K isolates originating from China 
and southwest Asia. In some respects, this view contradicts the phylogeny results from 
Schuenemann and colleagues as well as those from this study. Indeed, Branch 0 does not 
separate from the ancestral Branch 2, as would be expected when following the idea described 
above. On the contrary, Branch 2 seems to be as ancient as the other branches. The modern 
geographical repartition of M. leprae types and subtypes shows that the spread of leprosy 
followed human dispersals (Monot et al. 2009). Therefore, if strain 3K did not separate from an 
ancestral type 2 in Europe, it was likely brought into Europe along with a type 2 ancestor during 
successive human migration events. According to this data, the other type 3 strains seem to have 
evolved as has been suggested by Monot and colleagues. 
After spreading into Europe, strain 3K is believed to have migrated out of Europe towards Asia. 
This has been supported by the discovery of M. leprae 3K isolates from 7th-10th century Hungary 
and Turkey. The presence at a later time of 3K in Denmark suggests that the out-of-Europe 
migration of this strain was likely very progressive, following several centuries of human warfare 
and trade in this direction. This might also be the case for other type 3 strains (including 3L, which 
has not yet been found in ancient European remains). 
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The 3K and 3I types can still found to this day in the rare cases of European leprosy, in contrast to 
the 2F type. This observation is interesting because in the M. leprae genomes recovered, the 2F 
strain seemed to appear later than the type 3 strains. Not enough genomes were recovered to 
reliably establish the timespan of 2F’s presence. If confirmed, this trend would suggest that the 2F 
strain might have played a major role in the disappearance of leprosy from Europe. However, the 
absence of type 2F in the modern day could be due to the 20th century’s tremendous 
improvements in medical care and life quality. 
4.6.5 Outlook 
The results presented in this dissertation characterize medieval M. leprae as a genetically highly 
diverse bacteria with complex distribution patterns in southern Denmark. It is currently 
impossible to generalise the observations drawn from the St. Jørgen data, since it represents a 
very specific case (leprosarium hospital) and as the two other cemeteries did not yield positive 
results. Nevertheless, the high genetic diversity observed in southern Denmark should be used as 
an indication that isolated studies of a couple of cases from various periods and locations are 
likely to largely underestimate the genetic diversity of the pathogen in a specific area and time. It 
would be interesting to study other medieval leprosaria from Europe via the same method in 
order to evaluate the hypotheses drawn from this study and allow for some degree of 
generalisation. In addition, while this study only focussed on the causative agent of leprosy, the 
same approach might be applied to other ancient bacterial pathogens, such as M. tuberculosis. 
Indeed, other pathogens studied through ancient DNA methods are equally as likely to exhibit be 
underestimated in terms of their genetic diversity. 
The data presented in this study represent a first step towards understanding the etiology of 
leprosy in the late Middle-Ages. Combined with future data on the subject, this study might 
provide key information regarding the disappearance of the disease from medieval Europe, 
especially by allowing a direct comparison between ancient and modern European strains of the 
same type. Moreover, modern studies on leprosy would likely benefit from efforts made in this 
direction. Indeed, leprosy is still highly prevalent in some developing countries; about 200,000 
cases are still reported each year. Unravelling the reasons behind leprosy’s disappearance from 
Europe would certainly improve the chances of the eradication attempts made in countries where 
the disease is still endemic. 
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5 Summary 
Leprosy is an infectious disease mainly caused by the obligate intracellular pathogen 
Mycobacterium leprae (M. leprae). In Northern Europe, the disease reached its highest 
prevalence in the Middle-Ages, between the 11th and 15th centuries. It disappeared around the 
16th century before the introduction of modern medicine. Besides archaeological and medical 
studies, the direct recovery and analysis of medieval M. leprae genomes can greatly improve our 
understanding of the history and epidemiology of the disease. This thesis aims to analyse 
numerous medieval M. leprae genomes from Northern Europe at high genomic coverage using 
next-generation sequencing. Teeth from 140 human skeletal remains were collected from three 
cemeteries in Denmark and Germany (1000-1560 AD) in order to 1) screen the remains for M. 
leprae DNA with PCR, 2) use high-throughput sequencing to recover high-quality M. leprae 
genomes, 3) place the recovered genomes within the M. leprae phylogeny, and 4) investigate in-
silico the possible effects of the genomic variations. The St. Jørgen leprosarium in Denmark 
yielded the highest number of genetically confirmed leprosy cases ever reported from one 
cemetery (16 out of 34 specimens collected). None of the leprosy-positive DNA samples showed 
evidence of co-infection with tuberculosis. Of the 16 ancient M. leprae genomes obtained, 6 had 
complete high-coverage, while for the remaining 10 genomes, partial drafts were recovered. 
Strain SNP typing of the genomes showed the presence of strains 3I and 2F, already found in 
previous European medieval leprosy studies, and strain 3K, so far never described in medieval 
Northern Europe. The presence of 3K in late medieval Denmark changes the current hypothesis 
about the spread of this strain out of Europe towards China. The high quality of the genomic data 
allowed the construction of a new phylogenetic tree for M. leprae, which for the first time also 
included low-coverage genomes. Although the samples were obtained from one locale (St. 
Jørgen), the genomes all differed from each other and clustered in various branches. This finding 
indicates that medieval M. leprae genetic diversity has so far been greatly underestimated and 
suggests that it is likely to have been similar to the one observed today. The ancient type 3K 
grouped with the modern 3K strains from China and New Caledonia, confirming the existence of 
the recently described Branch 0. According to modern data, none of the 696 detected genetic 
variants seemed to be associated with a change in the virulence of the pathogen. However, the 
in-silico methods used to evaluate the variant effects are hampered by our current limited 
knowledge of protein expression and activity in M. leprae. Taken together, the results presented 
in this thesis draw a more detailed picture of the genetic diversity of medieval M. leprae and 
might contribute to the debate regarding both the disappearance of the disease from medieval 
Northern Europe and the current re-emergence of the disease in some developing countries. 
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6 Zusammenfassung 
Lepra ist eine chronische Infektionskrankheit, welche durch das obligat intrazelluläre Bakterium 
Mycobacterium leprae (M. leprae) ausgelöst wird. In Nordeuropa erreichte die Prävalenz der 
Krankheit im Mittelalter zwischen dem 11. und 15. Jahrhundert ihren Höhepunkt. Im 16. 
Jahrhundert verschwand die Krankheit weit vor der Einführung moderner Medizin. Neben 
archäologischen sowie medizinischen Studien kann die Isolierung und Analyse des 
mittelalterlichen M. leprae Genoms zum Verständnis der Geschichte sowie der Epidemiologie der 
Krankheit beitragen. Die vorliegende Arbeit hat die Analyse zahlreicher, gut abgedeckter 
mittelalterlicher M. leprae Genome aus Nordeuropa unter Verwendung von 
Hochdurchsatzsequenzierung zum Ziel. Im Laufe des Projektes wurden Zähne von insgesamt 140 
Individuen von drei unterschiedlichen mittelalterlichen Friedhöfen in Dänemark sowie 
Deutschland gesammelt (1000 – 1560 AD). Das Projekt umfasste folgende Arbeitsschritte: 1) Test 
auf M. leprae positive Proben mittels PCR, 2) Rekonstruktion möglichst gut abgedeckter M. leprae 
Genome unter Verwendung der Hochdurchsatzsequenzierung, 3) Einbindung der alten M. leprae 
Genome in einen phylogenetischen Baum, und 4) In silico-Modellierung der möglichen Effekte 
genomischer Variationen. Das St. Jørgen Leprosarium in Dänemark wies die höchste Anzahl 
genetisch bestätigter Lepra-Fälle auf, die bisher jemals mittels molekularbiologischer Methoden 
innerhalb eines Friedhofs nachgewiesen wurden (16 von 32 gesammelten Proben). Eine Ko-
Infektion mit Tuberkulose war in keiner der Lepra-positiven Proben genetisch zu bestätigen. 
Insgesamt konnten aus den 16 M. leprae positiven Proben sechs komplette Genome mit einer 
hohen Abdeckung sowie 10 Genome partiell rekonstruiert werden. Die Erregerstämme 3I und 2F, 
welche schon in anderen Publikationen für das mittelalterliche Nordeuropa beschrieben worden 
sind, wurden auch in den vorliegenden Proben mittels SNP-Typisierung identifiziert. Des Weiteren 
konnte ein bisher in Nordeuropa unbekannter Stamm (3K) beobachtet werden. Die Anwesenheit 
dieses Stammes im spätmittelalterlichen Dänemark verändert die bisher aufgestellte Hypothese 
über die Verbreitung des Stammes von Europa nach China. Die hohe Qualität der generierten 
Daten erlaubte die Erstellung eines phylogenetischen Baums für M. leprae, welcher erstmals nun 
auch Genome mit einer geringen Abdeckung beinhaltete. Obwohl die Proben aus einem engen 
geografischen Herkunftsraum stammten, unterschieden sich die Genome voneinander und 
konnten unterschiedlichen monophyletischen Gruppen zugeordnet werden. Der Befund weist 
darauf hin, dass die genetische Diversität von M. leprae im Mittelalter bisher stark unterschätzt 
worden ist und sie der heutigen Diversität moderner Stämme ähnelt. Der gefundene 
mittelalterliche Erregerstamm 3K fiel in dieselbe Gruppe wie die modernen 3K Stämmen aus 
China und Neukaledonien, was die Existenz der monophyletischen Gruppe 0 bestätigt. Eine im 
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Vergleich zu modernen Daten gesteigerte Virulenz des Pathogens konnte nicht nachgewiesen 
werden, da keine der 696 identifizierten Varianten auf eine solche Veränderung hinwiest. 
Nichtsdestotrotz sollte bemerkt werden, dass die verwendeten in-silico Methoden durch das 
fehlende Wissen über Proteinexpression sowie -aktivität in M. leprae limitiert sind. 
Zusammengefasst erweitert diese Arbeit unser Verständnis der genetischen Diversität der M. 
leprae Stämme im Mittelalter. Überdies tragen die gewonnenen Ergebnisse zu Debatten um das 
Verschwinden der Krankheit im 16. Jahrhundert aus Nordeuropa sowie um das Wiederauftreten 
der Krankheit in einigen Entwicklungsländern bei. 
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7 Résumé 
La lèpre est une maladie infectieuse dont l’agent principal est Mycobacterium leprae (M. leprae), 
une bactérie parasite intracellulaire. En Europe, la prévalence de atteint son paroxysme à la fin du 
Moyen-Age entre le 11ème et le 15ème siècle. Elle disparait ensuite entre le 15ème et le 16ème siècle, 
avant l’introduction de la médecine moderne. En complément des approches archéologiques et 
médicales, l’étude directe de génomes d’origine médiévale de M. leprae peut grandement 
améliorer notre compréhension de l’histoire et de l’épidémiologie de la maladie. Cette thèse a 
pour but d’analyser de nombreux génomes de M. leprae médiévaux avec une grande profondeur 
de séquençage en utilisant les nouvelles techniques de séquençage haut débit. 140 dents 
humaines provenant de trois cimetières d’Allemagne et du Danemark (1000-1560 ap. JC) ont été 
collectées et analysées afin de : 1) sélectionner via PCR les échantillons où l’ADN de M. leprae est 
préservé, 2) utiliser le séquençage haut-débit pour récupérer des génomes de M. leprae de haute 
qualité, 3) placer les génomes obtenus dans la phylogénie de M. leprae, et 4) étudier in-silico les 
effets possibles des variations génétiques. L’hôpital médiéval danois St. Jørgen, réservé aux 
lépreux, présente le plus grand nombre de cas de lèpre confirmés génétiquement pour un même 
endroit (16 génomes obtenus pour 34 individus testés). Aucun des échantillons positifs pour la 
lèpre ne présente de preuves de co-infection avec la tuberculose. Parmi les 16 génomes obtenus, 
6 ont pu être séquencés complètement et en profondeur. Pour les 10 génomes restants, seuls 
des assemblages incomplets ont pu être obtenus. L’analyse des variations génetiques montre la 
présence des souches 3I et 2F, déjà documentées dans d’autres populations médiévales en 
Europe, ainsi que de la souche 3K, dont c’est le premier cas identifié dans le nord de l’Europe 
avant le 16ème siècle. L’existence de la souche 3K au Danemark à la fin du Moyen-Age affine 
l’hypothèse existante concernant la migration de cette souche hors d’Europe vers la Chine. La 
haute qualité des donnés a permis de replacer tous les génomes dans la phylogénie de M. leprae, 
y compris les génomes incomplets. Malgré leur origine géographique commune (St. Jørgen), les 
génomes obtenus sont tous différents et se placent dans différentes branches. Ce résultat indique 
que la diversité génétique de M. leprae au Moyen-Age est certainement grandement sous-
estimée. L’ancien type 3K se place avec les souches 3K modernes de Chine et de Nouvelle-
Calédonie dans la branche 0 décrite récemment. D’après des données modernes, aucune des 696 
variations génétiques observées ne semble liée à un changement de virulence du pathogène. 
Cependant, le peu d’informations disponibles au sujet de l’expression et de l’activité des 
protéines chez M. leprae limite les méthodes de prédiction. Dans l’ensemble, les résultats 
présentés dans ce document permettent de mieux appréhender la diversité génétique de M. 
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leprae au Moyen Age, et pourront dans le futur contribuer à comprendre la disparition spontanée 
de la lèpre en Europe et sa réémergence actuelle dans certains pays en développement. 
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12 Appendices 
12.1 Supplementary material 
12.1.1 Lists of samples 
The archaeological and paleopathological data was provided by Dorthe Petersen and Jesper Boldsen. 
Disease status was based on observed disease-specific bone lesions. Undetermined status (und.) was 
used when the lesions observed were suggestive of a disease but not specific. When available, 
archaeological dating of the samples is provided. 
Supplementary Table 1: St Jørgen cemetery samples (Odense, Denmark) 
Thirty-four individuals from a leprosarium cemetery in use between 1270 and 1560 
 
,

 I 
 
Supplementary Table 2: Samples from the Rathausmarkt cemetery (Schleswig, Germany) 
Seventy-nine samples collected from the cemetery in use between 1000 and 1250 
Excavation ID Osteological sex Age Time period 
Leprosy 
status* 
Rhinomaxillary lesions TB status 
2 M 38-52 1070-1210 0 no + 
7 F 18-30 1070-1210 0 no Und. 
8 M 23-25 1070-1210 Und. yes Und. 
9 F 30-45 1070-1210 0 no 0 
20 F 16-18 1070-1210 Und. yes 0 
21 F 35-50 1070-1210 + yes + 
23 F 30-35 1070-1210 0 no Und. 
28 F 50-70 1070-1210 Und. yes Und. 
42 M 37-45 1070-1210 Und. yes + 
49 F 35-50 1070-1210 0 no + 
52 F 50-70 1070-1210 Und. yes Und. 
57 M 60-75 1070-1210 Und. yes + 
58 M 35-45 1070-1210 0 no nd 
60 M 35-50 1070-1210 + yes Und. 
70 M 35-45 1070-1210 Und. yes Und. 
73 F 38-53 1070-1210 0 no Und. 
78 F 40-50 1070-1210 Und. yes Und. 
80 M 28-35 1070-1210 Und. yes 0 
81 M 40-65 1070-1210 0 no + 
86 M 45-60 1070-1210 Und. yes Und. 
88 M 33-40 1070-1210 Und. no Und. 
90 F 55-65 1070-1210 0 no + 
91 M 16-18 1070-1210 0 no Und. 
92 M 30-45 1070-1210 Und. yes Und. 
94 M 28-33 1070-1210 Und. yes + 
95 M 47-60 1070-1210 0 no Und. 
100 F 18-20 1070-1210 0 no 0 
101 M 25-30 1070-1210 0 no Und. 
103 M 55-65 1070-1210 Und. yes + 
105 M 25-28 1070-1210 Und. yes Und. 
109 M 17-20 1070-1210 0 no Und. 
113 M 26-36 1070-1210 0 no Und. 
114 M 28-32 1070-1210 + yes + 
120 M 55-70 1070-1210 + yes + 
121 M 38-48 1070-1210 Und. yes nd 
125 F 40-50 1070-1210 Und. yes Und. 
131 F 50-70 1070-1210 0 no Und. 
133 M 45-60 1070-1210 Und. yes + 
134 3 55-70 1070-1210 Und. yes nd 
135 F 20-24 1070-1210 Und. yes 0 
137 M 26-32 1070-1210 0 no Und. 
139 F 45-55 1070-1210 Und. yes + 
140 M 19-21 1070-1210 + yes + 
142.1 M 21-25 1070-1210 Und. yes Und. 
146 M 40-60 1070-1210 Und. yes Und. 
155 M 20-30 1070-1210 Und. yes nd 
156 M 22-25 1070-1210 0 no 0 
158 F 18-20 1070-1210 0 no 0 
159 M 24-34 1070-1210 0 no Und. 
160 M 23-26 1070-1210 Und. yes 0 
163.9 F 30-70 1070-1210 0 no nd 
165 F 30-45 1070-1210 Und. yes Und. 
167 M 45-60 1070-1210 Und. yes 0 
170 M 22-26 1070-1210 0 no Und. 
171 M 30-45 1070-1210 Und. yes Und. 
172 F 27-35 1070-1210 Und. yes Und. 
173 F 23-25 1070-1210 Und. yes Und. 
178 M 40-70 1070-1210 0 no nd 
179 M 22-25 1070-1210 + yes Und. 
183 M 50-65 1070-1210 0 no Und. 
185 M 47-63 1070-1210 Und. yes + 
186 M 38-50 1070-1210 0 no Und. 
191 M 25-30 1070-1210 Und. no Und. 
,,,
 II 
 
 
  
193 M 22-25 1070-1210 0 no + 
195 M 25-40 1070-1210 Und. yes nd 
197 M 23-26 1070-1210 0 no Und. 
200 M 25-45 1070-1210 Und. yes Und. 
202 F 47-63 1070-1210 0 no + 
203 M 50-65 1070-1210 + yes Und. 
205 M 45-55 1070-1210 0 no + 
207 M 36-46 1070-1210 + yes Und. 
208 F 45-60 1070-1210 0 no + 
214 M 22-33 1070-1210 + yes Und. 
215 F 45-65 1070-1210 Und. yes + 
219 F 35-45 1070-1210 Und. yes Und. 
221 M 22-24 1070-1210 Und. no 0 
230 M 17-19 1070-1210 0 no Und. 
232 F 30-65 1070-1210 Und. yes Und. 
233 M 22-27 1070-1210 Und. yes 0 
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Supplementary Table 3: Samples from the Dagmargården cemetery (Ribe, Denmark) 
 
  
Excavation ID Osteological sex Age Time period Leprosy status Rhinomaxillary lesions TB status 
G17 M 25-30 1275-1536 0 no Und. 
G23 M 32-40 1275-1536 Und. no Und. 
G25A M 40-50 1275-1536 Und. no + 
G26 M 28-34 1275-1536 0 no + 
G35 M 50-60 1275-1536 Und. yes + 
G40 M 20-22 1275-1536 Und. yes + 
G43 M 30-40 1275-1536 0 no Und. 
G44 M 42-52 1275-1536 Und. yes + 
G48 M 32-40 1275-1536 Und. yes + 
G50 M 22-24 1275-1536 0 no Und. 
G56 M 38-48 1275-1536 Und. yes + 
G58 M 28-33 1275-1536 0 no 0 
G63 M 30-40 1275-1536 0 no Und. 
G69 M 28-34 1275-1536 + yes Und. 
G89 M 55-65 1275-1536 Und. yes + 
G99 M 24-28 1275-1536 Und. yes 0 
G100 M 20-23 1275-1536 Und. yes und. 
G108 M 24-26 1275-1536 0 no + 
G113 M 27-33 1275-1536 0 no + 
G117 M 23-26 1275-1536 Und. yes Und. 
G120 ? (child) 11-13 1275-1536 0 no + 
G131 M 23-25 1275-1536 0 no Und. 
G138 M 35-45 1275-1536 0 no + 
G159 M 30-38 1275-1536 0 no 0 
G160 M 35-43 1275-1536 0 no 0 
G176 M 37-47 1275-1536 0 no + 
G178 M 20-23 1275-1536 + yes Und. 
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12.1.2 List of enzymes, reagents and kits 
 
 
12.1.3 List of instruments 
 
 
 
 
Product Specificities Catalogue number Supplier 
AccuPrime pfx DNA amplification kit 200rxns 12344-024  Life Technologies 
Adapter Mix prepared according to (Meyer & Kircher 2010) 
Agilent DNA 1000 kit   5067-1504  Agilent technologies  
ATP 10mM P0756S  NEB 
Bleach 100%   
BSA   NEB 
BSM DNA Polymerase LF 1600U EP0691  Fermentas 
Buffer 2  B7002S6 NEB 
DMSO 100% D2650 Sigma-Aldrich 
dNTPs mix 
2.5mM 
each 
BIO-39053 Bioline 
dNTPs mix 
2.5mM 
each 
R1121 Fermentas 
EDTA pH8, 0.5M A4895.1000 Applichem 
Ethanol 96% T171. Roth 
EZ1 DNA Investigator Extraction Kit  952034 Qiagen 
Immolase DNA amplification kit 200U BIO-21046 Bioline 
Minelute PCR product purification kit 250 rxns  28006  Qiagen 
Quick ligation kit  M2200S  NEB 
T4 DNA Polymerase 750U M0203L NEB 
T4 Polynucleotide Kinase 2,500U  M0201L  NEB 
Thermopol Buffer  B9004S  NEB 
USER Enzyme 50U M550S NEB 
Water for molecular biology DNA-free W4502  Sigma-Aldrich 
Product Catalogue number / type Supplier 
Mixer Mill MM 200 20.746.0001 Retsch 
EZ1 DNA Investigator 9016387 Qiagen 
PCR-hood with UV-lights UVC/T-M-AR Grant 
Table centrifuge 5424 Eppendorf 
Dremel 3000 Dremel 
pipets 2.5μL, 200μL, 500μL - Eppendorf 
Thermomixer type TS1 Biometra 
9,
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12.1.4 List of consumables necessary for working with ancient DNA 
Common molecular biology consumables are not listed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consumables Catalogue number Supplier 
Lab coveralls Through central IKMB stock  
Latex gloves Through central IKMB stock 
Hair nets Through central IKMB stock  
Surgical masks Through central IKMB stock  
Rubber shoes Through central IKMB stock  
Aluminium foils   
DNA free pipet tips with filters (20μL, 200μL, 
1000μL) 
70.760.592, 70.760.213 Sarstedt 
Parafilm RO/H95.1.1 Th. Geyer 
DNA LoBing tubes (1.0 and 2.0mL) EPP/0030108051, 
EPP/0030108.078 
Th. Geyer 
9,,
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12.1.5 List of online databases, tools and software 
 
 
 
 
Sofware/databank 
Version/ 
Distribution/ 
Last access date 
Usage Reference 
Geneious R7 PCR product alignment (Drummond et al. 
2010) 
BLAST / PCR product control (Altschul et al. 1990) 
NCBI June 2016 / / 
Mycobrowser June 2016 / (Kapopoulou et al. 
2011) 
MAUVE  Multiple alignments (Darling et al. 2010) 
R  Statistical tests  
SNPeff  Variant annotation (Cingolani et al. 2012) 
Uniprot June 2016 / (Bateman et al. 2015) 
OrthoDB June 2016 / (Kriventseva et al. 
2015) 
EMBL QuickGo Browser June 2016 GO annotations (Binns et al. 2009) 
CFSSP June 2016 Secondary structure 
prediction 
(Chou & Fasman 
1974b; Chou & Fasman 
1974a) 
Jpred version 4 Secondary structure 
prediction 
(Drozdetskiy et al. 
2015) 
SOPMA June 2016 Secondary structure 
prediction 
(Combet et al. 2000) 
ExPASy June 2016 Resource portal (Artimo et al. 2012) 
ProtScale June 2016 Protein profiling (Janin 1979; Gasteiger 
E., Hoogland C., 
Gattiker A., Duvaud S., 
Wilkins M.R., Appel 
R.D. 2005; Grantham 
1974; Kyte & Doolittle 
1982) 
ProtParam / Protein characterisation (Gasteiger E., 
Hoogland C., Gattiker 
A., Duvaud S., Wilkins 
M.R., Appel R.D. 2005) 
SOSUI / Hydrophobic protein 
characterisation 
(Hirokawa et al. 1998) 
EAGER / Analysis of NGS data (Peltzer et al. 2016) 
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12.1.6 Oligonucleotide sequences and references 
Supplementary Table 4: Oligonucleotides primers for the PCR screening 
 
 
 
 
 
 
 
Target reference Primer name Reference 
Human mtDNA mt1 (Lee et al. 2012) 
mt2 (Lee et al. 2012) 
M. leprae LP1 - LP2 (Matheson et al. 2009) 
LP11 - LP12 (Schuenemann et al. 2013) 
M. tuberculosis IS3 - IS4 (Matheson et al. 2009) 
lns1 - Ins2 (Matheson et al. 2009) 
Tb-A - Tb-B (Matheson et al. 2009) 
Tb-C - Tb-D (Matheson et al. 2009) 
F-F2 - R-R3 (Matheson et al. 2009) 
IS1081-F2 - IS1081-F3 (Matheson et al. 2009) 
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12.2 Supplementary methods 
12.2.1 PCR screening target sequences 
Supplementary Table 5: List of PCR screening target sequences 
M. tuberculosis target sequences were not used because no clear PCR results could be 
obtained. They are therefore not shown 
 
12.2.2 MinElute purification of DNA fragments 
During the library preparation, indexing and amplification, several purifications are performed 
with MinElute columns from Qiagen. The manufacturer’s protocol was used with the following 
modifications: 
Reagent volumes: 
 
 
 
 
 
Target 
reference 
Primer pair Target sequence (5’ -> 3’) 
Human 
mtDNA 
mt1 CTCCACCATTAGCACCCAAAGCTAAGATTCTAATTTAAACTATTCTCTGT 
TCTTTCATGGGGAAGCAGATTTGGGTACCACCCAAGTATTGACTCACCCA 
TCAACAACCGCTATGTATTTCGTACATTACTGCCAGCCACCATGAATAT 
GTACGGTACCATAAATACTTGACCACCTGTAGTA 
mt2 GCCAGCCACCATGAATATGTACGGTACCATAAATACTTGACCACCTGTAG 
TACATAAAAACCCAATCCACATCAAAACCCCCTCCCCATGCTTACAAGCA 
AGTACAGCAATCAACCCTCAACTATCACACATCAACTGCAACTCCAAAGC 
M. leprae 
LP1 - LP2 TTGCATGTCATGGCCTTGAGGTGTCGGCGTGGTCAATGTGGCCGCACCTG 
AACAGGCACGTCCCCGTGCACGGTATAACTATTCGCACCTGATGTTATCC 
CTTGCACCATTTCTGCCGCTGGTATCGGTG 
LP11 - LP12 GAGCTGCTCACCACAACAAATAGAACAAATAGGGTGGTTCTGCTTCTATT 
GCACCGACCAACAGTAGGAATGGTCTGAACAGGTGCAACGGATACACA 
M. 
tuberculosis 
IS3 - IS4  
lns1 - Ins2  
Tb-A - Tb-B  
Tb-C - Tb-D  
F-F2 - R-R3  
IS1081-F2 - IS1081-F3  
PB Buffer 5X volume of DNA to purify 
(250µL for library preparation, 500µL for PCR purification) 
PE Buffer 700µL per column 
EB Buffer To fit next step requirements 
(18µL or 20µL for library preparation, 50µL for PCR purification) 
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Number of columns per sample: 
During library preparation, each sample was purified in one Minelute column. During the 
purification of the indexing and amplification PCRs products, all 4 PCR products of each sample 
were purified together in a column to optimize DNA recovery. To that end, 2 PCR products were 
mixed and bound to the column together and the process was repeated for the 2 remaining PCR 
products before washing the membrane with PE buffer. 
 
Centrifugation steps 
 
 
 
 
12.2.3 Sex determination from NGS data 
Ideally, a female individual displays two copies of the X chromosome and a male individual one 
copy of X and one copy of Y. Therefore, comparing the coverage statistics on the X and Y 
chromosomes should provide a good proxy for sex determination. The statistics tables provided 
by the Module δ include the coverage of the reference as well as the read depth on that 
reference. The EAGER pipeline and Modules α to δ were used to obtain statistics about the 
coverage of the human X and Y chromosomes. The read depths on the two references were 
compared and a Y/X ratio was calculated for each sample. The number of unique reads mapping 
to each chromosome was used as a reference for the interpretation of the ratios, as lower 
number of reads would suggest less reliable mapping results. The Y/X ratio is expected to vary 
between 0 (Y coverage null, female individual) and 1 (Y = X situation, male individual) 
  
DNA binding 30s at max. speed 
Washing with PE buffer 30s at max. speed 
Dry-clean to remove PE traces 60s at max. speed 
DNA elution in EB buffer 60s at max. speed 
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12.2.4 Bioinformatic pipeline descriptions 
The raw reads were processed using the EAGER (Efficient Algorithms for Ancient Human Genome 
Reconstruction, A. Peltzer, (Peltzer et al. 2016)) pipeline, which incorporates published 
bioinformatic softwares into a framework optimized for aDNA analysis. The softwares are 
implemented in the form of modules that can be called and set-up independently through a 
graphical user interface (GUI). The pipeline allows each module to be performed one after the 
other by automatically converting or preparing the output files from one step to fit input files 
requirements for the next step (see Supplementary Figure 1) 
 
 
Supplementary Figure 1: Schematic overview of the EAGER analysis pipeline 
The modules are listed in the blue text boxes, their function and references in the grey and 
transparent boxes, respectively. Modules with grey text were not used in this study, either 
because they were not relevant with our datasets or because they were replaced by manual 
analysis or self-made scripts. On the left part of the figure, an overview of the types of files 
used and created by each module is provided. Temporary files are not listed. 
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Module 1 and 2: 
Module 1 and 2 only consists in setting the memory requirements in the EAGER GUI before 
starting the analyses. All pooled sequencing runs were processed through the EAGER pipeline 
with 8 cores and 42GB of memory requirements. The single-lane re-sequencing runs were 
processed with 8 cores and 64BG of memory. 
 
Module 3: FastQC analysis 
FastQC is a software application that provides a quality control report from a high-throughput 
sequencing file, allowing the sequencing issues or problems in the library preparation to be 
identified. It was developed by the Babraham Bioinformatics institute. For each quality control 
performed (see list below), FastQC provides warning or error notifications if the data present any 
problematic feature: 
 
Basic statistics Includes the basic information about the input file, the 
number of raw sequences as well as average GC content and 
sequence length 
Per base sequence quality WhiskerBox plot of the sequencing quality (as provided by the 
sequencer) for each position along the read. 
Per tile sequence quality Heatmap representing the sequencing quality on the flowcell 
during the sequencing run cycles. 
Per base GC content Plot representing the GC content distribution in the sequences 
and builds a model normal distribution. 
Per sequence quality scores Plot representing the average read quality distribution in the 
sequences. 
Per base sequence content Plots of the A, T, C and G proportions for each position along 
the reads 
Per base N content Sequencers usually write an N in a sequence when unable to 
confidently call a conventional base. This module plots the 
percentage of Ns for each position along the reads. 
Sequence length distribution Plots the read length (bp) distribution in the sequencing run 
Sequence duplication levels A subset of the sequencing file is used to estimate the number 
of copies for each read. 
Overrepresented sequences Uses the duplication level results to display the sequences 
that are present in unexpectedly high number 
Adapter content Cumulative percentage plot of the percentage of sequencing 
library adapters along the sequencing reads. 
Kmer content Relative enrichment of 7-mers along the sequencing reads 
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For each raw reads file received from the sequencing platform, the FastQC controls were 
performed and the warnings manually evaluated to identify possible problems and 
inconsistencies with aDNA characteristics. 
Module 4: Merging 
This module is a java script written by A. Peltzer that combines adapter clipping, merging of 
overlapping forward and reverse reads and quality filtering of the merged reads. 
Since aDNA molecules are usually short, it is common to find belonging to the library or the 
indexing adapters at the ends of the reads sequences. If not removed, those adapter sequences 
might impair the rest of the analysis. Consequently, the first step of most aDNA analysis pipelines 
is to trim the end of the raw reads where the adapter is starting. All the adapter sequences used 
during library preparation and indexing are listed in a configuration file, allowing the Clip and 
Merge module to find them in the sequencing reads. The Clip and Merge module also integrates 
an option to merge forward and reverse reads from paired-end datasets. First, overlapping 
regions are detected in the forward and reverse FastQ files and when the overlap length is 
greater than the chosen threshold (10bp by default) the two reads are merged. Afterwards, new 
quality scores are calculated for the merged reads, taking into account the forward and reverse 
reads qualities. Clip and Merge writes an output file with merged reads marked as M while non-
merged read keep their F or R identifiers. Finally, the module trims the reads when the base call is 
lower than 20 (which correspond to a 99% accuracy on Illumina sequencers) and filters out reads 
shorter than 25bp. A single compressed FastQ file is written in the output directory. The 
temporary outputs from the individual steps are removed. 
 
Module 6: Mapping 
Most DNA sequencing projects fall into the “re-sequencing” category, in which a reference 
genome is used as model to assemble the reads obtained by NGS sequencing. In aDNA studies, 
the use of a reference is even more important since reads are commonly short and genome 
coverage usually incomplete. The 3rd module of the EAGER pipeline performs the mapping of the 
sequencing reads after Module 1 (or 2 when relevant) to a chosen reference in Fasta format. Both 
linear and circular reference genomes are supported. Several published alignment methods are 
implemented into the module and can be selected by the user. By default, the mapping is done by 
BWA (Burrows-Wheeler Alignment tool), an algorithm that combines local sequence alignments 
from Smith and Waterman (1981) and the Burrows-Wheeler data compression transform 
;,9
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(Burrows and Wheeler, 1994). The EAGER pipeline GUI allows setting up some parameters for the 
alignment (See list below). With BWA, the beginning nucleotides of each read (called seed) are 
used as an anchor point to align the read. Once an alignment is found between the seed and the 
reference genome, the algorithm progressively extends the alignment until the overall alignment 
quality drops (Li and Durbin, 2010; BWA sourceforge website, 2015). BWA alignment output 
format is SAM (Sequence Alignment/Map), a file format that gathers the reads alignments to the 
reference as well as information about the number of mismatches, gaps, mapping quality and 
specificity (existence of multiple hits). 
For the analyses performed in this project, BWA mapping with default settings was used. 
The mapping results saved in SAM format require large data storage capacity. In addition, non-
mapping reads usually form the bulk of the dataset for shotgun sequencing files, since only 
abokljut 1% of the reads are expected to hit the target species. To avoid rapid congestion of 
storing spaces, EAGER can perform several tools from the SAMtools package (Han et al. 2009; 
Peltzer et al. 2016). By default, EAGER sorts the mapping reads by position along the reference 
and compresses the file into a binary BAM file. In addition, EAGER was set up to remove non-
mapping reads from the SAM file before conversion to BAM. 
 
Module 8: Duplicate removal 
Reads present in high copy numbers artificially increase the read depth while decreasing the 
library complexity. Moreover, variant calling might be biased in highly-duplicated regions as the 
confidence score for variants takes into account the number of reads covering the position of 
interest (Isakov et al, 2013; Walker 2009). This module was developed by A. Petlzer to remove 
sequences originating from PCR amplification during the NGS library preparation. In this regard, 
two approaches are usually available: 1) keep only one read from all the reads starting and ending 
at the same position (Kircher ref) or 2) keep only one read from all reads with a similar sequence. 
The duplicates removal module uses a combination of both approaches. The algorithm isolates 
EAGER option for 
BWA 
description default value 
-n maximal number of mismatches allowed in the 
alignment 
5 
-l seed length (bp) 
BWA includes an option to set the number of allowed 
mismatches in the seed alignment itself (2 per default). 
In EAGER this parameter cannot be modified 
32 
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reads that start at the same position and display strong similarity (find numbers), and keeps only 
the read with the highest overall quality. 
 
Module 10: MapDamage 
Ancient DNA typically displays short fragments length (Green et al. 2009) and increased 
occurrence of G and T towards the 3’-end and 5’-end of the DNA strand, respectively (Briggs et al. 
2007; Overballe-Petersen et al. 2012; Brotherton et al. 2007; Lamers et al. 2009). Therefore, the 
study of the DNA fragments molecular characteristics (damage patterns) can differentiate 
between a young DNA sample (below 20yo) and an ancient DNA sample (Molak & Ho 2011; 
Krause 2010; Sawyer et al. 2012), although the molecular age of the sample cannot be used as a 
proxy to estimate the actual sample age (Sawyer et al. 2012). For a specific reference sequence, 
length distribution of the mapping reads as well as frequencies of misincorporated bases can be 
calculated (Briggs et al. 2007; Ginolhac et al. 2011; Jonsson et al. 2013). 
The MapDamage module, which applies the mapDamage2.0 alogrithms, uses the BAM file 
generated by the Duplicate removal module as well as the corresponding FASTA reference 
genome (Ginolhac et al. 2011; Jonsson et al. 2013). First of all, the BAM file is analysed to record 
the lenght of DNA fragments (in base pairs) and the number of occurrences of A, C, T or G bases 
for each position along each. Then, the reference sequence is used in comparison to compute the 
frequency at which a specific position on the end of the DNA fragment displays either a C->T or G-
>A misincorporation. Finally, as DNA fragment length is not constant and since the 
misincorporation frequencies are expected to increase towards the 3’- and 5’- ends, only the 
frequencies over the first and last 25bp are given as output. 
 
Module 12 and 13: SNP calling and filtering with GATK 
Modules 13 and 13 implement the Genome Analysis Toolkit (Van der Auwera et al. 2013; 
McKenna et al. 2010) software to call and filter the genetic variants seen on the sequenced 
genome compared to the reference genome. Two genotyping algorithms are available: 
UnifiedGenotyper (by default) and HaplotypeCaller. In Module 12 several advanced options are 
available to set up a SNP reference, the organism ploidy, the confidence of the variant calling or 
the type of output. In module 13 minimum coverage and base quality can be set to filter the 
variants called. All variants that do not fulfil those criteria will be marked as LowQuality. 
;9,
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12.2.5 Internally designed scripts 
Several scripts were designed internally by M. Nutsua (aDNA research group, IKMB, Kiel). Those 
modules are identifies with greek letters. 
 
Module α: 
Module α is a python script developed to create user-specific hard links to allow each user to 
work on the raw file from their own directories. It requires a text file containing the names of the 
sample-specific raw data directories and the location of the output hard links. The EAGER pipeline 
can then be started directly from the hard links. 
 
Module β: 
EAGER does not separate output files depending on the reference genome. However, it skips 
modules when the outputs for the modules are present in the output directory. In case multiple 
references were used for a single sample, there was a risk of false completion of the analysis since 
all output files could already present from a run with a different reference genome. To allow the 
analysis of several species per sample with the EAGER pipeline, Module β was created to move to 
reference-specific outputs to subfolders within the sample output directory. 
 
Module δ: 
Module δ was designed to combine and replace Modules 8, 10 and 15 of the EAGER pipeline. It 
consists in a perl script that gathers statistics from each step of the EAGER pipeline into a general 
CSV textfile with all the samples. This file can then be easily imported into Microsoft Excel or R for 
sample comparison. This module was designed to access the EAGER output files also from 
reference-specific subfolders, when necessary. The statistics include the number of reads after 
each step (raw reads, clip and merged reads, mapping reads, unique mapping reads) as well as 
coverage and read depth information for the reference genome used. It also offers the possibility 
to compute the coverage and read depth information over a target subset of the reference 
genome. 
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12.3 Supplementary results 
12.3.1 PCR results per sample for each primer pair 
A sample is considered positive for a primer pair when both PCR replicates yielded products of the 
expected length and sequence. In green are highlighted samples with a positive results for all the 
primers tested for a species .In red are shown the samples were results were negative or 
inconclusive. For every PCR batch, the extraction blanks and PCR blanks showed no signs of 
contamination. 
 
Supplementary Table 6: PCR screening results detailed for each sample 
 Human 
mtDNA 
Mycobacterium 
leprae 
Mycobacterium tuberculosis 
Sample mt1 mt2 LP 1-2 LP 11-12 TB1 TB2 TB3 TB4 TB5 TB6 TB7 
Ribe G100 + + - - + - - - - - - 
Ribe G108 - + - - - - - - - - + 
Ribe G113 + + - - + - - - - - - 
Ribe G117 + + - - - - - - - - - 
Ribe G120 + + + - + - - - - - - 
Ribe G131 + + + - + - - - - - - 
Ribe G138 - + - - + - - - - - + 
Ribe G159 + + + - + - - + - - - 
Ribe G160 + + - - - - - - - - - 
Ribe G17 - + - - + - - - - - - 
Ribe G176 - + - - - - - + - - - 
Ribe G178 + + - - - - - - - - - 
Ribe G23 + + + - - - - + - - - 
Ribe G25A - + - - - - - - - - - 
Ribe G26 + + + - - - - - - - + 
Ribe G35 - + - - - - - + - - - 
Ribe G40 + + + - - - - - - - - 
Ribe G43 + + - - - - - - - - - 
Ribe G44 + + - - - - - - - - - 
Ribe G48 + + + - - - - - - - - 
Ribe G50 + + - - - - - - - - - 
Ribe G56 + + - - - - - + - - - 
Ribe G58 + + - - - - - - - - - 
Ribe G63 + + - - - - - + - - - 
Ribe G69 + + - - - - - - - - - 
Ribe G89 - + + - + - - - - - + 
Ribe G99 + + - - + - - - - - - 
Rathausmarkt 100 + + - - - - - - - - - 
Rathausmarkt 101 + + - - - - - - - - + 
Rathausmarkt 103 + + - - - - - - - - - 
Rathausmarkt 105 - + - - - - - - - - - 
Rathausmarkt 109 - + - - - - - - - - - 
Rathausmarkt 113 + + - - - - - - - - - 
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Rathausmarkt 114 - + - - - - - - - - - 
Rathausmarkt 120 + + - - - - - - - - - 
Rathausmarkt 121 + + - - - - - - - - + 
Rathausmarkt 125 - + - - - - - - - - - 
Rathausmarkt 131 + + - - - - - + - - - 
Rathausmarkt 133 - + - - - - - - - - - 
Rathausmarkt 134 - + - - - - - - - - - 
Rathausmarkt 135 - + - - - - - - - - - 
Rathausmarkt 137 - + - - - - - - - - - 
Rathausmarkt 139 + + - - - - - + - - - 
Rathausmarkt 140 - + - - - - - - - - - 
Rathausmarkt 142.1 + + - - - - - - - - - 
Rathausmarkt 146 - + - - - - - - - - - 
Rathausmarkt 155 - - - - - - - - - - - 
Rathausmarkt 156 - + - - - - - - - - - 
Rathausmarkt 158 - + - - - - - - - - - 
Rathausmarkt 159 - - - - - - - - - - - 
Rathausmarkt 160 - + - - - - - + - - - 
Rathausmarkt 163.9 - - - - - - - - - - - 
Rathausmarkt 165 - + - - - - - - - - - 
Rathausmarkt 167 + + - - - - - - - - - 
Rathausmarkt 170 - + - - - - - - - - - 
Rathausmarkt 171 - + - - - - - + - - - 
Rathausmarkt 172 + + - - - - - - - - - 
Rathausmarkt 173 + + - - - - - + - - - 
Rathausmarkt 178 - + - - - - - - - - - 
Rathausmarkt 179 - + - - - - - - - - - 
Rathausmarkt 183 - - - - - - - - - - - 
Rathausmarkt 185 + + - - - - - - - - - 
Rathausmarkt 186 - + - - - - - - - - - 
Rathausmarkt 191 - + - - - - - - - - - 
Rathausmarkt 193 - + - - - - - - - - - 
Rathausmarkt 195 - + - - - - - - - - - 
Rathausmarkt 197 - + - - - - - - - - + 
Rathausmarkt 2 + + - - - - - - - - - 
Rathausmarkt 20 + + - - - - - - - - - 
Rathausmarkt 200 - + - - - - - - - - - 
Rathausmarkt 202 - + - - - - - - - - - 
Rathausmarkt 203 - + - - - - - - - - - 
Rathausmarkt 205 - + - - - - - - - - - 
Rathausmarkt 207 - + - - - - - - - - + 
Rathausmarkt 208 - + - - - - - - - - - 
Rathausmarkt 21 - + - - - - - - - - - 
Rathausmarkt 214 - + - - - - - - - - - 
Rathausmarkt 215 - + - - - - - - - - - 
Rathausmarkt 219 + + - - - - - - - - - 
Rathausmarkt 221 - + - - - - - - - - - 
Rathausmarkt 23 - + - - - - - - - - - 
Rathausmarkt 230 + + - - - - - - - - + 
Rathausmarkt 232 - + - - - - - - - - - 
Rathausmarkt 233 - + - - - - - - - - - 
Rathausmarkt 28 - + - - - - - - - - + 
Rathausmarkt 42 - - - - - - - - - - - 
Rathausmarkt 49 + + - - - - - - - - - 
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Rathausmarkt 52 - - - - - - - - - - + 
Rathausmarkt 57 - - - - - - - - - - + 
Rathausmarkt 58 - - - - - - - - - - + 
Rathausmarkt 60 - + - - - - - - - - - 
Rathausmarkt 7 + + - - - - - - - - - 
Rathausmarkt 70 - - - - - - - - - - - 
Rathausmarkt 73 - - - - - - - - - - - 
Rathausmarkt 78 + + - - - - - - - - - 
Rathausmarkt 8 + + - - - - - - - - - 
Rathausmarkt 80 + + - - - - - - - - - 
Rathausmarkt 81 - + - - - - - - - - - 
Rathausmarkt 86 - + - - - - - - - - - 
Rathausmarkt 88 - + - - - - - - - - - 
Rathausmarkt 9 + + - - - - - - - - - 
Rathausmarkt 90 + + - - - - - - - - + 
Rathausmarkt 91 + + - - - - - - - - - 
Rathausmarkt 92 - - - - - - - - - - - 
Rathausmarkt 94 + + - - - - - - - - - 
Rathausmarkt 95 - + - - - - - - - - - 
SJG 022 + + + + - - - - - - - 
SJG 035 + + - - - - - - - - - 
SJG 1035 + + - - - - - - - - - 
SJG 1087 + + - - - - - - - - - 
SJG 1137 + + + + - - - - - - - 
SJG 1159 + + - - - - - - - - - 
SJG 131 + + + + - - - - - - - 
SJG 149 - + + + - - - - - - - 
SJG 189 + + + + - - - - - - - 
SJG 271 + + - - - - - - - - - 
SJG 289 + + + + - - - + - - - 
SJG 295 + + - - - - - - - - - 
SJG 379 + + - - - - - - - - - 
SJG 404 + + + + - - - - - - - 
SJG 427 + + + + - - - + + - - 
SJG 472 + + + + - - - - - - - 
SJG 507 + + + + - - - - - - - 
SJG 533 + + + + - - - - - - - 
SJG 604 + + - - - - - - - - - 
SJG 611 + - + + - - - - - - - 
SJG 658 + + + + - - - - - - - 
SJG 711 + + - - - - - - - - - 
SJG 718 + + - - - - - - - - - 
SJG 722 + + + + - - - - - - - 
SJG 749 + + + + - - - - - - - 
SJG 792 + + - - - - - - - - - 
SJG 846 + + - - - - - - - - - 
SJG 859 + + - - - - - + - - - 
SJG 872 + + - - - - - - - - - 
SJG 887 + + - - - - - - - - - 
SJG 928 + + - - - - - - - - - 
SJG 947 + + - - - - - - - - - 
SJG 978 + + + + - - - + - - - 
SJG 988 + + - - - - - - - - - 
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12.3.2 Library quality control results 
Supplementary Table 7: Library quantification and quality control results 
 
  
Sample Library 
type 
Concentration 
(ng/μL) 
Fragment length 
(bp) 
Peak size 
(bp) 
Adapters 
chimeras 
SJG 022 non UDG 
UDG 
1.91 
18.67 
170-250 
170-250 
231 
203 
low 
no 
SJG 131 non UDG 
UDG 
1.63 
50.70 
150-250 
150-250 
220 
205 
no 
no 
SJG 149 non UDG 
UDG 
39.65 
15.08 
170-250 
170-250 
207 
196 
low 
no 
SJG 189 non UDG 
UDG 
21.0 
11.50 
150-250 
170-250 
205 
197 
low 
low 
SJG 289 non UDG 
UDG 
28.5 
34,96 
170-250 
150-250 
175 
198 
low 
no 
SJG 404 non UDG 
UDG 
7.27 
35.42 
150-250 
170-250 
206 
202 
no 
low 
SJG 427 non UDG 
UDG 
41.5 
28.96 
150-300 
150-250 
203 
217 
low 
no 
SJG 472 non UDG 
UDG 
41.5 
14.66 
170-250 
170-250 
203 
206 
low 
no 
SJG 507 non UDG 
UDG 
26.9 
7.53 
150-300 
170-250 
221 
208 
low 
low 
SJG 533 non UDG 
UDG 
12.0 
20.5 
150-250 
150-250 
224 
215 
no 
no 
SJG 611 non UDG 
UDG 
9.65 
6.06 
170-250 
150-250 
197 
198 
no 
no 
SJG 658 non UDG 
UDG 
2.47 
7.02 
150-250 
170-250 
212 
208 
no 
no 
SJG 722 non UDG 
UDG 
12.8 
11.09 
150-250 
170-250 
192 
197 
no 
no 
SJG 749 non UDG 
UDG 
63.6 
64.0 
150-250 
150-250 
213 
210 
low 
low 
SJG 978 non UDG 
UDG 
29.7 
18.2 
150-250 
150-250 
230 
238 
no 
no 
SJG 1137 non UDG 
UDG 
8.53 
25.27 
150-250 
170-250 
207 
217 
no 
no 
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12.3.2 FastQC results 
Supplementary Table 8: Summary tables of the FastQC results 
Legend: 
 
Non-UDG-treated library UDG-treated library 
Sample read 1 2 3 4 5 6 7 8 9 10 11 12 read 1 2 3 4 5 6 7 8 9 10 11 12 
SJG 022 
F             F             
R             R             
SJG 131 
F             F             
R             R             
SJG 149 
F             F             
R             R             
SJG 189 
F             F             
R             R             
SJG 289 
F             F             
R             R             
SJG 404 
F             F             
R             R             
SJG 427 
F             F             
R             R             
SJG 472 
F             F             
R             R             
SJG 507 
F             F             
R             R             
SJG 533 
F             F             
R             R             
SJG 611 
F             F             
R             R             
SJG 658K 
F             F             
R             R             
SJG 722 
F             F             
R             R             
SJG 749 
F             F             
R             R             
SJG 978 
F             F             
R             R             
SJG 1137 
F             F             
R             R             
1- Basic statistics 
2- Per base sequence quality 
3- Per tile sequence quality 
4- Per sequence quality score 
5- Per base sequence content 
6- Per base GC content 
7- Per base N content 
8- Sequence length distribution 
9- Sequence duplication levels 
10- Overrepresented sequences 
11- Adapter content 
12- K-mer content 
Green: Passed 
Orange: Warning 
Red: Failed 
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12.3.3 Mapping results for the non-UDG-treated sequencing libraries 
Supplementary Table 9: Mapping of the pooled-sequenced samples against the human mtDNA 
Sample 
Number of raw 
reads (millions) 
Reads mapping 
(%) 
Reference 1X 
covered 
(%) 
Reference 4X 
covered 
(%) 
SJG 022 7.1 0.02 98.42 73.09 
SJG 131 17.6 0.01 99.56 82.27 
SJG 149 8.0 0.01 97.46 71.52 
SJG 189 6.4 0.03 69.99 71.52 
SJG 289 17.1 0.01 99.79 92.32 
SJG 404 21.6 0.01 99.23 80.99 
SJG 427 28.9 0.01 99.92 99.19 
SJG 472 9.7 0.02 99.44 92.14 
SJG 507 19.6 0.01 99.96 99.95 
SJG 533 28.4 0.03 99.97 99.94 
SJG 611 27.2 0.01 99.78 95.18 
SJG 658 38.8 0.01 99.79 92.32 
SJG 722 25.0 0.02 99.91 99.79 
SJG 749 22.8 0.04 99.99 99.91 
SJG 978 22.3 0.01 99.57 88.30 
SJG 1137 9.6 0.01 98.32 66.32 
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13.3.4 Manual review of specificity of the genomic targets 
The figures below gather the MAUVE GUI views of each of the regions chosen as species-specific 
targets within the multiple alignment. For visibility, only M. leprae, M lepromatosis, M. 
tuberculosis, M. bovis and Y. pestis lines are shown. 
 
 
Supplementary Figure 2: Genomic synteny in the target regions for M. leprae 
Up: target 1, Down: Target 2 
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Supplementary Figure 3: Genomic synteny in the target regions for M. lepromatosis 
Up: target 1, Down: Target 2 
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Supplementary Figure 4: Genomic synteny in the target regions for M. tuberculosis 
Up: target 1, Down: Target 2 
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Supplementary Figure 5: Genomic synteny in the target regions for M. bovis 
Up: target 1, Down: Target 2 
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12.3.5 Mapping statistics on the species-specific target regions 
Supplementary Table 12: Y. pestis targets coverage statistics 
Samples 
Read Depth 
Whole reference Targets 
All Covered bases All Covered bases 
SJG 022 0.0020 1.8256 0.0004 1.3542 
SJG 131 0.0091 3.7127 0.0073 3.7134 
SJG 149 0.0030 2.3890 0.0022 2.4689 
SJG 189 0.0026 1.6058 0.0016 1.3843 
SJG 289 0.0064 3.4016 0.0058 3.7840 
SJG 404 0.0091 4.7609 0.0080 5.3561 
SJG 427 0.0097 5.2885 0.0066 5.1432 
SJG 472 0.0031 2.6223 0.0029 2.9697 
SJG 507 0.0036 2.4256 0.0023 2.3705 
SJG 533 0.0070 4.2372 0.0051 4.5644 
SJG 611 0.0152 5.9490 0.0119 5.9263 
SJG 658 0.0159 6.7292 0.0114 7.0229 
SJG 722 0.0106 5.1263 0.0072 4.7481 
SJG 749 0.0127 5.8911 0.0101 6.6945 
SJG 978 0.0168 5.9223 0.0124 5.6450 
SJG 1137 0.0058 3.1993 0.0046 2.9189 
Statistics computed from the UDG-treated sequencing reads obtained during the 1
st
 
sequencing phase (1/8
th
 of lane per sample) 
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Supplementary Table 13: M. tuberculosis targets coverage statistics 
Statistics computed from the pooled datasets of all the available UDG-treated sequencing 
reads 
 
Samples 
M. leprae M. tuberculosis 
Whole reference Whole reference Targets 
1X 4X 1X 4X 1X 4X 
SJG 022 0.3190 0.0086 0.0016 0.0003 0 0 
SJG 131 0.2104 0.0022 0.0027 0.0006 0 0 
SJG 149 0.0616 0.0070 0.0021 0.0007 0 0 
SJG 189 0.6970 0.2055 0.0028 0.0007 0 0 
SJG 289 0.0765 0.0008 0.0034 0.0007 0.0013 0.0014 
SJG 404 0.9999 0.9979 0.0167 0.0045 0.0014 0.0004 
SJG 427 1.0000 1.0000 0.0623 0.0478 0.0090 0.0017 
SJG 472 0.9966 0.9060 0.0150 0.0048 0.0014 0.0013 
SJG 507 1.0000 1.0000 0.0330 0.0169 0.0020 0.0019 
SJG 533 0.9999 0.9998 0.0082 0.0022 0.0018 0.0010 
SJG 611 0.1102 0.0007 0.0026 0.0005 0 0 
SJG 658 0.5462 0.1894 0.0187 0.0053 0.0014 0.0013 
SJG 722 1.0000 0.9999 0.0218 0.0080 0.0016 0.0014 
SJG 749 1.0000 1.0000 0.0145 0.0056 0.0016 0.0013 
SJG 978 0.9867 0.8081 0.0376 0.0246 0.0015 0.0014 
SJG 1137 0.8732 0.3175 0.0127 0.0042 0.0016 0.0014 
XXXI
  
XXX 
1
2
.3
.6
 V
ar
ia
n
t 
ca
lli
n
g 
an
d
 a
n
n
o
ta
ti
o
n
 
Su
p
p
le
m
en
ta
ry
 T
a
b
le
 1
4:
 L
is
t 
of
 a
ll 
th
e 
an
n
ot
ed
 v
a
ri
a
n
ts
 
Position 
Referee (TN) 
G022 
G131 
G149 
G189 
G289 
G404 
G427 
G472 
G507 
G533 
G611 
G658 
G722 
G749 
G978 
G1137 
SNP effect 
Impact 
Gene ID 
Gene Name  
(if not ID) 
G
en
e 
p
ro
d
u
ct
 
Fu
ti
o
n
al
 
ca
te
go
ry
 
(M
yc
o
b
ro
w
se
r)
 
A
A
 
ch
an
ge
 
P
ro
t.
 
le
n
gh
t 
(b
p
) 
7
3
 
A
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
A
 
 
G
 
m
is
s.
 
M
o
d
er
. 
M
L0
0
01
 
d
n
aA
 
ch
ro
m
o
so
m
al
 r
ep
lic
at
io
n
 in
it
ia
to
r 
In
f.
 p
at
h
w
ay
s 
Se
r2
5
G
l
y 
5
2
1 
8
8
3 
G
 
 
 
 
 
 
A
 
A
 
A
 
G
 
A
 
 
 
A
 
G
 
G
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
0
01
 
d
n
aA
 
ch
ro
m
o
so
m
al
 r
ep
lic
at
io
n
 in
it
ia
to
r 
In
f.
 p
at
h
w
ay
s 
G
ly
2
95
S
er
 
5
2
1 
4
1
8
0 
G
 
 
 
 
 
 
G
 
A
 
 
G
 
G
 
 
 
G
 
G
 
 
 
sy
n
. 
Lo
w
 
M
L0
0
02
 
d
n
aN
 
D
N
A
 p
o
ly
m
er
as
e 
III
 s
u
b
u
n
it
 D
n
aN
 
In
f.
 p
at
h
w
ay
s 
Se
r3
0
0
S
er
 
3
8
5 
7
6
1
4 
C
 
 
 
 
 
 
T 
T 
T 
C
 
T 
 
 
T 
C
 
 
 
sy
n
. 
Lo
w
 
M
L0
0
06
 
gy
rA
 
D
N
A
 g
yr
as
e 
su
b
u
n
it
 A
 
In
f.
 p
at
h
w
ay
s 
A
rg
9
9
A
r
g 
1
2
4
9 
7
8
7
0 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
A
 
 
 
G
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
0
06
 
gy
rA
 
D
N
A
 g
yr
as
e 
su
b
u
n
it
 A
 
In
f.
 p
at
h
w
ay
s 
G
lu
1
8
5L
ys
 
1
2
4
9 
8
4
5
3 
T 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
 
C
 
C
 
C
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
0
06
 
gy
rA
 
D
N
A
 g
yr
as
e 
su
b
u
n
it
 A
 
In
f.
 p
at
h
w
ay
s 
Le
u
3
7
9
P
ro
 
1
2
4
9 
1
2
2
2
0
 
A
 
 
 
 
 
 
A
 
A
 
A
 
A
 
A
 
 
 
A
 
A
 
a 
 
sy
n
. 
Lo
w
 
M
LP
0
00
0
0
1 
ile
T 
tR
N
A
-I
le
 a
n
ti
co
d
o
n
 G
A
T 
St
ab
le
 R
N
A
s 
A
la
9
A
la
 
2
4
 
1
3
9
0
7
 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
T 
T 
 
m
is
s.
 
M
o
d
er
. 
M
L0
0
09
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
P
ro
4
5
Se
r 
6
3
 
1
4
2
2
2
 
C
 
 
 
 
 
 
 
 
 
t 
 
 
 
 
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
4
2
2
6
 
C
 
 
 
 
 
 
 
t 
 
T 
 
 
 
 
c 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
4
6
1
0
 
T 
 
 
 
 
 
t 
T 
 
T 
T 
 
 
T 
T 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
7
1
5
7
 
G
 
 
 
 
 
 
G
 
G
 
 
A
 
G
 
 
 
G
 
G
 
G
 
 
sy
n
. 
Lo
w
 
M
L0
0
13
 
 
tr
an
sm
em
b
ra
n
e 
p
ro
te
in
 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
Le
u
8
7
Le
u
 
9
3
 
1
7
6
6
9
 
C
 
 
 
 
 
 
 
C
 
 
T 
C
 
 
 
C
 
C
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
0
14
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
7
9
2
8
 
G
 
 
 
 
 
 
 
a 
 
G
 
 
 
 
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
0
14
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
9
0
7
1
 
G
 
 
 
 
 
 
a 
A
 
A
 
G
 
G
 
 
 
A
 
G
 
 
 
d
o
w
n
st
. 4
8
b
. 
M
o
d
i
f.
 
M
L0
0
15
 
tr
p
G
 
an
th
ra
n
ila
te
 s
yn
th
as
e 
co
m
p
o
n
en
t 
II 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
 
2
3
3 
XXXII
  
XXXI 
1
9
0
7
1
 
G
 
 
 
 
 
 
a 
A
 
A
 
G
 
G
 
 
 
A
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
0
16
 
p
kn
B
 
se
ri
n
e/
th
re
o
n
in
e 
p
ro
te
in
 k
in
as
e 
B
 
R
eg
. p
ro
te
in
s 
A
la
6
0
0
V
al
 
6
2
2 
2
8
9
3
8
 
C
 
 
 
 
 
 
 
c 
 
C
 
C
 
 
 
C
 
C
 
t 
 
d
o
w
n
st
. 1
6
b
. 
M
o
d
i
f.
 
M
L0
0
25
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
 
9
7
 
2
8
9
3
8
 
C
 
 
 
 
 
 
 
c 
 
C
 
C
 
 
 
C
 
C
 
t 
 
m
is
s.
 
M
o
d
er
. 
M
L0
0
24
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
Le
u
1
7
P
h
e 
8
4
 
4
4
8
3
2
 
G
 
 
 
 
 
 
a 
A
 
A
 
G
 
G
 
 
 
A
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
0
37
 
ec
cD
2 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
4
5
4
0
7
 
C
 
 
 
 
 
 
 
C
 
 
T 
C
 
 
 
C
 
C
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
0
38
 
ec
cE
2 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
4
8
1
9
6
 
G
 
 
 
 
 
 
a 
A
 
A
 
G
 
G
 
 
 
A
 
G
 
 
A
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
0
39
 
ec
cA
2 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
5
2
0
8
4
 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
T 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
0
42
 
ec
cE
1 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
Th
r3
1
Ile
 
4
6
7 
5
2
0
8
4
 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
T 
 
 
d
o
w
n
st
. 8
8
b
. 
M
o
d
i
f.
 
M
L0
0
41
 
m
yc
P
1 
se
cr
et
ed
 p
ro
te
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
 
4
4
7 
5
2
8
5
1
 
T 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
 
C
 
C
 
 
C
 
m
is
s.
 
M
o
d
er
. 
M
L0
0
42
 
ec
cE
1 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
Tr
p
2
8
7
A
rg
 
4
6
7 
6
1
4
2
5
 
A
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
G
 
G
 
G
 
G
 
G
 
m
is
s.
 
M
o
d
er
. 
M
L0
0
49
 
es
xA
 
6
 k
D
a 
ea
rl
y 
se
cr
et
o
ry
 a
n
ti
ge
n
ic
 t
ar
ge
t 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
M
et
9
0
T
h
r 
9
5
 
6
1
5
3
0
 
C
 
 
 
 
 
 
T 
T 
T 
T 
T 
 
 
T 
T 
T 
 
m
is
s.
 
M
o
d
er
. 
M
L0
0
49
 
es
xA
 
6
 k
D
a 
ea
rl
y 
se
cr
et
o
ry
 a
n
ti
ge
n
ic
 t
ar
ge
t 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
A
rg
5
5
G
l
n
 
9
5
 
7
1
6
8
7
 
G
 
 
 
 
 
 
 
G
 
 
A
 
 
 
 
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
0
57
 
es
p
G
1 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
7
1
7
2
1
 
G
 
 
 
 
 
 
 
 
 
g 
 
 
 
 
t 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
0
57
 
es
p
G
1 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
7
1
7
2
2
 
T 
 
 
 
 
 
 
 
 
t 
 
 
 
 
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
0
57
 
es
p
G
1 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
7
1
7
3
9
 
G
 
 
 
 
 
 
 
 
 
A
 
 
 
 
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
0
57
 
es
p
G
1 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
7
3
0
9
0
 
A
 
 
 
 
 
 
 
 
 
a 
 
 
 
 
A
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
0
58
 
es
p
E 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
7
3
0
9
4
 
T 
 
 
 
 
 
 
t 
 
t 
t 
 
 
 
t 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
0
58
 
es
p
E 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
7
7
8
6
4
 
T 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
C
 
C
 
C
 
C
 
 
sy
n
. 
Lo
w
 
M
L0
0
61
 
gl
tB
 
fe
rr
ed
o
xi
n
-d
ep
en
d
an
t 
gl
u
ta
m
at
e 
sy
n
th
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
G
ly
5
2G
l
y 
1
5
2
7 
8
5
6
3
0
 
T 
 
 
 
 
 
T 
T 
 
T 
T 
 
 
T 
T 
C
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
0
63
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
8
6
8
5
1
 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
T 
C
 
 
 
sy
n
. 
Lo
w
 
M
L0
0
65
 
et
h
A
 
m
o
n
o
o
xy
ge
n
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
G
ly
5
7G
l
y 
4
9
4 
9
4
3
1
4
 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
 
G
 
A
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
0
73
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
G
ly
7
5
Se
r 
3
4
4 
XXXIII
  
XXXII 
1
0
0
5
7
4
 
A
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
A
 
 
 
d
o
w
n
st
. 7
4
b
. 
M
o
d
i
f.
 
M
L0
0
81
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
 
 
1
0
0
5
7
4
 
A
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
A
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
0
80
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
1
6
2
2
5
 
C
 
 
 
 
 
 
T 
T 
T 
C
 
T 
 
T 
T 
C
 
C
 
 
sy
n
. 
Lo
w
 
M
L0
0
93
 
M
L0
0
9
3
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
G
ly
2
85
G
ly
 
6
4
3 
1
2
2
4
8
5
 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
G
 
 
 
C
 
C
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
0
98
 
fb
p
D
 
se
cr
et
ed
 M
PB
5
1
/M
P
T5
1
 a
n
ti
ge
n
 
Li
p
id
 m
et
ab
o
lis
m
 
A
la
5
9
G
l
y 
3
0
1 
1
5
6
5
5
6
 
G
 
 
 
 
 
 
G
 
G
 
G
 
A
 
G
 
 
 
G
 
G
 
 
 
sy
n
. 
Lo
w
 
M
L0
1
16
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
Ile
4
5
8
Il
e 
6
5
4 
1
5
6
9
4
8
 
C
 
 
 
 
T 
 
T 
T 
T 
C
 
T 
T 
 
T 
C
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
1
18
 
 
o
xi
d
o
re
d
u
ct
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
V
al
3
28
Il
e 
6
5
4 
1
6
5
1
5
2
 
C
 
 
 
 
 
 
 
C
 
c 
C
 
C
 
 
 
C
 
C
 
C
 
 
sy
n
. 
Lo
w
 
M
LP
0
00
0
6
 
ar
gU
 
tR
N
A
-A
rg
 
St
ab
le
 R
N
A
s 
P
ro
2
P
ro
 
2
3
 
1
6
5
1
5
2
 
C
 
 
 
 
 
 
 
C
 
c 
C
 
C
 
 
 
C
 
C
 
C
 
 
d
o
w
n
st
.2
5
 b
. 
M
o
d
i
f.
 
M
LP
0
00
0
5
 
se
rT
 
tR
N
A
-S
er
 
St
ab
le
 R
N
A
s 
 
2
3
 
1
6
5
1
9
5
 
A
 
 
 
 
 
 
g 
a 
a 
A
 
A
 
 
g 
a 
A
 
a 
g 
m
is
s.
 
M
o
d
er
. 
M
LP
0
00
0
6
 
ar
gU
 
tR
N
A
-A
rg
 
St
ab
le
 R
N
A
s 
A
rg
1
7
G
l
y 
2
3
 
1
6
5
1
9
5
 
A
 
 
 
 
 
 
g 
a 
a 
A
 
A
 
 
g 
a 
A
 
a 
g 
d
o
w
n
st
. 6
8
b
. 
M
o
d
i
f.
 
M
LP
0
00
0
5
 
se
rT
 
tR
N
A
-S
er
 
St
ab
le
 R
N
A
s 
 
2
3
 
1
6
8
0
7
9
 
A
 
 
 
 
 
 
A
 
A
 
 
G
 
A
 
 
 
A
 
A
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
1
25
 
 
gl
yc
o
sy
l t
ra
n
sf
er
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
Ty
r1
6
1
C
ys
 
4
3
8 
1
9
3
8
4
8
 
C
 
 
 
 
T 
 
T 
T 
T 
C
 
T 
 
T 
T 
C
 
 
 
u
p
st
. 9
6
b
. 
M
o
d
i
f.
 
M
L0
1
38
 
fa
d
D
2
8
 
ac
yl
-C
o
A
 s
yn
th
et
as
e 
Li
p
id
 m
et
ab
o
lis
m
 
 
5
8
0 
1
9
3
8
4
8
 
C
 
 
 
 
T 
 
T 
T 
T 
C
 
T 
 
T 
T 
C
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
0
2
4
4
0
 
A
 
 
 
 
 
 
A
 
A
 
 
a 
A
 
 
 
A
 
A
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
1
41
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
Le
u
4
1
P
r
o
 
8
4
 
2
0
2
4
4
1
 
G
 
 
 
 
 
 
G
 
G
 
 
g 
G
 
 
 
G
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
1
41
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
Le
u
4
1
P
h
e 
8
4
 
2
0
2
4
4
3
 
G
 
 
 
 
 
 
G
 
G
 
 
g 
G
 
 
 
G
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
1
41
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
Se
r4
0
P
h
e 
8
4
 
2
2
7
0
7
7
 
A
 
 
 
 
 
 
g 
G
 
G
 
A
 
A
 
 
 
G
 
A
 
 
 
sy
n
. 
Lo
w
 
M
L0
1
62
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
H
is
7
0
H
i
s 
9
2
 
2
3
3
8
9
3
 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
A
 
 
 
G
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
1
67
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
4
3
8
6
0
 
G
 
 
 
 
 
 
G
 
G
 
T 
G
 
G
 
 
 
G
 
G
 
 
 
sy
n
. 
Lo
w
 
M
L0
1
76
 
p
ep
D
 
se
ri
n
e 
p
ro
te
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
G
ly
2
69
G
ly
 
3
8
2 
2
5
0
8
3
7
 
C
 
 
 
 
 
 
C
 
C
 
 
T 
C
 
 
 
C
 
C
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
1
85
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
Th
r2
0
6
Il
e 
3
4
2 
2
5
3
6
2
3
 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
T 
T 
 
sy
n
. 
Lo
w
 
M
L0
1
87
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
V
al
3
22
V
al
 
3
5
3 
XXXIV
  
XXXIII 
2
6
1
7
4
4
 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
C
 
T 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
1
95
 
M
L0
1
9
5
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
6
4
5
0
1
 
A
 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
 
C
 
C
 
C
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
1
97
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
9
8
5
7
2
 
A
 
 
 
 
G
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
G
 
 
sy
n
. 
Lo
w
 
M
L0
2
27
 
M
L0
2
2
7
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
V
al
1
9
V
a
l 
1
5
8 
2
9
8
5
7
2
 
A
 
 
 
 
G
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
G
 
 
d
o
w
n
st
. 5
6
b
. 
M
o
d
i
f.
 
M
L0
2
26
 
fo
lK
 
p
yr
o
p
h
o
sp
h
o
ki
n
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
 
1
9
2 
3
0
5
5
8
5
 
G
 
 
 
 
 
 
 
G
 
G
 
G
 
A
 
 
 
G
 
G
 
G
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
2
34
 
ls
r2
 
ls
r2
 p
ro
te
in
 p
re
cu
rs
o
r 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
G
ly
7
3G
l
u
 
1
1
2 
3
0
5
6
5
4
 
C
 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
 
C
 
T 
C
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
2
34
 
ls
r2
 
ls
r2
 p
ro
te
in
 p
re
cu
rs
o
r 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
Th
r9
6
Ile
 
1
1
2 
3
1
3
3
6
1
 
A
 
 
 
 
G
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
G
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
2
38
 
m
et
S 
m
et
h
io
n
yl
-t
R
N
A
 s
yn
th
et
as
e 
In
f.
 p
at
h
w
ay
s 
Le
u
1
5
4
P
ro
 
5
3
7 
3
2
6
1
4
0
 
T 
 
 
 
 
 
T 
T 
 
T 
T 
 
 
T 
T 
t 
 
m
is
s.
 
M
o
d
er
. 
M
LP
0
00
0
0
9 
gl
n
T 
tR
N
A
-G
ln
 a
n
ti
co
d
o
n
 T
TG
 
St
ab
le
 R
N
A
s 
Th
r2
2
A
l
a 
2
3
 
3
2
8
6
0
4
 
G
 
 
 
 
 
 
a 
A
 
A
 
G
 
G
 
 
 
A
 
G
 
G
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
2
52
 
m
fd
 
tr
an
sc
ri
p
ti
o
n
-r
ep
ai
r 
co
u
p
lin
g 
fa
ct
o
r 
In
f.
 p
at
h
w
ay
s 
A
sp
1
80
A
sn
 
1
2
2
4 
3
3
0
1
2
5
 
G
 
 
 
 
 
 
A
 
A
 
A
 
A
 
A
 
 
 
A
 
G
 
G
 
A
 
m
is
s.
 
M
o
d
er
. 
M
L0
2
52
 
m
fd
 
tr
an
sc
ri
p
ti
o
n
-r
ep
ai
r 
co
u
p
lin
g 
fa
ct
o
r 
In
f.
 p
at
h
w
ay
s 
A
la
6
8
7
T
h
r 
1
2
2
4 
3
3
0
4
7
8
 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
 
G
 
G
 
g 
 
sy
n
. 
Lo
w
 
M
L0
2
52
 
m
fd
 
tr
an
sc
ri
p
ti
o
n
-r
ep
ai
r 
co
u
p
lin
g 
fa
ct
o
r 
In
f.
 p
at
h
w
ay
s 
Le
u
8
0
4
L
eu
 
1
2
2
4 
3
3
0
9
1
2
 
A
 
 
 
 
 
 
A
 
A
 
 
G
 
A
 
 
 
A
 
A
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
2
52
 
m
fd
 
tr
an
sc
ri
p
ti
o
n
-r
ep
ai
r 
co
u
p
lin
g 
fa
ct
o
r 
In
f.
 p
at
h
w
ay
s 
H
is
9
4
9
A
rg
 
1
2
2
4 
3
3
6
2
6
6
 
T 
 
 
 
 
 
T 
T 
 
C
 
T 
 
 
T 
T 
 
 
sy
n
. 
Lo
w
 
M
L0
2
57
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
A
la
1
5
4
A
la
 
1
6
7 
3
3
6
2
6
6
 
T 
 
 
 
 
 
T 
T 
 
C
 
T 
 
 
T 
T 
 
 
u
p
st
. 3
9
b
. 
M
o
d
i
f.
 
M
L0
2
58
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
 
 
3
4
7
3
8
5
 
T 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
 
C
 
C
 
C
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
2
66
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
3
4
7
3
8
5
 
T 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
 
C
 
C
 
C
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
2
66
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
3
4
9
7
4
7
 
G
 
 
 
 
 
 
 
G
 
 
A
 
G
 
 
 
G
 
G
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
3
6
5
4
1
1
 
A
 
 
 
 
 
 
G
 
G
 
G
 
A
 
G
 
 
 
G
 
A
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
2
83
 
 
ca
ti
o
n
-e
ff
lu
x 
tr
an
sp
o
rt
er
 c
o
m
p
o
n
en
t 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
Ly
s1
66
G
lu
 
2
6
8 
3
6
5
5
4
0
 
G
 
 
 
 
 
 
G
 
G
 
 
T 
G
 
 
 
G
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
2
83
 
 
ca
ti
o
n
-e
ff
lu
x 
tr
an
sp
o
rt
er
 c
o
m
p
o
n
en
t 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
V
al
2
09
L
eu
 
2
6
8 
3
7
3
0
5
9
 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
T 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
3
8
3
5
9
9
 
C
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
G
 
G
 
G
 
G
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
3
01
 
m
u
tT
3 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
XXXV
  
XXXIV 
3
8
3
5
9
9
 
C
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
G
 
G
 
G
 
G
 
 
d
o
w
n
st
.:
 
5
7
b
. 
M
o
d
i
f.
 
M
L0
3
00
 
th
iE
 
th
ia
m
in
e-
p
h
o
sp
h
at
e 
p
yr
o
p
h
o
sp
h
o
ry
la
se
 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
 
7
0
8 
3
8
4
3
9
2
 
C
 
 
 
 
 
 
 
 
 
c 
 
 
 
 
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
3
02
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
3
8
4
3
9
3
 
G
 
 
 
 
 
 
 
 
 
c 
 
 
 
 
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
3
02
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
3
9
3
0
4
3
 
G
 
 
 
 
 
 
G
 
G
 
 
A
 
G
 
 
 
G
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
3
06
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
3
9
6
0
5
9
 
G
 
 
 
 
 
 
 
G
 
G
 
T 
G
 
 
 
G
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
3
09
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
4
0
5
6
7
3
 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
C
 
c 
 
sy
n
. 
Lo
w
 
M
L0
3
17
 
gr
o
EL
2 
6
5
 k
D
a 
ch
ap
er
o
n
in
 2
 
V
ir
u
le
e,
 
d
et
o
xi
fi
ca
ti
o
n
, 
ad
ap
ta
ti
o
n
 
G
ly
5
2G
l
y 
5
4
2 
4
0
8
0
6
3
 
A
 
 
 
 
 
 
A
 
A
 
 
a 
A
 
 
 
A
 
A
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
4
0
8
0
6
8
 
A
 
 
 
 
 
 
A
 
A
 
 
c 
A
 
 
 
A
 
A
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
4
0
8
0
7
2
 
C
 
 
 
 
 
 
C
 
C
 
 
A
 
C
 
 
 
C
 
C
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
4
1
6
9
7
2
 
C
 
 
 
 
 
 
T 
T 
T 
C
 
C
 
 
 
T 
C
 
 
T 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
3
27
 
es
xS
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
4
1
7
3
4
0
 
C
 
 
 
 
 
 
C
 
C
 
T 
C
 
C
 
 
 
C
 
C
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
3
28
 
P
P
E 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
4
3
6
2
1
7
 
T 
 
 
 
 
 
T 
T 
 
C
 
T 
 
 
T 
T 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
3
54
 
ilv
X 
ac
et
o
h
yd
ro
xy
ac
id
 s
yn
th
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
 
5
1
6 
4
5
1
4
9
8
 
C
 
 
 
 
 
 
C
 
C
 
 
T 
C
 
 
 
C
 
C
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
3
57
 
fa
d
E2
6 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
4
5
9
5
4
5
 
G
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
T 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
3
67
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
4
7
4
0
7
1
 
G
 
 
 
C
 
 
 
G
 
G
 
 
G
 
G
 
 
 
G
 
G
 
G
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
3
81
 
gr
o
EL
1 
6
0
 k
D
a 
ch
ap
er
o
n
in
 1
 
V
ir
u
le
e,
 
d
et
o
xi
fi
ca
ti
o
n
, 
ad
ap
ta
ti
o
n
 
V
al
1
72
Il
e 
5
3
7 
4
8
1
4
7
6
 
A
 
G
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
G
 
 
G
 
G
 
G
 
G
 
sy
n
. 
Lo
w
 
M
L0
3
87
 
gu
aB
2 
in
o
si
n
e 
5
'-
m
o
n
o
p
h
o
sp
h
at
e 
d
eh
yd
ro
ge
n
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
Le
u
2
7
2
L
eu
 
5
2
9 
4
8
5
1
3
8
 
T 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
C
 
C
 
C
 
C
 
C
 
m
is
s.
 
M
o
d
er
. 
M
L0
3
89
 
ch
o
D
 
ch
o
le
st
er
o
l o
xi
d
as
e 
p
re
cu
rs
o
r 
Li
p
id
 m
et
ab
o
lis
m
 
Le
u
5
6
3
P
ro
 
5
6
9 
4
9
4
6
7
4
 
T 
G
 
 
 
G
 
 
G
 
G
 
G
 
G
 
G
 
G
 
 
G
 
G
 
G
 
G
 
m
is
s.
 
M
o
d
er
. 
M
L0
3
97
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
G
lu
3
5
8
A
sp
 
6
0
2 
5
0
8
4
8
1
 
T 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
C
 
C
 
C
 
C
 
C
 
m
is
s.
 
M
o
d
er
. 
M
L0
4
10
 
P
E3
 
P
E-
fa
m
ily
 p
ro
te
in
 
P
E/
P
P
E 
V
al
5
2A
l
a 
4
0
8 
5
0
9
0
6
5
 
G
 
 
 
 
 
 
G
 
G
 
 
A
 
G
 
 
 
G
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
4
11
 
 
se
ri
n
e-
ri
ch
 a
n
ti
ge
n
 p
ro
te
in
 
P
E/
P
P
E 
G
ly
1
04
A
sp
 
4
0
8 
5
0
9
1
7
8
 
G
 
 
 
 
 
 
G
 
G
 
 
A
 
G
 
 
 
G
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
4
11
 
 
se
ri
n
e-
ri
ch
 a
n
ti
ge
n
 p
ro
te
in
 
P
E/
P
P
E 
A
sp
1
42
A
sn
 
4
0
8 
XXXVI
  
XXXV 
5
0
9
3
2
5
 
C
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
G
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
4
11
 
 
se
ri
n
e-
ri
ch
 a
n
ti
ge
n
 p
ro
te
in
 
P
E/
P
P
E 
.H
is
1
9
1
A
sp
 
4
0
8 
5
0
9
6
6
2
 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
 
G
 
G
 
A
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
4
11
 
 
se
ri
n
e-
ri
ch
 a
n
ti
ge
n
 p
ro
te
in
 
P
E/
P
P
E 
G
ly
3
03
A
sp
 
4
0
8 
5
0
9
6
7
3
 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
 
G
 
A
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
4
11
 
 
se
ri
n
e-
ri
ch
 a
n
ti
ge
n
 p
ro
te
in
 
P
E/
P
P
E 
V
al
3
07
M
et
 
4
0
8 
5
0
9
6
7
4
 
T 
 
 
 
 
 
T 
T 
 
C
 
T 
 
 
T 
T 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
4
11
 
 
se
ri
n
e-
ri
ch
 a
n
ti
ge
n
 p
ro
te
in
 
P
E/
P
P
E 
V
al
3
07
A
la
 
4
0
8 
5
0
9
8
5
1
 
G
 
 
 
 
 
 
G
 
G
 
G
 
T 
G
 
 
 
G
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
4
11
 
 
se
ri
n
e-
ri
ch
 a
n
ti
ge
n
 p
ro
te
in
 
P
E/
P
P
E 
G
ly
3
66
V
al
 
4
0
8 
5
2
3
3
6
6
 
G
 
 
 
 
 
 
 
 
 
a 
 
 
 
 
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
5
2
3
8
1
0
 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
T 
T 
 
m
is
s.
 
M
o
d
er
. 
M
L0
4
24
 
b
cp
 
b
ac
te
ri
o
fe
rr
it
in
 
co
m
ig
ra
to
ry
 
an
ti
o
xi
d
an
t 
V
ir
u
le
e,
 
d
et
o
xi
fi
ca
ti
o
n
, 
ad
ap
ta
ti
o
n
 
C
ys
16
0
T
yr
 
1
6
1 
5
3
3
4
0
3
 
A
 
 
 
 
G
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
G
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
4
33
 
fa
d
D
3
5
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
5
3
7
5
0
3
 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
 
G
 
T 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
4
37
 
ac
cA
1 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
5
5
8
2
5
4
 
C
 
 
 
 
 
 
 
C
 
 
C
 
A
 
 
 
C
 
C
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
4
68
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
 
2
6
1 
5
6
3
7
9
6
 
G
 
 
 
 
 
 
G
 
G
 
 
C
 
G
 
 
 
G
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
4
66
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
G
lu
5
5A
s
p
 
3
0
1 
5
6
4
0
2
9
 
A
 
 
 
 
 
 
A
 
a 
 
A
 
A
 
 
 
A
 
A
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
4
66
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
A
sp
1
33
G
ly
 
3
0
1 
5
7
8
4
7
2
 
C
 
 
 
 
 
 
 
 
 
C
 
 
 
 
 
A
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
4
76
 
sp
eE
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
5
7
8
4
7
6
 
A
 
 
 
 
 
 
 
A
 
 
A
 
 
 
 
 
C
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
4
76
 
sp
eE
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
6
0
1
4
0
4
 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
T 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
4
76
 
sp
eE
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
6
0
3
3
8
6
 
A
 
 
 
 
 
 
 
A
 
 
G
 
A
 
 
 
A
 
A
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
4
76
 
sp
eE
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
6
0
4
3
2
5
 
T 
 
 
 
C
 
 
C
 
C
 
C
 
T 
C
 
 
 
C
 
T 
 
C
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
4
98
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
6
1
4
6
0
6
 
A
 
 
 
 
 
 
A
 
A
 
A
 
a 
A
 
 
 
A
 
A
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
6
1
4
6
0
7
 
A
 
 
 
 
 
 
A
 
A
 
A
 
a 
A
 
 
 
A
 
A
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
6
1
4
6
1
0
 
G
 
 
 
 
 
 
G
 
G
 
G
 
g 
G
 
 
 
G
 
G
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
6
3
7
1
8
5
 
C
 
 
 
 
 
 
C
 
C
 
 
T 
C
 
 
 
C
 
C
 
C
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
2
54
 
ad
i 
am
in
o
 a
ci
d
 d
ec
ar
b
o
xy
la
se
 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
Th
r8
4
8
Il
e 
9
5
0 
XXXVII
  
XXXVI 
6
3
7
5
3
5
 
G
 
 
 
 
 
 
G
 
G
 
 
T 
G
 
 
 
G
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
5
25
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
A
rg
1
5
Le
u
 
5
8
 
6
3
7
5
3
5
 
G
 
 
 
 
 
 
G
 
G
 
 
T 
G
 
 
 
G
 
G
 
 
 
d
o
w
n
st
. 4
0
b
. 
M
o
d
i
f.
 
M
L0
2
54
 
ad
i 
am
in
o
 a
ci
d
 d
ec
ar
b
o
xy
la
se
 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
 
9
5
0 
6
4
8
6
2
0
 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
C
 
g 
 
m
is
s.
 
M
o
d
er
. 
M
L0
5
35
 
ca
rA
 
ca
rb
am
o
yl
-p
h
o
sp
h
at
e 
sy
n
th
as
e 
sm
al
l 
ch
ai
n
 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
G
ln
6
7
G
l
u
 
3
7
6 
6
5
6
9
3
0
 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
 
G
 
G
 
g 
 
sy
n
. 
Lo
w
 
M
L0
5
40
 
m
ih
F 
 in
te
gr
at
io
n
 h
o
st
 f
ac
to
r 
M
ih
F 
In
f.
 p
at
h
w
ay
s 
A
la
1
2
A
l
a 
1
0
6 
6
5
7
7
3
6
 
G
 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
 
C
 
C
 
C
 
 
sy
n
. 
Lo
w
 
M
L0
5
41
 
gm
k 
gu
an
yl
at
e 
ki
n
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
A
rg
1
5
7
A
rg
 
2
1
0 
6
8
7
1
0
5
 
T 
 
 
 
 
 
 
T 
 
t 
 
 
 
T 
T 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
5
68
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
Le
u
9
8
P
r
o
 
1
9
7 
6
8
7
1
3
2
 
C
 
 
 
 
 
 
 
C
 
 
t 
 
 
 
C
 
C
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
5
68
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
P
ro
1
0
7
L
eu
 
1
9
7 
6
9
2
4
8
7
 
C
 
 
 
 
 
 
C
 
C
 
c 
C
 
C
 
 
 
C
 
C
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
6
9
4
0
9
0
 
T 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
C
 
C
 
C
 
C
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
5
69
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
Th
r1
1
3
A
la
 
2
7
1 
7
1
1
1
9
7
 
T 
 
 
 
 
 
T 
T 
 
C
 
T 
 
 
T 
T 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
5
85
 
q
o
r 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
7
3
6
5
8
4
 
G
 
 
 
 
 
 
 
g 
 
G
 
G
 
 
 
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
6
05
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
G
lu
1
2A
s
p
 
5
6
1 
7
3
6
5
8
5
 
A
 
 
 
 
 
 
 
a 
 
A
 
A
 
 
 
 
A
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
6
05
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
Th
r1
3
P
r
o
 
5
6
1 
7
4
9
1
7
8
 
C
 
 
 
 
 
 
 
C
 
 
T 
 
 
 
C
 
C
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
6
15
 
su
b
I 
su
lp
h
at
e-
b
in
d
in
g 
lip
o
p
ro
te
in
 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
Th
r2
6
6
Il
e 
3
4
8 
7
5
0
9
1
0
 
G
 
 
 
 
 
 
a 
G
 
 
G
 
G
 
 
 
G
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
6
17
 
cy
sW
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
7
5
1
9
8
2
 
T 
 
 
 
 
 
T 
T 
T 
G
 
T 
 
 
T 
T 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
6
19
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
7
6
3
5
7
2
 
G
 
 
 
 
 
 
G
 
G
 
 
A
 
G
 
 
 
G
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
6
31
 
er
a 
G
TP
-b
in
d
in
g 
p
ro
te
in
 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
V
al
3
3
Ile
 
3
0
2 
7
8
0
2
8
0
 
T 
 
 
 
 
 
T 
T 
 
T 
T 
 
 
t 
T 
t 
 
u
p
st
. 4
 b
. 
M
o
d
i
f.
 
M
LP
0
00
0
1
3 
m
et
U
 
tR
N
A
-M
et
 
St
ab
le
 R
N
A
s 
 
2
4
 
7
8
0
2
8
0
 
T 
 
 
 
 
 
T 
T 
 
T 
T 
 
 
t 
T 
t 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
7
8
0
2
9
9
 
C
 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
c 
C
 
C
 
C
 
 
m
is
s.
 
M
o
d
er
. 
M
LP
0
00
0
1
3 
m
et
U
 
tR
N
A
-M
et
 
St
ab
le
 R
N
A
s 
Le
u
6
P
h
e 
2
4
 
7
8
0
3
4
1
 
G
 
 
A
 
 
 
 
g 
g 
g 
G
 
G
 
 
a 
G
 
G
 
a 
G
 
m
is
s.
 
M
o
d
er
. 
M
LP
0
00
0
1
3 
m
et
U
 
tR
N
A
-M
et
 
St
ab
le
 R
N
A
s 
G
lu
2
0
Ly
s 
2
4
 
8
0
5
2
9
0
 
C
 
 
 
 
 
 
C
 
C
 
 
T 
C
 
 
 
C
 
C
 
C
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
6
68
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
XXXVIII
  
XXXVII 
8
1
6
8
3
5
 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
T 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
6
81
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
8
3
2
1
5
2
 
T 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
 
C
 
C
 
C
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
6
94
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
8
4
0
5
8
4
 
A
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
 
G
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
7
02
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
8
4
0
9
7
4
 
C
 
 
 
 
 
 
g 
C
 
 
C
 
C
 
 
 
C
 
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
7
03
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
A
la
3
9
4
P
ro
 
4
2
3 
8
7
0
3
8
1
 
G
 
 
 
 
 
 
G
 
G
 
G
 
A
 
G
 
 
 
G
 
G
 
G
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
7
28
 
ss
eA
 
th
io
su
lf
at
e 
su
lf
u
rt
ra
n
sf
er
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
Le
u
1
8
0
P
h
e 
2
9
6 
8
8
9
6
9
4
 
G
 
 
 
T 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
G
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
7
47
 
ct
p
C
 
m
et
al
 
ca
ti
o
n
-t
ra
n
sp
o
rt
in
g 
P
-t
yp
e 
A
TP
as
e 
C
 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
P
ro
4
2
6
H
is
 
7
2
5 
8
9
0
4
5
3
 
A
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
G
 
G
 
m
is
s.
 
M
o
d
er
. 
M
L0
7
47
 
ct
p
C
 
m
et
al
 
ca
ti
o
n
-t
ra
n
sp
o
rt
in
g 
P
-t
yp
e 
A
TP
as
e 
C
 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
V
al
1
73
A
la
 
7
2
5 
9
0
4
8
2
4
 
G
 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
 
C
 
C
 
C
 
C
 
sy
n
. 
Lo
w
 
M
L0
7
63
 
p
m
m
A
 
p
h
o
sp
h
o
m
an
n
o
m
u
ta
se
 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
V
al
5
0
V
a
l 
4
6
8 
9
0
6
5
1
2
 
T 
 
 
 
 
 
T 
T 
 
T 
T 
 
 
C
 
T 
 
 
sy
n
. 
Lo
w
 
M
L0
7
64
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
A
rg
1
4
5
A
rg
 
3
6
5 
9
1
9
4
8
2
 
G
 
 
 
 
 
 
G
 
G
 
G
 
C
 
G
 
 
 
G
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
7
75
 
lp
q
B
 
lip
o
p
ro
te
in
 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
G
ly
3
72
A
la
 
5
8
9 
9
2
1
5
2
3
 
C
 
 
 
 
 
 
 
C
 
 
C
 
C
 
 
 
C
 
C
 
T 
 
m
is
s.
 
M
o
d
er
. 
M
L0
7
78
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
In
f.
 p
at
h
w
ay
s 
Le
u
1
9
1
P
h
e 
2
3
0 
9
2
4
8
8
2
 
G
 
 
 
 
 
 
G
 
G
 
 
T 
G
 
 
 
G
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
7
80
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
9
2
4
8
8
3
 
C
 
 
 
 
 
 
C
 
C
 
 
c 
C
 
 
 
C
 
C
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
7
80
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
9
2
6
8
6
1
 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
A
 
 
 
G
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
7
82
 
 
tr
an
sm
em
b
ra
n
e 
tr
an
sp
o
rt
 p
ro
te
in
 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
V
al
2
32
M
et
 
3
8
5 
9
3
8
7
8
7
 
T 
 
 
 
 
 
g 
T 
 
T 
T 
 
 
T 
T 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
7
94
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
9
4
4
1
9
0
 
A
 
 
 
 
 
 
 
 
 
a 
 
 
 
 
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
7
97
 
P
P
E 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
9
4
4
1
9
1
 
C
 
 
 
 
 
 
 
 
 
a 
 
 
 
 
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
7
97
 
P
P
E 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
9
4
4
1
9
3
 
G
 
 
 
 
 
 
 
 
 
g 
 
 
 
 
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
7
97
 
P
P
E 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
9
5
4
0
3
7
 
C
 
 
 
 
 
 
 
C
 
 
G
 
C
 
 
 
C
 
C
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
9
5
8
2
2
8
 
A
 
 
 
 
 
 
 
a 
 
a 
 
 
 
 
A
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
8
09
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
9
5
8
2
3
1
 
T 
 
 
 
 
 
 
 
 
t 
 
 
 
 
T 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
8
09
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
XXXIX
  
XXXVIII 
9
6
3
3
3
9
 
C
 
 
 
 
 
 
 
C
 
 
T 
C
 
 
 
C
 
C
 
C
 
 
u
p
st
. 4
5
b
. 
M
o
d
i
f.
 
M
L0
8
13
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
 
 
9
6
3
3
3
9
 
C
 
 
 
 
 
 
 
C
 
 
T 
C
 
 
 
C
 
C
 
C
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
9
6
6
6
9
0
 
G
 
 
 
 
 
 
 
G
 
 
C
 
G
 
 
 
G
 
G
 
G
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
8
17
 
m
o
eB
1
 
m
o
ly
b
d
o
p
te
ri
n
 
co
fa
ct
o
r 
b
io
sy
n
th
es
is
 
p
ro
te
in
 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
A
rg
2
5
4
T
h
r 
3
9
5 
9
7
2
0
0
5
 
T 
 
 
 
G
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
 
G
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
8
21
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
9
8
1
1
3
2
 
C
 
 
 
 
 
 
C
 
C
 
 
T 
C
 
 
 
C
 
C
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
9
9
7
9
4
7
 
C
 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
 
C
 
C
 
T 
 
m
is
s.
 
M
o
d
er
. 
M
L0
8
40
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
V
al
2
15
Il
e 
4
3
4 
1
0
1
7
4
0
7 
G
 
 
 
 
 
 
A
 
A
 
A
 
G
 
A
 
 
A
 
A
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
8
55
 
p
ep
R
 
zi
 p
ro
te
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
G
lu
3
8
7L
ys
 
4
2
4 
1
0
4
4
4
4
7 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
C
 
A
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
8
79
 
q
cr
B
 
cy
to
ch
ro
m
e 
C
 r
ed
u
ct
as
e 
cy
to
ch
ro
m
e 
B
 s
u
b
u
n
it
 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
A
la
1
2
2
S
er
 
5
5
1 
1
0
4
4
6
7
8 
A
 
 
 
 
 
 
A
 
A
 
a 
A
 
A
 
 
 
A
 
A
 
A
 
 
sy
n
. 
Lo
w
 
M
L0
8
79
 
q
cr
B
 
-c
yt
o
ch
ro
m
e 
C
 r
ed
u
ct
as
e 
cy
to
ch
ro
m
e 
B
 s
u
b
u
n
it
 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
Le
u
4
5
Le
u
 
5
5
1 
1
0
5
6
5
9
4 
A
 
 
 
 
 
 
A
 
A
 
 
G
 
A
 
 
 
A
 
A
 
 
 
sy
n
. 
Lo
w
 
M
L0
8
90
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
Se
r1
1
8
S
er
 
4
1
5 
1
0
6
7
4
1
8 
C
 
 
 
 
 
 
C
 
C
 
 
T 
C
 
 
 
C
 
C
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
0
7
3
6
4
1 
C
 
 
 
 
 
 
C
 
C
 
C
 
T 
C
 
 
 
C
 
C
 
 
 
sy
n
. 
Lo
w
 
M
L0
9
07
 
 
m
em
b
ra
n
e 
p
ro
te
in
 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
Le
u
3
1
4
L
eu
 
3
7
7 
1
0
8
1
2
6
7 
A
 
 
 
 
 
 
g 
A
 
 
A
 
A
 
 
 
A
 
A
 
 
 
sy
n
. 
Lo
w
 
M
L0
9
12
 
m
u
rD
 
U
D
P-
N
-a
ct
yl
m
u
ra
m
o
yl
-L
-a
la
n
yl
-D
-
gl
u
ta
m
at
e 
lig
as
e 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
V
al
3
49
V
al
 
4
9
0 
1
0
8
7
3
9
7 
T 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
C
 
C
 
C
 
sy
n
. 
Lo
w
 
M
L0
9
17
 
ft
sZ
 
ce
ll 
d
iv
is
io
n
 p
ro
te
in
 F
ts
Z 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
G
ly
3
4G
l
y 
3
7
9 
1
0
8
9
5
6
0 
T 
 
 
 
 
 
T 
T 
T 
C
 
T 
 
 
T 
T 
 
 
sy
n
. 
Lo
w
 
M
L0
9
19
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
Th
r1
1
9
T
h
r 
2
6
0 
1
0
9
2
1
9
8 
A
 
 
 
 
 
 
 
A
 
 
A
 
A
 
 
 
A
 
G
 
 
 
d
o
w
n
st
r.
 
5
0
b
. 
M
o
d
i
f.
 
M
L0
9
22
 
w
ag
3
1 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
 
2
6
7 
1
0
9
2
1
9
8 
A
 
 
 
 
 
 
 
A
 
 
A
 
A
 
 
 
A
 
G
 
 
 
u
p
st
. 2
3
b
. 
M
o
d
i
f.
 
M
L0
9
23
 
 
tr
an
sm
em
b
ra
n
e 
p
ro
te
in
 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
 
1
3
1 
1
0
9
2
1
9
8 
A
 
 
 
 
 
 
 
A
 
 
A
 
A
 
 
 
A
 
G
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
0
9
3
1
1
4 
C
 
 
 
 
 
 
 
C
 
 
G
 
 
 
 
 
C
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
0
9
3
1
1
7 
G
 
 
 
 
 
 
 
G
 
 
T 
 
 
 
 
G
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
1
0
4
2
3
2 
C
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
C
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
9
34
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
XL
  
XXXIX 
1
1
2
6
1
5
8 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
 
G
 
g 
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
9
57
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
P
ro
2
4
Le
u
 
1
2
4 
1
1
2
6
1
5
8 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
 
G
 
g 
 
 
u
p
st
. 8
1
b
. 
M
o
d
i
f.
 
M
L0
9
58
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
1
2
7
1
9
2 
A
 
 
 
 
 
 
 
A
 
 
A
 
A
 
 
 
A
 
A
 
C
 
 
m
is
s.
 
M
o
d
er
. 
M
L0
9
59
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
A
sp
9
4A
l
a 
1
1
7 
1
1
3
3
4
9
2 
T 
 
 
 
 
 
T 
T 
 
G
 
T 
 
 
T 
T 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
1
4
1
2
5
1 
C
 
 
 
 
 
 
C
 
c 
 
C
 
C
 
 
 
C
 
C
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
9
73
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
1
4
3
4
2
3 
T 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
C
 
C
 
C
 
C
 
C
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
9
75
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
1
4
3
8
1
2 
G
 
 
 
 
 
 
a 
A
 
A
 
G
 
G
 
 
 
A
 
G
 
 
A
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
9
75
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
1
4
7
5
2
6 
G
 
 
 
 
 
 
 
G
 
 
A
 
G
 
 
 
G
 
G
 
G
 
 
sy
n
. 
Lo
w
 
M
L0
9
78
 
 
ac
et
yl
tr
an
sf
er
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
H
is
6
1
H
i
s 
1
8
0 
1
1
4
9
6
0
7 
T 
 
 
 
 
 
T 
T 
 
C
 
T 
 
 
T 
T 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
9
81
 
3
5
kd
_
ag
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
1
5
5
5
8
2 
T 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
 
 
sy
n
. 
Lo
w
 
M
L0
9
88
 
re
cX
 
re
co
m
b
in
at
io
n
 r
eg
u
la
to
r 
R
eg
. p
ro
te
in
s 
A
la
1
4
2
A
la
 
1
7
1 
1
1
6
0
4
2
6 
C
 
 
 
 
 
 
g 
G
 
G
 
C
 
C
 
 
 
G
 
C
 
 
G
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
1
6
1
0
6
3 
A
 
 
 
 
 
 
A
 
A
 
 
G
 
A
 
 
 
A
 
A
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L0
9
93
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
1
6
2
7
9
7 
G
 
 
 
 
 
 
g 
T 
 
G
 
G
 
 
 
T 
G
 
 
T 
m
is
s.
 
M
o
d
er
. 
M
L0
9
94
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
G
ly
6
0C
y
s 
2
3
2 
1
1
7
9
2
6
0 
G
 
 
 
 
 
 
G
 
A
 
 
G
 
G
 
 
 
G
 
G
 
 
A
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
0
08
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
1
9
1
8
2
1 
G
 
 
 
 
 
 
a 
A
 
 
G
 
G
 
 
 
A
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
0
23
 
p
p
gK
 
p
o
ly
p
h
o
sp
h
at
e 
gl
u
co
ki
n
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
A
la
2
5
V
a
l 
3
2
4 
1
2
0
5
3
2
0 
C
 
 
 
 
 
 
c 
C
 
 
C
 
C
 
 
 
C
 
C
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
0
40
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
G
ly
4
06
V
al
 
4
2
9 
1
2
0
5
7
7
3 
A
 
 
 
 
 
 
 
A
 
 
A
 
G
 
 
 
A
 
A
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
0
40
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
Le
u
2
5
5
S
er
 
4
2
9 
1
2
0
5
8
1
8 
A
 
 
 
 
 
 
 
A
 
 
g 
A
 
 
 
A
 
A
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
0
40
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
Ile
2
4
0
T
h
r 
4
2
9 
1
2
0
5
8
2
1 
C
 
 
 
 
 
 
c 
C
 
 
C
 
C
 
 
 
C
 
C
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
0
40
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
G
ly
2
39
A
sp
 
4
2
9 
1
2
0
5
8
4
1 
G
 
 
 
 
 
 
 
G
 
 
g 
G
 
 
 
G
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
0
40
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
A
sp
2
32
G
lu
 
4
2
9 
1
2
0
5
8
4
2 
T 
 
 
 
 
 
 
T 
 
t 
T 
 
 
T 
T 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
0
40
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
A
sp
2
32
V
al
 
4
2
9 
XLI
  
XL 
1
2
0
6
1
3
0 
C
 
 
 
 
 
 
C
 
c 
 
C
 
C
 
 
 
C
 
C
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
0
40
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
A
rg
1
3
6
H
is
 
4
2
9 
1
2
1
8
7
0
5 
C
 
 
 
 
 
 
c 
C
 
 
C
 
C
 
 
 
C
 
C
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
0
52
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
G
lu
3
7
5
G
ln
 
4
2
1 
1
2
2
7
6
3
1 
C
 
 
 
 
A
 
 
A
 
A
 
A
 
A
 
A
 
 
 
A
 
A
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
0
62
 
fa
d
D
6 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
2
3
2
6
3
7 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
 
G
 
A
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
0
68
 
gl
gA
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
2
5
6
1
2
7 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
 
A
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
0
92
 
P
E-
P
G
R
S3
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
2
5
7
0
0
9 
A
 
 
 
 
 
 
A
 
A
 
 
G
 
A
 
 
 
A
 
A
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
2
5
7
1
8
5 
T 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
C
 
C
 
C
 
C
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
2
6
2
0
1
0 
T 
 
 
 
 
 
T 
T 
T 
C
 
T 
 
 
T 
T 
T 
 
m
is
s.
 
M
o
d
er
. 
M
L1
0
95
 
su
cA
 
2
-o
xo
gl
u
ta
ra
te
 d
eh
yd
ro
ge
n
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
Th
r5
7
9
A
la
 
1
2
3
8 
1
2
6
5
2
6
7 
T 
 
 
 
G
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
G
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
0
97
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
2
7
6
0
1
1 
C
 
 
 
 
 
 
C
 
C
 
C
 
T 
C
 
 
 
C
 
C
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
1
02
 
cy
p
1
3
0
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
2
7
6
8
4
7 
C
 
 
 
 
 
 
C
 
C
 
C
 
T 
C
 
 
 
C
 
C
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
1
03
 
 
o
xi
d
o
re
d
u
ct
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
A
la
3
2
5
T
h
r 
4
5
3 
1
2
8
0
1
9
4 
G
 
 
 
 
 
 
g 
C
 
C
 
G
 
G
 
 
 
C
 
G
 
 
C
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
2
9
1
0
1
8 
G
 
 
 
 
 
 
A
 
A
 
A
 
G
 
A
 
 
 
A
 
G
 
 
A
 
sy
n
. 
Lo
w
 
M
L1
1
14
 
 
tr
an
sm
em
b
ra
n
e 
A
TP
-b
in
d
in
g 
p
ro
te
in
 
A
B
C
 t
ra
n
sp
o
rt
er
. 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
A
sn
1
20
A
sn
 
5
8
4 
1
2
9
5
1
9
2 
A
 
 
 
 
 
 
A
 
A
 
 
G
 
A
 
 
 
A
 
A
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
1
19
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
 
3
8
4 
1
3
2
4
0
0
9 
C
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
G
 
G
 
G
 
G
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
1
32
 
rh
o
 
tr
an
sc
ri
p
ti
o
n
 t
er
m
in
at
io
n
 f
ac
to
r 
rh
o
 
In
f.
 p
at
h
w
ay
s 
G
ln
2
2
7
G
lu
 
6
1
0 
1
3
2
9
4
5
9 
C
 
 
 
 
 
 
T 
T 
T 
C
 
T 
 
 
T 
C
 
C
 
T 
sy
n
. 
Lo
w
 
M
L1
1
37
 
rf
e 
ac
et
yl
gl
u
co
sa
m
in
yl
tr
an
sf
er
as
e 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
A
rg
3
2
0
A
rg
 
3
9
9 
1
3
3
9
8
1
3 
T 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
C
 
C
 
C
 
C
 
 
sy
n
. 
Lo
w
 
M
L1
1
50
 
m
u
rA
 
ca
rb
o
xy
vi
n
yl
tr
an
sf
er
as
e 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
A
sp
7
8A
sp
 
4
1
8 
1
3
4
1
1
3
9 
G
 
 
 
 
 
 
 
G
 
 
G
 
G
 
 
 
G
 
G
 
g 
 
u
p
st
. 5
 b
. 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
1
3
9 
G
 
 
 
 
 
 
 
G
 
 
G
 
G
 
 
 
G
 
G
 
g 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
3
4
1
1
4
2 
T 
 
 
 
 
 
g 
t 
g 
T 
T 
 
G
 
t 
T 
t 
g 
u
p
st
. 2
 b
. 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
1
4
2 
T 
 
 
 
 
 
g 
t 
g 
T 
T 
 
G
 
t 
T 
t 
g 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
XLII
  
XLI 
1
3
4
1
1
7
9 
C
 
 
t 
C
 
 
C
 
C
 
C
 
C
 
C
 
C
 
t 
C
 
C
 
C
 
C
 
C
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
2
1
5 
A
 
 
 
 
 
 
a 
A
 
 
A
 
A
 
 
a 
a 
A
 
A
 
g 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
4
1
7 
C
 
 
T 
 
 
 
c 
c 
 
C
 
C
 
 
T 
t 
C
 
T 
t 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
4
6
0 
A
 
 
 
 
 
 
 
c 
 
A
 
A
 
 
c 
A
 
A
 
C
 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
4
8
1 
T 
 
C
 
c 
c 
c 
t 
t 
c 
T 
t 
 
t 
c 
T 
t 
c 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
5
2
3 
C
 
g 
C
 
c 
 
 
C
 
C
 
C
 
C
 
c 
g 
C
 
C
 
C
 
C
 
C
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
5
3
4 
C
 
 
g 
 
 
 
c 
C
 
c 
C
 
C
 
 
c 
c 
C
 
c 
c 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
5
4
9 
G
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
G
 
G
 
G
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
5
6
0 
G
 
 
 
 
 
A
 
 
G
 
a 
G
 
G
 
 
a 
G
 
G
 
 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
5
7
2 
T 
 
 
 
 
 
T 
t 
 
T 
T 
 
c 
T 
T 
c 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
6
3
6 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
 
G
 
G
 
G
 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
6
3
7 
G
 
 
 
 
 
 
G
 
g 
 
G
 
G
 
 
 
G
 
G
 
c 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
6
5
3 
C
 
 
 
 
 
 
c 
C
 
c 
C
 
C
 
 
 
c 
C
 
c 
t 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
6
8
8 
T 
 
 
 
 
t 
g 
 
t 
T 
T 
 
T 
t 
T 
t 
t 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
7
0
9 
C
 
 
 
 
 
 
C
 
C
 
c 
C
 
C
 
 
C
 
c 
C
 
C
 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
7
4
7 
T 
 
 
 
 
 
T 
T 
T 
T 
T 
 
T 
T 
T 
c 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
7
5
5 
T 
 
 
 
 
 
T 
T 
 
T 
T 
 
 
T 
T 
t 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
7
7
3 
A
 
 
 
 
 
 
A
 
a 
 
A
 
A
 
 
 
A
 
A
 
a 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
7
9
8 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
G
 
G
 
G
 
g 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
8
0
7 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
C
 
C
 
C
 
c 
C
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
8
1
6 
C
 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
C
 
C
 
C
 
C
 
c 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
XLIII
  
XLII 
1
3
4
1
8
2
2 
T 
 
 
 
 
 
t 
 
 
T 
T 
 
t 
t 
T 
T 
t 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
8
6
6 
A
 
 
 
 
 
G
 
g 
g 
g 
A
 
 
 
G
 
g 
A
 
G
 
G
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
9
0
7 
A
 
T 
t 
 
t 
a 
a 
a 
a 
A
 
a 
T 
a 
a 
A
 
 
a 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
9
2
5 
A
 
A
 
a 
a 
A
 
a 
g 
a 
a 
A
 
A
 
 
a 
g 
A
 
g 
a 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
9
6
4 
G
 
 
 
 
 
G
 
 
G
 
a 
G
 
G
 
 
g 
G
 
G
 
 
G
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
9
9
1 
T 
 
 
 
 
 
t 
T 
 
T 
T 
 
T 
T 
T 
T 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
1
9
9
2 
T 
 
 
 
 
 
t 
T 
 
T 
T 
 
T 
t 
T 
g 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
0
0
1 
T 
 
 
 
 
 
T 
T 
T 
T 
T 
 
T 
T 
T 
T 
t 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
0
2
2 
T 
 
T 
 
 
T 
T 
T 
t 
T 
T 
 
T 
T 
T 
T 
T 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
0
2
3 
A
 
 
t 
 
 
g 
g 
a 
g 
A
 
A
 
 
g 
g 
A
 
g 
g 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
0
6
4 
G
 
G
 
G
 
G
 
G
 
G
 
G
 
G
 
G
 
G
 
G
 
G
 
 
G
 
G
 
G
 
G
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
0
9
9 
T 
T 
t 
c 
t 
C
 
c 
t 
c 
T 
t 
T 
c 
c 
 
c 
T 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
1
5
3 
T 
 
 
 
 
 
T 
T 
 
T 
T 
 
 
T 
T 
c 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
1
7
0 
A
 
 
 
 
 
 
A
 
A
 
 
A
 
A
 
 
 
A
 
A
 
g 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
1
7
1 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
C
 
t 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
1
8
9 
G
 
 
 
 
 
 
 
G
 
g 
G
 
G
 
 
G
 
 
G
 
G
 
G
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
1
9
6 
G
 
c 
g 
g 
c 
g 
g 
g 
g 
g 
g 
c 
g 
g 
 
g 
g 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
2
0
4 
C
 
 
C
 
C
 
 
c 
c 
c 
c 
C
 
C
 
 
c 
c 
c 
c 
c 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
2
6
0 
T 
 
 
 
 
 
t 
T 
t 
T 
T 
 
T 
 
T 
T 
t 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
2
6
1 
T 
 
 
 
 
 
T 
T 
 
T 
T 
 
T 
 
T 
t 
T 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
2
6
4 
C
 
 
 
 
 
 
C
 
c 
C
 
C
 
C
 
 
C
 
C
 
C
 
C
 
C
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
XLIV
  
XLIII 
1
3
4
2
2
6
6 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
C
 
C
 
C
 
C
 
c 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
2
6
7 
A
 
 
 
 
 
 
 
A
 
 
A
 
A
 
 
 
a 
A
 
A
 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
2
8
2 
A
 
 
 
 
 
 
A
 
a 
 
A
 
A
 
 
A
 
A
 
A
 
A
 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
3
1
0 
C
 
G
 
 
 
c 
 
c 
g 
G
 
C
 
C
 
G
 
G
 
g 
C
 
G
 
g 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
3
4
4 
G
 
 
 
 
G
 
 
G
 
G
 
G
 
G
 
G
 
 
G
 
G
 
G
 
G
 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
3
5
3 
C
 
 
 
 
C
 
 
c 
C
 
C
 
C
 
C
 
 
C
 
C
 
C
 
C
 
C
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
3
7
5 
A
 
 
 
 
 
 
a 
A
 
a 
A
 
 
 
a 
a 
A
 
a 
g 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
3
9
7 
A
 
 
 
 
 
 
A
 
A
 
a 
A
 
A
 
 
A
 
a 
A
 
A
 
A
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
4
0
9 
G
 
 
 
 
 
 
G
 
 
 
G
 
G
 
 
 
G
 
G
 
a 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
4
5
5 
C
 
 
 
 
 
 
 
C
 
c 
C
 
 
 
t 
c 
C
 
t 
c 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
4
7
6 
G
 
 
G
 
 
G
 
 
g 
g 
g 
G
 
g 
 
g 
G
 
G
 
a 
G
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
4
8
3 
C
 
 
C
 
C
 
C
 
 
c 
C
 
C
 
C
 
C
 
 
C
 
c 
C
 
C
 
C
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
5
3
1 
C
 
 
C
 
C
 
C
 
t 
c 
c 
c 
C
 
C
 
 
c 
c 
C
 
c 
c 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
5
5
7 
C
 
 
C
 
 
C
 
C
 
C
 
C
 
C
 
C
 
C
 
 
C
 
C
 
C
 
c 
C
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
5
6
2 
T 
 
t 
c 
c 
 
T 
T 
c 
T 
T 
 
t 
t 
T 
t 
T 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
5
6
2 
T 
 
t 
c 
c 
 
T 
T 
c 
T 
T 
 
t 
t 
T 
t 
T 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
5
7
2 
T 
 
t 
c 
T 
 
t 
T 
t 
T 
t 
 
t 
t 
T 
T 
T 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
5
7
2 
T 
 
t 
c 
T 
 
t 
T 
t 
T 
t 
 
t 
t 
T 
T 
T 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
5
8
6 
A
 
 
 
 
 
 
a 
a 
a 
A
 
A
 
 
a 
a 
A
 
a 
A
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
5
9
3 
T 
 
 
 
 
 
T 
T 
 
T 
T 
 
T 
 
T 
T 
C
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
6
1
1 
T 
 
 
 
 
 
T 
T 
 
T 
T 
 
 
T 
T 
t 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
XLV
  
XLIV 
1
3
4
2
6
1
5 
C
 
 
 
 
 
 
C
 
c 
 
C
 
C
 
 
g 
C
 
C
 
g 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
6
2
6 
C
 
 
 
 
 
 
c 
c 
 
C
 
C
 
 
 
c 
C
 
C
 
c 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
6
2
7 
G
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
g 
G
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
6
2
9 
C
 
 
 
 
 
 
c 
c 
c 
C
 
C
 
 
c 
c 
C
 
c 
t 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
6
9
4 
A
 
 
 
 
 
 
A
 
A
 
a 
A
 
A
 
 
a 
A
 
A
 
A
 
 
d
o
w
n
st
. 2
 b
. 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
6
9
4 
A
 
 
 
 
 
 
A
 
A
 
a 
A
 
A
 
 
a 
A
 
A
 
A
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
3
4
2
6
9
7 
A
 
 
 
 
 
 
a 
A
 
 
A
 
A
 
 
A
 
 
A
 
A
 
a 
d
o
w
n
st
. 5
 b
. 
M
o
d
i
f.
 
M
LP
0
00
0
1
6 
rr
s 
1
6
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
2
6
9
7 
A
 
 
 
 
 
 
a 
A
 
 
A
 
A
 
 
A
 
 
A
 
A
 
a 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
3
4
3
0
6
6 
T 
 
 
 
 
 
 
T 
T 
T 
T 
 
T 
T 
T 
c 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
3
0
7
2 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
G
 
G
 
G
 
g 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
3
0
7
6 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
G
 
G
 
G
 
g 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
3
0
9
0 
T 
 
 
 
 
 
T 
T 
 
T 
T 
 
G
 
T 
T 
g 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
3
4
3
4 
T 
 
 
 
 
 
 
T 
 
T 
T 
 
 
T 
T 
t 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
3
4
9
6 
A
 
 
 
 
 
 
A
 
a 
 
A
 
A
 
 
 
A
 
A
 
g 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
3
5
2
3 
T 
 
 
 
 
 
T 
T 
T 
T 
T 
 
T 
T 
T 
t 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
3
5
2
4 
C
 
 
 
 
 
 
c 
C
 
c 
C
 
C
 
 
c 
c 
C
 
c 
G
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
3
5
7
1 
T 
 
 
 
 
c 
t 
T 
t 
T 
T 
 
c 
t 
T 
t 
t 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
3
5
8
5 
G
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
G
 
G
 
G
 
g 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
3
6
3
1 
T 
 
 
 
 
 
T 
t 
 
T 
T 
 
 
T 
T 
T 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
3
6
8
1 
T 
 
 
 
 
 
T 
t 
 
T 
T 
 
 
T 
T 
T 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
3
6
8
3 
T 
 
 
 
 
 
T 
T 
 
T 
T 
 
 
T 
T 
T 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
XLVI
  
XLV 
1
3
4
3
7
5
1 
C
 
 
 
 
 
 
C
 
c 
 
C
 
C
 
 
 
C
 
C
 
g 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
3
8
2
9 
A
 
 
 
 
 
 
A
 
a 
 
A
 
A
 
 
 
A
 
A
 
g 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
3
8
3
8 
T 
 
 
 
 
 
 
t 
 
T 
T 
 
 
T 
T 
c 
c 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
3
8
5
0 
G
 
 
 
 
 
 
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
G
 
G
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
3
8
5
1 
T 
 
 
 
 
 
 
t 
c 
T 
T 
 
t 
t 
T 
T 
T 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
3
8
5
7 
G
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
g 
g 
G
 
g 
G
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
3
8
8
1 
T 
 
 
 
 
 
t 
T 
t 
T 
T 
 
t 
t 
T 
T 
t 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
3
9
2
5 
T 
 
 
 
 
 
 
T 
t 
T 
T 
 
 
t 
T 
t 
T 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
3
9
2
7 
C
 
 
 
 
 
 
c 
C
 
C
 
C
 
C
 
 
C
 
C
 
C
 
C
 
c 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
3
9
2
8 
G
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
G
 
G
 
G
 
g 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
3
9
3
1 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
 
 
G
 
g 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
3
9
7
5 
T 
 
 
 
 
 
T 
T 
T 
T 
T 
 
 
T 
T 
 
A
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
4
0
5
3 
A
 
 
 
 
 
 
A
 
a 
 
A
 
A
 
 
g 
A
 
A
 
a 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
4
0
6
0 
A
 
 
 
 
 
 
 
a 
a 
A
 
A
 
 
g 
a 
A
 
g 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
4
0
9
4 
T 
 
 
 
 
 
T 
t 
T 
T 
T 
 
T 
T 
T 
a 
T 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
4
1
0
3 
G
 
 
 
 
 
 
 
G
 
G
 
G
 
G
 
 
G
 
G
 
G
 
G
 
G
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
4
1
2
3 
C
 
 
 
 
 
 
 
C
 
C
 
C
 
C
 
 
C
 
c 
C
 
C
 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
4
1
3
0 
A
 
 
 
 
 
 
 
g 
 
A
 
A
 
 
G
 
a 
A
 
g 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
4
1
6
4 
C
 
 
 
 
 
 
c 
c 
c 
C
 
C
 
 
c 
c 
C
 
c 
c 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
4
1
6
9 
G
 
 
 
 
 
 
g 
G
 
G
 
G
 
G
 
 
G
 
G
 
G
 
G
 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
4
2
0
4 
G
 
 
 
 
 
 
 
G
 
G
 
G
 
G
 
 
G
 
g 
G
 
G
 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
XLVII
  
XLVI 
1
3
4
4
2
5
3 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
C
 
c 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
4
2
5
4 
A
 
 
 
 
 
 
A
 
A
 
 
A
 
A
 
 
 
A
 
A
 
a 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
4
3
6
4 
A
 
 
 
 
 
 
A
 
A
 
 
A
 
A
 
 
A
 
A
 
A
 
a 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
4
3
9
0 
T 
 
 
 
 
 
 
t 
 
T 
T 
 
A
 
T 
T 
a 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
4
4
2
2 
G
 
 
 
 
 
 
G
 
g 
G
 
G
 
G
 
 
G
 
G
 
G
 
t 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
4
4
2
6 
A
 
 
 
 
 
 
a 
a 
 
A
 
A
 
 
A
 
a 
A
 
A
 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
4
4
3
1 
G
 
 
A
 
 
 
 
G
 
g 
g 
G
 
G
 
 
g 
G
 
G
 
g 
G
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
4
5
0
4 
T 
 
 
 
 
 
T 
T 
 
T 
T 
 
 
T 
T 
t 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
4
6
6
5 
A
 
 
 
 
 
 
A
 
A
 
 
A
 
A
 
 
 
A
 
A
 
a 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
4
8
8
0 
T 
 
 
 
T 
 
 
T 
t 
T 
T 
 
c 
t 
T 
c 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
4
9
5
3 
G
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
g 
G
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
4
9
5
9 
T 
 
 
 
 
 
T 
T 
t 
T 
T 
 
 
 
T 
T 
T 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
4
9
6
1 
A
 
 
 
 
 
 
A
 
A
 
A
 
A
 
A
 
 
 
A
 
A
 
a 
g 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
0
0
3 
T 
 
 
c 
C
 
 
 
t 
c 
T 
T 
 
t 
t 
T 
c 
c 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
0
0
7 
A
 
 
 
 
 
 
 
A
 
A
 
A
 
A
 
 
a 
a 
A
 
A
 
A
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
0
1
0 
A
 
 
 
 
 
 
A
 
A
 
A
 
A
 
A
 
 
a 
A
 
A
 
A
 
A
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
0
4
4 
G
 
 
 
 
 
 
G
 
G
 
g 
G
 
G
 
 
G
 
G
 
G
 
G
 
G
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
0
4
7 
T 
 
 
 
 
 
t 
t 
 
T 
T 
 
 
 
T 
 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
0
5
7 
T 
 
 
 
 
 
T 
T 
 
T 
T 
 
 
T 
T 
g 
T 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
0
7
9 
G
 
 
 
 
t 
 
G
 
g 
g 
G
 
G
 
 
g 
g 
G
 
t 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
0
8
1 
A
 
 
 
 
 
 
 
a 
a 
A
 
A
 
 
a 
 
A
 
a 
a 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
XLVIII
  
XLVII 
1
3
4
5
0
8
5 
T 
 
 
 
 
 
t 
T 
T 
T 
T 
 
 
t 
T 
t 
t 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
0
8
7 
T 
 
 
 
 
 
t 
t 
T 
T 
T 
 
T 
 
T 
T 
T 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
0
9
2 
C
 
 
G
 
 
 
C
 
 
C
 
c 
C
 
C
 
 
c 
c 
C
 
c 
C
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
0
9
8 
A
 
 
A
 
A
 
 
a 
a 
a 
a 
A
 
A
 
 
a 
a 
A
 
a 
a 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
1
8
3 
T 
 
 
T 
T 
 
t 
T 
T 
T 
T 
 
T 
 
T 
T 
t 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
1
8
5 
T 
 
 
C
 
 
 
 
T 
t 
T 
 
 
 
 
T 
T 
c 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
1
8
7 
A
 
 
 
 
g 
 
A
 
A
 
g 
A
 
A
 
 
 
a 
A
 
A
 
a 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
1
8
8 
A
 
 
 
 
 
 
 
A
 
 
A
 
A
 
 
g 
a 
A
 
A
 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
2
2
0 
C
 
 
 
 
 
 
C
 
c 
C
 
C
 
C
 
 
C
 
C
 
C
 
T 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
2
4
4 
T 
 
 
 
 
 
T 
t 
t 
T 
T 
 
c 
 
T 
c 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
4
3
5 
C
 
 
 
 
 
 
 
c 
t 
C
 
C
 
 
 
c 
C
 
t 
t 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
4
6
9 
T 
 
 
 
 
 
T 
T 
 
T 
T 
 
 
T 
T 
 
T 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
5
0
4 
T 
 
 
 
 
 
T 
T 
 
T 
T 
 
 
T 
T 
a 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
5
6
4 
A
 
 
 
 
 
 
 
A
 
 
A
 
A
 
 
 
A
 
A
 
a 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
5
8
5 
T 
 
 
 
 
 
T 
t 
 
T 
T 
 
 
T 
T 
c 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
6
0
1 
T 
 
 
 
 
 
 
t 
 
T 
T 
 
C
 
T 
T 
t 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
6
0
3 
T 
 
 
 
 
 
 
t 
 
T 
T 
 
C
 
T 
T 
t 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
6
1
1 
A
 
 
 
 
 
 
A
 
A
 
A
 
A
 
A
 
 
a 
A
 
A
 
A
 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
6
1
3 
G
 
 
 
 
 
 
g 
G
 
 
G
 
G
 
 
G
 
g 
G
 
G
 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
6
1
6 
T 
 
 
 
 
 
 
T 
t 
T 
T 
 
 
t 
T 
t 
T 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
6
2
9 
A
 
 
A
 
A
 
 
 
A
 
A
 
A
 
A
 
 
 
a 
A
 
A
 
A
 
A
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
XLIX
  
XLVIII 
1
3
4
5
6
6
3 
C
 
 
C
 
C
 
 
C
 
c 
C
 
c 
C
 
C
 
 
C
 
C
 
C
 
C
 
c 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
6
8
5 
G
 
 
G
 
G
 
 
g 
g 
g 
g 
G
 
G
 
 
g 
g 
G
 
g 
c 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
7
1
2 
G
 
 
G
 
G
 
G
 
G
 
G
 
G
 
G
 
G
 
G
 
 
G
 
G
 
G
 
G
 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
7
2
9 
A
 
 
g 
G
 
 
g 
g 
g 
g 
A
 
a 
 
g 
g 
 
g 
g 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
7
3
2 
C
 
T 
t 
T 
t 
c 
c 
C
 
t 
C
 
c 
T 
c 
c 
c 
C
 
c 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
7
7
0 
C
 
 
c 
 
 
t 
c 
c 
c 
C
 
C
 
 
c 
c 
C
 
c 
t 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
7
8
5 
T 
 
 
T 
t 
t 
 
T 
t 
T 
t 
 
t 
T 
t 
T 
t 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
7
9
5 
T 
 
T 
c 
T 
T 
T 
T 
T 
T 
T 
 
t 
T 
T 
T 
T 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
8
1
0 
T 
 
 
 
 
 
t 
T 
c 
T 
 
 
c 
t 
T 
T 
c 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
8
3
3 
A
 
 
 
 
 
 
A
 
a 
A
 
A
 
A
 
 
G
 
A
 
A
 
t 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
8
4
3 
A
 
 
 
 
 
 
a 
A
 
 
A
 
A
 
 
 
a 
A
 
A
 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
5
8
4
4 
T 
 
 
 
 
 
t 
T 
t 
T 
T 
 
C
 
t 
T 
c 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
6
2
2
6 
A
 
 
 
 
 
 
A
 
A
 
 
A
 
A
 
 
 
A
 
A
 
a 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
6
2
7
0 
A
 
 
 
 
 
 
A
 
A
 
 
A
 
A
 
 
 
A
 
A
 
a 
 
_e
xo
n
 
M
o
d
i
f.
 
M
LP
0
00
0
1
7 
rr
l 
2
3
S 
ri
b
o
so
m
al
 R
N
A
 
St
ab
le
 R
N
A
s 
 
 
1
3
4
8
4
2
6 
T 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
 
C
 
C
 
C
 
C
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
3
5
1
1
4
9 
C
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
G
 
G
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
3
6
8
0
3
1 
C
 
 
 
 
 
 
C
 
C
 
 
T 
C
 
 
 
C
 
C
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
1
70
 
cy
sM
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
3
7
2
1
6
6 
C
 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
 
C
 
T 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
1
75
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
P
ro
1
2
9
S
er
 
2
2
0 
1
4
0
9
8
2
6 
G
 
 
 
 
 
 
 
G
 
 
A
 
G
 
 
 
G
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
1
94
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
4
1
4
6
6
6 
A
 
 
 
 
 
 
 
 
 
a 
 
 
 
 
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
4
1
4
6
7
4 
A
 
 
 
 
 
 
 
 
 
a 
 
 
 
 
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
L
  
XLIX 
1
4
1
5
3
7
0 
C
 
 
 
 
 
 
C
 
C
 
 
T 
C
 
 
 
C
 
C
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
1
97
 
d
in
X 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
4
5
6
0
9
1 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
A
 
 
 
C
 
C
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
2
29
 
p
ks
4
 
p
ks
3 
p
o
ly
ke
ti
d
e 
b
et
a-
ke
to
ac
yl
 s
yn
th
as
e 
Li
p
id
 m
et
ab
o
lis
m
 
Th
r5
9
8
L
ys
 
2
1
1
8 
1
4
5
9
8
7
8 
C
 
 
 
 
 
 
C
 
C
 
 
T 
C
 
 
 
C
 
C
 
 
 
sy
n
. 
Lo
w
 
M
L1
2
29
 
p
ks
4 
p
o
ly
ke
ti
d
e 
b
et
a-
ke
to
ac
yl
 s
yn
th
as
e 
Li
p
id
 m
et
ab
o
lis
m
 
V
al
1
86
0
V
al
 
2
1
1
8 
1
4
7
7
9
6
4 
T 
 
 
 
 
 
T 
T 
 
t 
T 
 
 
T 
T 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
4
7
7
9
6
5 
T 
 
 
 
 
 
T 
T 
 
T 
T 
 
 
T 
T 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
5
0
0
8
3
4 
C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
5
2
9
0
8
8 
A
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
G
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
2
84
 
cy
d
A
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
5
3
0
4
7
6 
T 
 
 
 
 
 
 
T 
t 
T 
T 
 
 
T 
T 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
2
85
 
cy
a 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
5
3
0
7
1
8 
A
 
 
 
 
 
 
A
 
A
 
A
 
G
 
A
 
 
 
A
 
A
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
2
85
 
cy
a 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
5
3
1
1
8
5 
A
 
 
 
 
 
 
A
 
A
 
 
a 
A
 
 
 
 
A
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
2
85
 
cy
a 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
5
3
3
3
1
5 
C
 
 
 
 
 
 
 
 
 
c 
 
 
 
 
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
2
87
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
5
3
3
3
1
6 
A
 
 
 
 
 
 
 
 
 
a 
 
 
 
 
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
2
87
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
5
3
3
3
1
7 
T 
 
 
 
 
 
 
 
 
t 
 
 
 
 
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
2
87
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
5
4
2
2
4
8 
C
 
 
 
 
 
 
c 
C
 
C
 
C
 
C
 
 
 
C
 
C
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
5
4
8
4
8
6 
T 
 
 
 
 
 
t 
T 
T 
T 
T 
 
 
T 
T 
T 
 
m
is
s.
 
M
o
d
er
. 
M
L1
3
00
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
V
al
3
2A
l
a 
2
6
2 
1
5
7
9
0
3
6 
T 
 
 
 
 
 
T 
T 
 
C
 
T 
 
 
T 
T 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
3
27
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
5
7
9
1
0
9 
T 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
G
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
3
27
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
5
8
5
8
0
0 
A
 
 
 
 
 
 
g 
G
 
G
 
A
 
A
 
 
 
G
 
A
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
3
33
 
h
el
Y 
D
N
A
 h
el
ic
as
e 
In
f.
 p
at
h
w
ay
s 
Th
r4
3
6
A
la
 
9
2
0 
1
5
8
7
6
6
1 
C
 
 
 
 
 
 
 
C
 
 
t 
C
 
 
 
C
 
C
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
3
34
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
P
ro
1
1
4
S
er
 
2
7
2 
1
5
8
7
6
9
7 
C
 
 
 
 
 
 
 
 
 
C
 
C
 
 
 
t 
C
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
3
34
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
P
ro
1
2
6
S
er
 
2
7
2 
1
6
0
1
9
0
2 
C
 
 
 
 
 
 
C
 
C
 
 
A
 
C
 
 
 
C
 
C
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
LI
  
L 
1
6
0
2
3
9
5 
T 
 
 
 
 
 
 
T 
T 
T 
T 
 
 
 
T 
t 
 
d
o
w
n
st
. 
7
0 
b
. 
M
o
d
i
f.
 
M
LP
0
00
0
2
4 
cy
sU
 
tR
N
A
-C
ys
 a
n
ti
co
d
o
n
 G
C
A
 
St
ab
le
 R
N
A
s 
 
2
4
 
1
6
0
2
3
9
5 
T 
 
 
 
 
 
 
T 
T 
T 
T 
 
 
 
T 
t 
 
m
is
s.
 
M
o
d
er
. 
M
LP
0
00
0
2
3 
va
lU
 
tR
N
A
-V
al
 a
n
ti
co
d
o
n
 G
A
C
 
St
ab
le
 R
N
A
s 
G
ln
1
9A
r
g 
2
4
 
1
6
0
2
4
2
6 
T 
 
 
 
 
 
 
T 
t 
T 
T 
 
 
 
T 
T 
 
d
o
w
n
st
. 
3
9 
b
. 
M
o
d
i
f.
 
M
LP
0
00
0
2
4 
cy
sU
 
tR
N
A
-C
ys
 a
n
ti
co
d
o
n
 G
C
A
 
St
ab
le
 R
N
A
s 
 
2
4
 
1
6
0
2
4
2
6 
T 
 
 
 
 
 
 
T 
t 
T 
T 
 
 
 
T 
T 
 
m
is
s.
 
M
o
d
er
. 
M
LP
0
00
0
2
3 
va
lU
 
tR
N
A
-V
al
 a
n
ti
co
d
o
n
 G
A
C
 
St
ab
le
 R
N
A
s 
Th
r9
A
la
 
2
4
 
1
6
0
2
5
3
9 
A
 
 
 
 
 
 
A
 
A
 
A
 
A
 
A
 
 
 
A
 
A
 
a 
 
U
P
ST
R
EA
M
: 
1
 b
as
e 
M
o
d
i
f.
 
M
LP
0
00
0
2
4 
cy
sU
 
tR
N
A
-C
ys
 a
n
ti
co
d
o
n
 G
C
A
 
St
ab
le
 R
N
A
s 
 
2
4
 
1
6
0
2
5
3
9 
A
 
 
 
 
 
 
A
 
A
 
A
 
A
 
A
 
 
 
A
 
A
 
a 
 
d
o
w
n
st
. 
2
5 
b
. 
M
o
d
i
f.
 
M
LP
0
00
0
2
5 
gl
yT
 
tR
N
A
-G
ly
 a
n
ti
co
d
o
n
 G
C
C
 
St
ab
le
 R
N
A
s 
 
2
4
 
1
6
0
2
5
3
9 
A
 
 
 
 
 
 
A
 
A
 
A
 
A
 
A
 
 
 
A
 
A
 
a 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
6
0
2
5
7
3 
T 
 
 
 
 
 
T 
T 
t 
T 
T 
 
 
T 
T 
 
T 
u
p
st
. 3
5
 b
. 
M
o
d
i
f.
 
M
LP
0
00
0
2
4 
cy
sU
 
tR
N
A
-C
ys
 a
n
ti
co
d
o
n
 G
C
A
 
St
ab
le
 R
N
A
s 
 
2
4
 
1
6
0
2
5
7
3 
T 
 
 
 
 
 
T 
T 
t 
T 
T 
 
 
T 
T 
 
T 
m
is
s.
 
M
o
d
er
. 
M
LP
0
00
0
2
5 
gl
yT
 
tR
N
A
-G
ly
 a
n
ti
co
d
o
n
 G
C
C
 
St
ab
le
 R
N
A
s 
Ile
2
3
V
al
 
2
4
 
1
6
0
2
5
8
1 
T 
 
 
 
 
C
 
c 
T 
t 
T 
T 
 
 
t 
T 
c 
t 
U
P
ST
R
 4
3
 b
. 
M
o
d
i
f.
 
M
LP
0
00
0
2
4 
cy
sU
 
tR
N
A
-C
ys
 a
n
ti
co
d
o
n
 G
C
A
 
St
ab
le
 R
N
A
s 
 
2
4
 
1
6
0
2
5
8
1 
T 
 
 
 
 
C
 
c 
T 
t 
T 
T 
 
 
t 
T 
c 
t 
m
is
s.
 
M
o
d
er
. 
M
LP
0
00
0
2
5 
gl
yT
 
tR
N
A
-G
ly
 a
n
ti
co
d
o
n
 G
C
C
 
St
ab
le
 R
N
A
s 
A
sn
2
0
S
er
 
2
4
 
1
6
0
2
6
1
7 
G
 
 
 
 
 
 
 
G
 
 
G
 
G
 
 
t 
 
G
 
g 
 
u
p
st
. 7
9
 b
. 
M
o
d
i
f.
 
M
LP
0
00
0
2
4 
cy
sU
 
tR
N
A
-C
ys
 a
n
ti
co
d
o
n
 G
C
A
 
St
ab
le
 R
N
A
s 
 
2
4
 
1
6
0
2
6
1
7 
G
 
 
 
 
 
 
 
G
 
 
G
 
G
 
 
t 
 
G
 
g 
 
m
is
s.
 
M
o
d
er
. 
M
LP
0
00
0
2
5 
gl
yT
 
tR
N
A
-G
ly
 a
n
ti
co
d
o
n
 G
C
C
 
St
ab
le
 R
N
A
s 
A
la
8
G
lu
 
2
4
 
1
6
0
2
6
2
4 
A
 
 
 
 
 
 
A
 
A
 
a 
A
 
A
 
 
 
 
A
 
a 
 
u
p
st
. 8
6
 b
. 
M
o
d
i
f.
 
M
LP
0
00
0
2
4 
cy
sU
 
tR
N
A
-C
ys
 a
n
ti
co
d
o
n
 G
C
A
 
St
ab
le
 R
N
A
s 
 
2
4
 
1
6
0
2
6
2
4 
A
 
 
 
 
 
 
A
 
A
 
a 
A
 
A
 
 
 
 
A
 
a 
 
sy
n
. 
Lo
w
 
M
LP
0
00
0
2
5 
gl
yT
 
tR
N
A
-G
ly
 a
n
ti
co
d
o
n
 G
C
C
 
St
ab
le
 R
N
A
s 
Le
u
6
Le
u
 
2
4
 
1
6
0
4
3
2
0 
A
 
 
 
 
 
 
A
 
A
 
 
A
 
A
 
 
 
A
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
3
45
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
6
0
5
9
5
6 
G
 
 
 
 
 
 
A
 
A
 
A
 
A
 
A
 
 
 
A
 
A
 
 
A
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
6
1
4
0
6
9 
T 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
C
 
C
 
C
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
3
53
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
6
2
5
0
4
5 
T 
G
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
G
 
 
G
 
G
 
G
 
G
 
sy
n
. 
Lo
w
 
M
L1
3
63
 
p
yr
G
 
C
TP
 s
yn
th
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
P
ro
2
9
8
P
ro
 
5
9
0 
1
6
3
5
9
6
7 
G
 
 
 
 
 
 
g 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
6
3
5
9
6
9 
G
 
 
 
 
 
 
g 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
LII
  
LI 
1
6
3
8
4
1
0 
T 
 
 
 
 
 
t 
 
t 
T 
T 
 
T 
t 
T 
t 
g 
m
is
s.
 
M
o
d
er
. 
M
LP
0
00
0
2
7 
p
ro
T 
tR
N
A
-P
ro
 a
n
ti
co
d
o
n
 G
G
G
 
St
ab
le
 R
N
A
s 
Se
r1
5
A
r
g 
2
4
 
1
6
4
2
8
7
5 
G
 
 
 
 
T 
 
T 
T 
T 
T 
T 
 
 
T 
T 
T 
T 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
3
78
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
6
4
3
1
6
2 
T 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
C
 
C
 
C
 
C
 
C
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
3
78
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
6
4
8
0
2
6 
T 
 
 
 
 
 
 
 
 
C
 
 
 
 
 
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
6
4
8
1
0
5 
C
 
 
 
 
 
 
 
T 
 
C
 
T 
 
 
 
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
6
5
7
3
7
3 
G
 
 
 
 
T 
 
G
 
G
 
 
G
 
G
 
 
 
G
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
3
85
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
6
6
5
9
0
2 
G
 
 
 
 
 
 
G
 
G
 
 
C
 
G
 
 
 
G
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
3
89
 
 
tr
an
sm
em
b
ra
n
e 
p
ro
te
in
 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
P
ro
2
8
6
A
la
 
5
2
7 
1
6
7
7
4
9
3 
G
 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
C
 
C
 
C
 
C
 
 
sy
n
. 
Lo
w
 
M
L1
3
97
 
ts
n
R
 
2
3
S 
rR
N
A
 m
et
h
yl
tr
an
sf
er
as
e 
In
f.
 p
at
h
w
ay
s 
A
la
1
2
9
A
la
 
2
6
0 
1
6
7
9
7
6
8 
A
 
 
 
 
 
 
 
A
 
A
 
G
 
A
 
 
 
A
 
A
 
A
 
 
sy
n
. 
Lo
w
 
M
L1
3
99
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
A
rg
1
8
5
A
rg
 
3
2
4 
1
7
0
1
5
9
0 
G
 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
 
C
 
C
 
C
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
7
3
1
0
8
3 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
T 
C
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
4
37
 
p
ks
12
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
7
3
2
1
1
5 
A
 
 
 
 
 
 
A
 
A
 
 
a 
A
 
 
 
A
 
A
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
4
37
 
p
ks
12
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
7
3
2
1
1
6 
T 
 
 
 
 
 
T 
T 
 
t 
T 
 
 
T 
T 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
4
37
 
p
ks
12
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
7
3
2
1
1
7 
A
 
 
 
 
 
 
A
 
A
 
 
a 
A
 
 
 
A
 
A
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
4
37
 
p
ks
12
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
7
5
3
5
4
8 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
A
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
4
59
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
7
5
8
3
9
0 
T 
 
 
 
 
 
t 
T 
 
T 
T 
 
 
T 
T 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
4
61
 
rb
sK
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
7
5
9
6
5
1 
G
 
 
 
 
 
 
A
 
A
 
 
G
 
A
 
 
 
A
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
4
63
 
n
ad
E 
gl
u
ta
m
in
e-
d
ep
en
d
en
t 
N
A
D
(+
) 
sy
n
th
et
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
A
la
5
6
6
V
al
 
6
8
0 
1
7
7
3
3
7
9 
G
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
A
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
7
8
5
0
9
1 
G
 
 
 
 
 
 
G
 
g 
 
G
 
G
 
 
 
G
 
G
 
a 
 
u
p
st
. 2
 b
. 
M
o
d
i
f.
 
M
LP
0
00
0
2
8 
p
ro
U
 
tR
N
A
-P
ro
 a
n
ti
co
d
o
n
 T
G
G
 
St
ab
le
 R
N
A
s 
 
 
1
7
8
5
0
9
1 
G
 
 
 
 
 
 
G
 
g 
 
G
 
G
 
 
 
G
 
G
 
a 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
7
8
7
3
9
9 
C
 
 
 
 
 
 
T 
T 
 
C
 
T 
 
 
T 
C
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
4
84
 
 
is
o
m
er
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
G
ly
1
59
A
sp
 
1
6
2 
LIII
  
LII 
1
7
9
2
6
7
0 
A
 
 
 
 
 
 
c 
C
 
C
 
A
 
A
 
 
 
C
 
A
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
7
9
6
5
1
3 
G
 
T 
 
 
 
 
G
 
G
 
 
G
 
G
 
T 
 
G
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
4
90
 
fa
d
H
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
8
0
3
2
9
1 
C
 
 
 
 
 
 
C
 
C
 
 
T 
C
 
 
 
C
 
C
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
4
96
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
8
1
9
5
4
3 
G
 
 
 
 
 
 
t 
T 
T 
G
 
G
 
 
 
T 
G
 
 
 
d
o
w
n
st
. 
1
4 
b
. 
M
o
d
i
f.
 
M
L1
5
08
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
 
 
1
8
2
2
9
6
3 
G
 
 
 
 
 
 
G
 
a 
 
G
 
G
 
 
 
G
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
5
12
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
P
ro
5
4
9
S
er
 
5
5
8 
1
8
2
8
1
2
6 
A
 
 
 
 
 
 
A
 
A
 
A
 
G
 
A
 
 
 
A
 
A
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
8
3
6
4
6
4 
T 
 
 
 
 
 
T 
T 
 
C
 
T 
 
 
T 
T 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
5
21
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
8
4
1
2
7
9 
C
 
 
 
 
 
 
 
 
 
c 
 
 
 
 
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
5
27
 
d
ap
B
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
8
4
1
2
8
1 
C
 
 
 
 
 
 
 
g 
 
c 
 
 
 
 
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
5
27
 
d
ap
B
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
8
4
1
2
8
2 
T 
 
 
 
 
 
 
 
 
t 
 
 
 
 
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
5
27
 
d
ap
B
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
8
4
3
2
8
3 
C
 
 
 
 
 
 
A
 
A
 
A
 
A
 
A
 
 
 
A
 
A
 
A
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
5
28
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
8
4
6
7
7
8 
C
 
 
 
 
 
 
C
 
T 
 
C
 
C
 
 
 
C
 
C
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
5
31
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
8
4
8
1
7
8 
G
 
 
 
 
 
 
 
G
 
 
T 
 
 
 
 
G
 
 
 
d
o
w
n
st
. 
9
7 
b
. 
M
o
d
i
f.
 
M
L1
5
32
 
al
d
 
se
cr
et
ed
 L
-a
la
n
in
e 
d
eh
yd
ro
ge
n
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
 
 
1
8
4
8
1
7
8 
G
 
 
 
 
 
 
 
G
 
 
T 
 
 
 
 
G
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
8
4
8
1
8
1 
T 
 
 
 
 
 
 
T 
 
G
 
 
 
 
 
T 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
8
4
9
0
2
4 
T 
 
 
 
 
 
 
 
 
t 
 
 
 
 
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
5
33
 
P
P
E 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
8
4
9
0
2
6 
G
 
 
 
 
 
 
 
 
 
g 
 
 
 
 
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
5
33
 
P
P
E 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
8
4
9
0
2
9 
G
 
 
 
 
 
 
 
 
 
g 
 
 
 
 
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
5
33
 
P
P
E 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
8
7
2
7
8
5 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
T 
C
 
C
 
 
sy
n
. 
Lo
w
 
M
L1
5
48
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
P
ro
2
7
3
P
ro
 
3
2
1 
1
8
8
1
6
7
1 
T 
 
 
 
 
 
T 
T 
 
T 
T 
 
 
T 
T 
T 
g 
sy
n
. 
Lo
w
 
M
L1
5
56
 
in
fB
 
in
it
ia
ti
o
n
 f
ac
to
r 
IF
-2
 
In
f.
 p
at
h
w
ay
s 
V
al
4
27
V
al
 
9
2
4 
1
8
9
0
2
4
3 
C
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
 
G
 
G
 
G
 
G
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
5
64
 
co
b
B
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
LIV
  
LIII 
1
8
9
0
2
4
4 
G
 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
 
C
 
C
 
C
 
C
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
5
64
 
co
b
B
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
8
9
2
0
7
6 
C
 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
 
C
 
C
 
T 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
5
67
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
8
9
7
1
8
7 
C
 
 
 
 
A
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
C
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
5
71
 
n
ic
T 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
9
0
0
0
0
6 
G
 
 
 
 
A
 
 
A
 
A
 
A
 
G
 
A
 
 
 
A
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
5
74
 
gl
n
A
4 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
9
1
2
4
5
6 
A
 
 
 
 
 
 
 
 
 
a 
 
 
 
 
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
5
86
 
m
p
t5
3 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
9
2
3
7
2
7 
A
 
 
 
 
 
 
 
A
 
 
A
 
A
 
 
 
A
 
A
 
 
a 
sy
n
. 
Lo
w
 
M
L1
5
98
 
rp
sB
 
3
0
S 
ri
b
o
so
m
al
 p
ro
te
in
 S
2 
In
f.
 p
at
h
w
ay
s 
G
ly
9
8G
l
y 
2
7
7 
1
9
2
6
6
9
6 
T 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
C
 
C
 
T 
 
 
d
o
w
n
st
. 
5
8 
b
. 
M
o
d
i
f.
 
M
L1
6
01
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
 
 
1
9
2
6
6
9
6 
T 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
C
 
C
 
T 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
9
3
4
2
9
3 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
 
G
 
T 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
1
9
3
7
2
3
3 
G
 
 
 
 
 
 
G
 
G
 
 
A
 
G
 
 
 
G
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
6
13
 
rp
lS
 
5
0
S 
ri
b
o
so
m
al
 p
ro
te
in
 L
1
9 
In
f.
 p
at
h
w
ay
s 
P
ro
7
4
Le
u
 
1
1
3 
1
9
4
4
3
1
9 
C
 
 
 
 
 
 
c 
C
 
 
C
 
C
 
 
 
C
 
C
 
C
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
6
22
 
ff
h
 
si
gn
al
 r
ec
o
gn
it
io
n
 p
ar
ti
cl
e 
p
ro
te
in
 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
G
ly
3
50
S
er
 
5
2
1 
1
9
6
2
0
3
6 
C
 
 
 
 
 
 
T 
T 
 
C
 
T 
 
T 
T 
C
 
C
 
T 
sy
n
. 
Lo
w
 
M
L1
6
30
 
gl
n
E 
gl
u
ta
m
at
e-
am
m
o
n
ia
-l
ig
as
e 
ad
en
yl
tr
an
sf
er
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
Th
r2
8
8
T
h
r 
1
0
0
4 
1
9
6
3
5
2
4 
G
 
 
 
 
 
 
 
G
 
 
G
 
G
 
 
 
G
 
A
 
A
 
 
sy
n
. 
Lo
w
 
M
L1
6
31
 
gl
n
A
2 
gl
u
ta
m
in
e 
sy
n
th
as
e 
cl
as
s 
II 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
Se
r2
5
1
S
e 
4
4
8 
1
9
7
2
1
4
6 
A
 
 
 
 
 
 
A
 
A
 
 
A
 
A
 
 
 
A
 
A
 
a 
 
_e
xo
n
 
M
o
d
i
f.
 
M
L1
6
36
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
9
7
2
2
1
4 
T 
 
 
 
 
 
T 
T 
 
T 
T 
 
 
T 
T 
t 
 
u
p
st
. 4
 b
. 
M
o
d
i
f.
 
M
L1
6
36
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
1
9
7
2
2
1
4 
T 
 
 
 
 
 
T 
T 
 
T 
T 
 
 
T 
T 
t 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
0
0
7
1
6
6 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
T 
C
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
6
65
 
p
ca
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
0
0
8
0
2
1 
G
 
 
 
 
 
 
g 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
G
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
6
65
 
p
ca
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
0
1
1
7
4
7 
T 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
G
 
G
 
G
 
G
 
G
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
6
68
 
lip
N
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
0
1
5
3
2
0 
G
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
6
71
 
re
cG
 
A
TP
-d
ep
en
d
en
t 
D
N
A
 h
el
ic
as
e 
In
f.
 p
at
h
w
ay
s 
A
sp
5
45
G
lu
 
7
4
3 
2
0
1
7
9
4
3 
A
 
 
 
 
 
 
A
 
A
 
A
 
G
 
A
 
 
 
A
 
A
 
A
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
6
72
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
LV
  
LIV 
2
0
2
3
4
0
4 
A
 
 
 
 
 
 
A
 
A
 
A
 
C
 
A
 
 
 
A
 
A
 
A
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
6
79
 
gp
d
A
 
gl
yc
er
o
l-
3
-p
h
o
sp
h
at
e 
d
eh
yd
ro
ge
n
as
e 
Li
p
id
 m
et
ab
o
lis
m
 
V
al
2
46
G
ly
 
3
5
1 
2
0
2
9
4
0
3 
C
 
 
 
 
 
 
C
 
T 
 
C
 
C
 
 
 
C
 
C
 
C
 
 
u
p
st
. 8
4
 b
. 
M
o
d
i
f.
 
M
L1
6
83
 
h
u
p
B
 
D
N
A
-b
in
d
in
g 
p
ro
te
in
 H
U
 h
o
m
o
lo
g 
In
f.
 p
at
h
w
ay
s 
 
 
2
0
2
9
4
0
3 
C
 
 
 
 
 
 
C
 
T 
 
C
 
C
 
 
 
C
 
C
 
C
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
0
3
9
3
3
0 
C
 
 
 
 
 
 
C
 
C
 
C
 
A
 
C
 
 
 
C
 
C
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
6
92
 
se
rA
1 
D
-3
-p
h
o
sp
h
o
gl
yc
er
at
e 
d
eh
yd
ro
ge
n
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
A
la
1
5
8
S
er
 
5
2
8 
2
0
4
3
2
8
7 
A
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
G
 
 
sy
n
. 
Lo
w
 
M
L1
6
94
 
ilv
C
 
ke
to
l-
ac
id
 r
ed
u
ct
o
is
o
m
er
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
P
ro
1
4
5
P
ro
 
3
3
3 
2
0
5
5
2
2
2 
T 
 
 
 
 
 
T 
T 
 
C
 
T 
 
 
T 
T 
 
 
sy
n
. 
Lo
w
 
M
L1
7
04
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
A
sp
6
0A
sp
 
2
3
2 
2
0
6
5
1
9
4 
C
 
 
 
 
 
 
 
C
 
C
 
C
 
G
 
 
 
C
 
C
 
C
 
 
sy
n
. 
Lo
w
 
M
L1
7
12
 
fi
xA
 
el
ec
tr
o
n
 
tr
an
sf
er
 
fl
av
o
p
ro
te
in
 
b
et
a-
su
b
u
n
it
 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
Se
r2
2
9
S
er
 
2
6
6 
2
0
7
7
0
0
4 
G
 
 
 
 
 
 
G
 
G
 
A
 
G
 
G
 
 
 
G
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
7
20
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
V
al
3
02
Il
e 
3
6
4 
2
0
8
5
7
4
8 
C
 
 
 
 
 
 
C
 
C
 
c 
C
 
C
 
 
 
C
 
C
 
C
 
 
sy
n
. 
Lo
w
 
M
L1
7
28
 
ct
aD
 
cy
to
ch
ro
m
e 
C
 o
xi
d
as
e,
 p
o
ly
p
ep
ti
d
e 
I 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
G
ly
2
00
G
ly
 
5
7
4 
2
1
0
0
5
2
3 
C
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
G
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
7
40
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
A
la
1
3
3
P
ro
 
3
1
2 
2
1
0
4
1
2
7 
T 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
C
 
C
 
C
 
C
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
1
0
4
8
4
0 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
 
A
 
G
 
G
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
1
1
4
6
9
6 
G
 
 
 
 
 
 
A
 
A
 
 
A
 
A
 
 
 
A
 
A
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
1
1
5
6
6
2 
G
 
 
 
 
 
 
G
 
g 
 
G
 
G
 
 
 
G
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
7
50
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
Se
r4
4
4
L
eu
 
6
2
3 
2
1
1
6
2
9
8 
T 
 
 
 
 
 
t 
T 
T 
T 
T 
 
 
T 
T 
T 
 
m
is
s.
 
M
o
d
er
. 
M
L1
7
50
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
A
sp
2
32
G
ly
 
6
2
3 
2
1
1
6
7
4
8 
G
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
g 
G
 
G
 
m
is
s.
 
M
o
d
er
. 
M
L1
7
50
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
A
la
8
2
A
s
p
 
6
2
3 
2
1
1
6
8
6
6 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
c 
C
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
7
50
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
V
al
4
3M
et
 
6
2
3 
2
1
1
9
4
6
8 
T 
 
 
 
 
 
 
T 
T 
C
 
T 
 
 
T 
T 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
1
2
6
5
9
0 
C
 
 
 
 
 
 
C
 
C
 
 
A
 
C
 
 
 
C
 
C
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
7
53
 
 
tr
an
sc
ri
p
ti
o
n
al
 r
eg
u
la
to
ry
 p
ro
te
in
 
R
eg
. p
ro
te
in
s 
A
sp
1
67
Ty
r 
1
1
0
6 
2
1
2
7
7
6
9 
A
 
 
 
 
 
 
 
A
 
 
a 
A
 
 
 
A
 
A
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
1
2
7
7
7
0 
C
 
 
 
 
 
 
 
C
 
 
A
 
C
 
 
 
C
 
C
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
LVI
  
LV 
2
1
2
7
7
7
1 
G
 
 
 
 
 
 
 
G
 
 
A
 
G
 
 
 
G
 
G
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
1
3
9
6
7
5 
G
 
 
 
 
 
 
 
G
 
 
G
 
A
 
 
 
G
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
7
64
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
1
4
6
8
9
7 
G
 
 
 
 
 
 
G
 
G
 
G
 
G
 
A
 
 
 
G
 
G
 
G
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
7
71
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
1
5
5
0
1
3 
T 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
G
 
G
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
7
78
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
1
5
5
0
1
3 
T 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
G
 
G
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
7
78
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
1
6
5
0
9
8 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
T 
C
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
1
7
4
8
6
5 
G
 
C
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
C
 
 
C
 
C
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
1
7
5
5
8
7 
C
 
 
 
 
 
 
C
 
C
 
 
G
 
C
 
 
 
C
 
C
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
7
96
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
G
ln
9
6
G
l
u
 
1
3
7 
2
1
7
9
1
6
4 
G
 
 
 
 
 
 
G
 
G
 
 
A
 
G
 
 
 
G
 
G
 
G
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
7
99
 
m
u
tB
 
m
et
h
yl
m
al
o
n
yl
-C
o
A
 m
u
ta
se
 
Li
p
id
 m
et
ab
o
lis
m
 
A
la
3
3
9
V
al
 
7
5
8 
2
1
8
4
9
8
4 
G
 
 
 
 
 
 
 
G
 
 
G
 
A
 
 
 
G
 
G
 
G
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
8
04
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
G
ly
4
7A
s
p
 
2
9
8 
2
2
0
2
1
3
9 
T 
 
 
 
 
 
T 
T 
 
T 
T 
 
 
T 
C
 
C
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
8
19
 
ct
p
D
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
2
0
4
0
0
5 
T 
 
 
 
 
 
c 
T 
C
 
T 
T 
 
 
C
 
T 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
8
20
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
2
1
1
0
3
6 
C
 
 
 
 
 
 
 
C
 
 
C
 
C
 
 
 
 
c 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
2
1
4
8
7
6 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
A
 
 
 
G
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
8
29
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
V
al
2
2
Ile
 
1
2
5 
2
2
3
5
0
4
8 
C
 
 
 
 
 
 
C
 
C
 
 
T 
C
 
 
 
C
 
C
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
8
51
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
2
3
5
8
1
0 
C
 
 
 
 
 
 
 
C
 
 
T 
C
 
 
 
C
 
C
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
8
52
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
2
5
6
0
1
2 
T 
 
 
 
 
 
T 
T 
 
T 
T 
 
c 
T 
T 
 
 
sy
n
. 
Lo
w
 
M
L1
8
77
 
tu
f 
ir
o
n
-r
eg
u
la
te
d
 e
lo
n
ga
ti
o
n
 f
ac
to
r 
In
f.
 p
at
h
w
ay
s 
Th
r3
2
3
T
h
 
3
9
6 
2
2
5
6
7
0
8 
A
 
 
 
 
 
 
A
 
A
 
 
A
 
A
 
 
 
a 
A
 
 
 
sy
n
. 
Lo
w
 
M
L1
8
77
 
tu
f 
ir
o
n
-r
eg
u
la
te
d
 e
lo
n
ga
ti
o
n
 f
ac
to
r 
In
f.
 p
at
h
w
ay
s 
Ile
9
1
Ile
 
3
9
6 
2
2
6
9
8
2
6 
A
 
 
 
 
 
 
A
 
A
 
 
C
 
A
 
 
 
A
 
A
 
A
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
8
90
 
rp
o
C
 
D
N
A
-d
ir
ec
te
d
 
R
N
A
 p
o
ly
m
er
as
e,
 
b
et
a 
ch
ai
n
 
In
f.
 p
at
h
w
ay
s 
Ile
1
1
3
2
Se
 
1
3
1
6 
2
2
9
1
4
8
4 
G
 
 
 
 
 
 
 
G
 
G
 
G
 
G
 
 
 
 
G
 
g 
 
sy
n
. 
Lo
w
 
M
L1
9
05
 
rp
lK
 
5
0
S 
ri
b
o
so
m
al
 p
ro
te
in
 L
1
1 
In
f.
 p
at
h
w
ay
s 
G
ly
3
1G
l
y 
1
4
2 
2
2
9
2
9
1
5 
T 
 
 
 
 
 
T 
t 
 
T 
T 
 
 
 
T 
t 
 
m
is
s.
 
M
o
d
er
. 
M
LP
0
00
0
3
5 
tr
p
T 
tR
N
A
-T
rp
 a
n
ti
co
d
o
n
 C
C
A
 
St
ab
le
 R
N
A
s 
A
sn
2
0
S
er
 
2
3
 
LVII
  
LVI 
2
2
9
2
9
6
8 
G
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
G
 
 
sy
n
. 
Lo
w
 
M
LP
0
00
0
3
5 
tr
p
T 
tR
N
A
-T
rp
 a
n
ti
co
d
o
n
 C
C
A
 
St
ab
le
 R
N
A
s 
G
ly
2
G
ly
 
2
3
 
2
2
9
7
5
6
2 
T 
 
 
 
 
 
T 
T 
 
A
 
T 
 
 
T 
T 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L1
9
14
 
lp
q
N
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
3
1
2
0
5
9 
C
 
 
 
 
 
 
C
 
C
 
 
G
 
C
 
 
 
C
 
C
 
C
 
 
d
o
w
n
st
. 
3
3 
b
. 
M
o
d
i
f.
 
M
L1
9
27
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
 
1
0
3 
2
3
1
2
0
5
9 
C
 
 
 
 
 
 
C
 
C
 
 
G
 
C
 
 
 
C
 
C
 
C
 
 
ST
A
R
T_
LO
ST
 
H
ig
h
 
M
L1
9
26
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
Le
u
1
? 
1
6
7 
2
3
3
8
9
4
8 
C
 
 
 
 
 
 
C
 
C
 
C
 
G
 
C
 
 
 
C
 
C
 
C
 
 
d
o
w
n
st
. 
4
0 
b
. 
M
o
d
i
f.
 
M
L1
9
47
 
fu
m
 
fu
m
ar
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
 
4
7
5 
2
3
3
8
9
4
8 
C
 
 
 
 
 
 
C
 
C
 
C
 
G
 
C
 
 
 
C
 
C
 
C
 
 
u
p
st
. 2
8
 b
. 
M
o
d
i
f.
 
M
L1
9
51
 
p
h
o
H
2 
p
h
o
h
-l
ik
e 
p
ro
te
in
 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
 
4
3
4 
2
3
3
8
9
4
8 
C
 
 
 
 
 
 
C
 
C
 
C
 
G
 
C
 
 
 
C
 
C
 
C
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
3
6
9
3
6
6 
C
 
 
 
 
 
 
C
 
C
 
 
A
 
C
 
 
 
C
 
C
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
3
7
8
3
4
1 
G
 
 
 
 
 
 
a 
A
 
A
 
G
 
G
 
 
 
A
 
G
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
3
8
8
0
7
1 
G
 
 
 
 
 
 
G
 
G
 
 
C
 
G
 
 
 
G
 
G
 
G
 
 
m
is
s.
 
M
o
d
er
. 
M
L1
9
97
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
P
ro
3
2
A
l
a 
2
1
0 
2
3
9
2
8
1
7 
C
 
 
 
 
 
 
c 
C
 
 
C
 
C
 
 
 
C
 
C
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L2
0
00
 
ct
p
B
 
ca
ti
o
n
-t
ra
n
sp
o
rt
er
 P
-t
yp
e 
A
TP
as
e 
B
 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
Le
u
2
5
1
P
h
e 
7
5
0 
2
3
9
6
3
2
6 
C
 
 
 
 
 
 
c 
C
 
C
 
C
 
T 
 
 
C
 
C
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
4
1
1
4
9
8 
T 
 
 
 
 
 
T 
T 
 
T 
T 
 
 
T 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L2
0
20
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
Ty
r6
2
A
s
p
 
3
0
4 
2
4
3
2
3
1
4 
A
 
 
 
 
 
 
A
 
A
 
 
A
 
A
 
 
 
A
 
A
 
G
 
 
sy
n
. 
Lo
w
 
M
L2
0
41
 
o
xy
R
 
h
yd
ro
ge
n
 
p
er
o
xi
d
e-
in
d
u
ci
b
le
 
ge
n
es
 
ac
ti
va
to
r 
R
eg
. p
ro
te
in
s 
A
sp
2
02
A
sp
 
3
1
1 
2
4
3
3
3
2
9 
G
 
 
 
 
 
 
g 
G
 
 
G
 
A
 
 
 
G
 
G
 
G
 
 
m
is
s.
 
M
o
d
er
. 
M
L2
0
42
 
ah
p
C
 
al
ky
l h
yd
ro
p
er
o
xi
d
e 
re
d
u
ct
as
e 
V
ir
u
le
e,
 
d
et
o
xi
fi
ca
ti
o
n
, 
ad
ap
ta
ti
o
n
 
G
lu
1
0
1L
ys
 
1
9
5 
2
4
5
9
7
6
6 
A
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
G
 
G
 
m
is
s.
 
M
o
d
er
. 
M
L2
0
69
 
gl
cB
 
m
al
at
e 
sy
n
th
as
e 
G
 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
Ly
s5
91
G
lu
 
7
3
1 
2
4
8
3
9
0
7 
C
 
 
 
 
 
 
C
 
C
 
 
c 
C
 
 
 
C
 
C
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
0
89
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
4
8
3
9
0
8 
A
 
 
 
 
 
 
A
 
A
 
 
a 
A
 
 
 
A
 
A
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
0
89
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
4
8
3
9
0
9 
A
 
 
 
 
 
 
A
 
A
 
 
a 
A
 
 
 
A
 
A
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
0
89
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
4
8
3
9
1
0 
C
 
 
 
 
 
 
C
 
C
 
 
c 
C
 
 
 
C
 
C
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
0
89
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
4
9
4
2
1
5 
T 
 
 
 
 
 
 
T 
 
C
 
T 
 
 
T 
T 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
0
97
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
LVIII
  
LVII 
2
4
9
8
2
8
1 
C
 
 
 
 
 
 
 
C
 
 
C
 
C
 
 
 
C
 
T 
T 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
5
0
0
0
1
1 
G
 
 
 
 
 
 
T 
G
 
 
A
 
G
 
 
 
G
 
G
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
5
0
1
4
7
9 
G
 
 
 
 
 
 
g 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
1
03
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
5
0
3
2
8
9 
A
 
G
 
 
 
 
 
 
A
 
 
A
 
A
 
G
 
 
A
 
A
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
5
0
4
9
2
5 
C
 
 
 
 
 
 
C
 
C
 
T 
C
 
C
 
 
 
C
 
C
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
5
1
4
9
6
5 
A
 
 
 
 
 
 
a 
A
 
 
A
 
A
 
 
 
A
 
A
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
1
15
 
ct
p
E 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
5
4
2
1
8
8 
A
 
 
 
 
 
 
A
 
A
 
 
A
 
A
 
 
 
A
 
C
 
C
 
 
m
is
s.
 
M
o
d
er
. 
M
L2
1
40
 
 
tr
an
sc
ri
p
ti
o
n
al
 r
eg
u
la
to
ry
 p
ro
te
in
 
R
eg
. p
ro
te
in
s 
P
h
e7
7
V
al
 
1
4
3 
2
5
4
2
3
1
3 
G
 
 
 
 
 
 
A
 
A
 
A
 
G
 
A
 
 
 
A
 
G
 
G
 
 
m
is
s.
 
M
o
d
er
. 
M
L2
1
40
 
 
tr
an
sc
ri
p
ti
o
n
al
 r
eg
u
la
to
ry
 p
ro
te
in
 
R
eg
. p
ro
te
in
s 
Se
r3
5
Le
u
 
1
4
3 
2
5
4
8
2
7
8 
A
 
 
 
 
 
 
A
 
A
 
A
 
A
 
A
 
 
 
A
 
A
 
a 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
1
45
 
cy
cA
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
5
5
3
1
7
6 
T 
 
 
 
G
 
 
G
 
G
 
G
 
G
 
G
 
 
G
 
G
 
G
 
G
 
G
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
1
49
 
m
o
aA
2
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
5
5
6
5
3
8 
G
 
 
 
 
 
 
 
G
 
 
G
 
A
 
 
 
G
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
1
49
 
m
o
aC
2
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
5
6
4
8
7
2 
T 
 
 
 
 
 
T 
T 
 
C
 
T 
 
 
T 
T 
T 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
5
6
7
2
6
4 
G
 
 
 
 
 
 
 
G
 
G
 
g 
G
 
 
 
G
 
t 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
5
8
1
8
8
3 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
 
A
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
1
71
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
5
8
2
3
5
3 
A
 
 
 
 
 
 
A
 
A
 
 
A
 
G
 
 
 
A
 
A
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
1
71
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
5
8
7
0
8
0 
C
 
 
 
C
 
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
C
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
5
9
4
7
0
2 
C
 
 
 
 
 
 
c 
c 
c 
C
 
C
 
 
c 
c 
C
 
c 
c 
m
is
s.
 
M
o
d
er
. 
M
LP
0
00
0
4
0 
as
p
T 
tR
N
A
-A
sp
 a
n
ti
co
d
o
n
 G
TC
 
St
ab
le
 R
N
A
s 
G
lu
2
0
Ly
s 
2
4
 
2
5
9
4
7
0
2 
C
 
 
 
 
 
 
c 
c 
c 
C
 
C
 
 
c 
c 
C
 
c 
c 
d
o
w
n
st
. 
8
8 
b
. 
M
o
d
i
f.
 
M
LP
0
00
0
4
1 
gl
u
T 
tR
N
A
-G
lu
 a
n
ti
co
d
o
n
 T
TC
 
St
ab
le
 R
N
A
s 
 
2
4
 
2
5
9
4
7
3
4 
G
 
 
 
 
 
 
G
 
G
 
g 
G
 
G
 
 
G
 
G
 
G
 
G
 
G
 
m
is
s.
 
M
o
d
er
. 
M
LP
0
00
0
4
0 
as
p
T 
tR
N
A
-A
sp
 a
n
ti
co
d
o
n
 G
TC
 
St
ab
le
 R
N
A
s 
A
la
9
V
al
 
2
4
 
2
5
9
4
7
3
4 
G
 
 
 
 
 
 
G
 
G
 
g 
G
 
G
 
 
G
 
G
 
G
 
G
 
G
 
d
o
w
n
st
. 
5
6 
b
. 
M
o
d
i
f.
 
M
LP
0
00
0
4
1 
gl
u
T 
tR
N
A
-G
lu
 a
n
ti
co
d
o
n
 T
TC
 
St
ab
le
 R
N
A
s 
 
2
4
 
2
5
9
4
7
3
4 
G
 
 
 
 
 
 
G
 
G
 
g 
G
 
G
 
 
G
 
G
 
G
 
G
 
G
 
u
p
st
. 8
0
 b
. 
M
o
d
i
f.
 
M
LP
0
00
0
3
9 
p
h
eU
 
tR
N
A
-P
h
e 
an
ti
co
d
o
n
 G
A
A
 
St
ab
le
 R
N
A
s 
 
2
4
 
LIX
  
LVIII 
2
5
9
4
8
4
7 
A
 
 
 
 
 
 
A
 
A
 
 
A
 
A
 
 
 
A
 
A
 
g 
 
m
is
s.
 
M
o
d
er
. 
M
LP
0
00
0
4
1 
gl
u
T 
tR
N
A
-G
lu
 a
n
ti
co
d
o
n
 T
TC
 
St
ab
le
 R
N
A
s 
Tr
p
6
A
rg
 
2
4
 
2
5
9
4
8
4
7 
A
 
 
 
 
 
 
A
 
A
 
 
A
 
A
 
 
 
A
 
A
 
g 
 
u
p
st
. 8
8
 b
. 
M
o
d
i
f.
 
M
LP
0
00
0
3
9 
p
h
eU
 
tR
N
A
-P
h
e 
an
ti
co
d
o
n
 G
A
A
 
St
ab
le
 R
N
A
s 
 
2
4
 
2
6
5
0
2
4
0 
A
 
 
 
 
 
 
A
 
A
 
 
G
 
A
 
 
 
A
 
A
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
2
32
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
6
5
4
1
1
9 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
T 
T 
 
m
is
s.
 
M
o
d
er
. 
M
L2
2
35
 
p
u
rD
 
p
h
o
sp
h
o
ri
b
o
sy
la
m
in
e-
gl
yc
in
e 
lig
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
A
sp
1
63
A
sn
 
4
2
2 
2
6
5
9
8
4
1 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
 
A
 
G
 
 
 
d
o
w
n
st
. 
7
5 
b
. 
M
o
d
i
f.
 
M
LP
0
00
0
4
3 
th
rV
 
tR
N
A
-T
h
r 
an
ti
co
d
o
n
 T
G
T 
St
ab
le
 R
N
A
s 
 
2
4
 
2
6
5
9
8
4
1 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
 
A
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
2
41
 
P
E_
P
G
R
S 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
6
6
2
6
2
9 
C
 
 
 
 
 
 
C
 
C
 
C
 
T 
C
 
 
 
C
 
C
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
7
0
6
2
3
6 
T 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
 
G
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
2
81
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
7
1
0
1
9
4 
A
 
 
 
 
 
 
A
 
A
 
 
G
 
A
 
 
 
A
 
A
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
2
86
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
7
1
2
8
4
2 
G
 
 
 
 
 
 
g 
G
 
 
G
 
G
 
 
 
G
 
G
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
7
2
0
8
1
7 
G
 
 
 
 
 
 
G
 
G
 
 
A
 
G
 
 
 
G
 
G
 
 
 
sy
n
. 
Lo
w
 
M
L2
2
95
 
 
p
ro
te
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
G
ly
1
48
G
ly
 
2
3
4 
2
7
3
1
4
0
5 
G
 
 
 
 
 
 
G
 
G
 
G
 
A
 
G
 
 
 
G
 
G
 
 
 
d
o
w
n
st
. 
4
7 
b
. 
M
o
d
i
f.
 
M
L2
3
06
 
 
an
io
n
 t
ra
n
sp
o
rt
er
 A
TP
as
e 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
 
3
8
2 
2
7
3
1
4
0
5 
G
 
 
 
 
 
 
G
 
G
 
G
 
A
 
G
 
 
 
G
 
G
 
 
 
d
o
w
n
st
. 
5
8 
b
. 
M
o
d
i
f.
 
M
L2
3
07
 
w
h
iB
4 
w
h
iB
-l
ik
e 
re
gu
la
to
ry
 p
ro
te
in
 
R
eg
. p
ro
te
in
s 
 
1
1
7 
2
7
3
6
8
1
2 
C
 
 
 
 
 
 
 
C
 
C
 
C
 
C
 
 
c 
 
C
 
c 
c 
m
is
s.
 
M
o
d
er
. 
M
LP
0
00
0
4
5 
p
ro
Y 
tR
N
A
-P
ro
 a
n
ti
co
d
o
n
 C
G
G
 
St
ab
le
 R
N
A
s 
Le
u
6
P
h
e 
2
3
 
2
7
3
6
8
4
4 
C
 
 
 
 
 
 
c 
c 
c 
C
 
C
 
 
t 
c 
C
 
c 
t 
sy
n
. 
Lo
w
 
M
LP
0
00
0
4
5 
p
ro
Y 
tR
N
A
-P
ro
 a
n
ti
co
d
o
n
 C
G
G
 
St
ab
le
 R
N
A
s 
G
ly
1
6G
l
y 
2
3
 
2
7
5
1
7
8
3 
A
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
A
 
 
 
sy
n
. 
Lo
w
 
M
L2
3
22
 
as
d
 
as
p
ar
ta
te
 
se
m
ia
ld
eh
yd
e 
d
eh
yd
ro
ge
n
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
A
la
2
9
9
A
la
 
3
5
1 
2
7
6
9
0
4
7 
A
 
 
 
 
 
 
 
A
 
 
A
 
A
 
 
 
A
 
A
 
a 
 
u
p
st
. 4
 b
. 
M
o
d
i
f.
 
M
L2
3
36
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
 
4
2
7 
2
7
6
9
0
4
7 
A
 
 
 
 
 
 
 
A
 
 
A
 
A
 
 
 
A
 
A
 
a 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
7
6
9
0
8
2 
A
 
 
 
 
 
 
A
 
A
 
 
A
 
A
 
 
 
A
 
A
 
a 
 
u
p
st
. 3
9
 b
. 
M
o
d
i
f.
 
M
L2
3
36
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
 
 
2
7
6
9
0
8
2 
A
 
 
 
 
 
 
A
 
A
 
 
A
 
A
 
 
 
A
 
A
 
a 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
7
7
5
0
5
0 
G
 
 
 
 
 
 
G
 
G
 
G
 
A
 
G
 
 
 
G
 
G
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
LX
  
LIX 
2
7
8
5
4
6
2 
A
 
 
 
 
 
 
 
A
 
 
a 
A
 
 
 
 
A
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
7
8
5
4
6
6 
G
 
 
 
 
 
 
 
 
 
g 
G
 
 
 
 
G
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
7
8
9
2
2
5 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
A
 
G
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L2
3
47
 
 
m
em
b
ra
n
e 
p
ro
te
in
 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
A
rg
3
0
9
H
is
 
3
3
6 
2
8
0
2
5
6
9 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
T 
 
 
sy
n
. 
Lo
w
 
M
L2
3
54
 
p
p
sD
 
ty
p
e-
I p
o
ly
ke
ti
d
e 
sy
n
th
as
e 
Li
p
id
 m
et
ab
o
lis
m
 
A
la
7
6
8
A
la
 
1
8
2
2 
2
8
1
4
7
5
8 
G
 
 
 
 
 
 
 
G
 
 
G
 
A
 
 
 
G
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L2
3
56
 
p
p
sB
 
ty
p
e-
I p
o
ly
ke
ti
d
e 
sy
n
th
as
e 
Li
p
id
 m
et
ab
o
lis
m
 
Le
u
4
4
6
P
h
e 
1
5
4
0 
2
8
1
5
2
3
2 
G
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
A
 
G
 
 
 
sy
n
. 
Lo
w
 
M
L2
3
56
 
p
p
sB
 
ty
p
e-
I p
o
ly
ke
ti
d
e 
sy
n
th
as
e 
Li
p
id
 m
et
ab
o
lis
m
 
Le
u
2
8
8
L
eu
 
1
5
4
0 
2
8
1
8
5
2
1 
T 
 
 
 
C
 
 
C
 
C
 
C
 
C
 
C
 
 
 
C
 
C
 
C
 
C
 
sy
n
. 
Lo
w
 
M
L2
3
57
 
p
p
sA
 
ty
p
e-
I p
o
ly
ke
ti
d
e 
sy
n
th
as
e 
Li
p
id
 m
et
ab
o
lis
m
 
G
ln
1
0
63
G
ln
 
1
8
7
1 
2
8
2
0
1
6
7 
A
 
 
 
 
 
 
A
 
A
 
A
 
G
 
A
 
 
 
A
 
A
 
A
 
 
m
is
s.
 
M
o
d
er
. 
M
L2
3
57
 
p
p
sA
 
ty
p
e-
I p
o
ly
ke
ti
d
e 
sy
n
th
as
e 
Li
p
id
 m
et
ab
o
lis
m
 
P
h
e5
1
5
Le
u
 
1
8
7
1 
2
8
2
2
9
6
7 
A
 
 
 
 
 
 
A
 
A
 
 
G
 
A
 
 
 
A
 
A
 
A
 
 
m
is
s.
 
M
o
d
er
. 
M
L2
3
58
 
fa
d
D
2
6
 
fa
tt
y-
ac
id
-C
o
A
 s
yn
th
et
as
e 
Li
p
id
 m
et
ab
o
lis
m
 
P
h
e1
6
4
Se
r 
5
8
3 
2
8
3
1
8
1
9 
C
 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
T 
C
 
C
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
8
5
6
3
8
7 
G
 
 
 
 
 
 
G
 
A
 
G
 
G
 
G
 
 
 
G
 
G
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
8
7
3
4
1
2 
T 
 
 
 
 
 
T 
T 
T 
C
 
T 
 
 
T 
T 
T 
 
sy
n
. 
Lo
w
 
M
L2
4
02
 
ec
h
A
8 
en
o
yl
-C
o
A
 h
yd
ra
ta
se
 
Li
p
id
 m
et
ab
o
lis
m
 
Th
r1
9
4
T
h
 
2
5
7 
2
8
8
1
0
8
7 
G
 
 
 
 
 
 
G
 
G
 
G
 
A
 
G
 
 
 
G
 
G
 
 
 
sy
n
. 
Lo
w
 
M
L2
4
10
 
M
L2
4
1
0
 
tr
an
sm
em
b
ra
n
e 
p
ro
te
in
 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
A
la
5
2
1
A
la
 
5
4
2 
2
8
8
7
0
9
4 
C
 
 
 
 
 
 
 
 
 
C
 
 
 
 
 
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
8
9
3
0
9
1 
G
 
 
 
 
 
 
 
 
 
t 
 
 
 
 
t 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
8
9
3
0
9
3 
G
 
 
 
 
 
 
 
 
 
g 
 
 
 
 
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
9
0
0
2
7
6 
C
 
 
 
 
 
 
C
 
C
 
 
G
 
C
 
 
 
C
 
C
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L2
4
24
 
se
r1
B
 
p
h
o
sp
h
o
se
ri
n
e 
p
h
o
sp
h
at
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
A
la
9
3
G
l
y 
3
0
0 
2
9
0
2
2
5
7 
C
 
 
 
 
 
 
C
 
C
 
C
 
G
 
C
 
 
 
C
 
C
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L2
4
26
 
cm
aA
2 
cy
cl
o
p
ro
p
an
e 
m
yc
o
lic
 a
ci
d
 s
yn
th
as
e 
Li
p
id
 m
et
ab
o
lis
m
 
A
rg
2
4
8
G
ly
 
3
0
8 
2
9
0
5
3
2
2 
G
 
 
 
 
 
 
G
 
G
 
G
 
G
 
A
 
 
 
G
 
G
 
G
 
 
m
is
s.
 
M
o
d
er
. 
M
L2
4
29
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
A
rg
1
0
Tr
p
 
8
6
 
2
9
1
5
0
9
8 
A
 
 
 
 
 
 
A
 
A
 
 
a 
A
 
 
 
A
 
A
 
A
 
 
u
p
st
. 1
3
 b
. 
M
o
d
i
f.
 
M
L2
4
39
 
re
gX
3 
se
n
so
ry
 t
ra
n
sd
u
ct
io
n
 p
ro
te
in
 
R
eg
. p
ro
te
in
s 
 
1
9
9 
2
9
1
5
0
9
8 
A
 
 
 
 
 
 
A
 
A
 
 
a 
A
 
 
 
A
 
A
 
A
 
 
d
o
w
n
st
. 
3
0 
b
. 
M
o
d
i
f.
 
M
L2
4
40
 
se
n
X
3 
se
n
so
r 
h
is
ti
d
in
e 
ki
n
as
e 
R
eg
. p
ro
te
in
s 
 
4
4
2 
LXI
  
LX 
2
9
1
5
0
9
8 
A
 
 
 
 
 
 
A
 
A
 
 
a 
A
 
 
 
A
 
A
 
A
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
9
3
5
6
8
5 
A
 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
 
C
 
A
 
A
 
C
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
4
62
 
ic
l 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
9
3
6
4
0
1 
G
 
 
 
 
 
 
G
 
G
 
G
 
A
 
G
 
 
 
G
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
4
62
 
ic
l 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
2
9
4
4
1
7
8 
C
 
 
 
 
 
 
C
 
C
 
 
a 
C
 
 
 
G
 
G
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
9
4
4
1
8
1 
A
 
 
 
 
 
 
A
 
A
 
 
C
 
A
 
 
 
A
 
A
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
9
4
5
5
1
0 
A
 
 
 
 
 
 
 
A
 
 
G
 
A
 
 
 
 
A
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
9
4
5
5
1
2 
A
 
 
 
 
 
 
 
A
 
 
g 
A
 
 
 
 
A
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
9
4
5
5
1
3 
A
 
 
 
 
 
 
 
A
 
 
g 
A
 
 
 
 
A
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
9
4
5
5
3
0 
A
 
 
 
 
 
 
 
 
 
t 
A
 
 
 
 
A
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
9
4
5
5
3
1 
T 
 
 
 
 
 
 
 
 
T 
T 
 
 
 
T 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
9
4
5
5
3
2 
C
 
 
 
 
 
 
 
 
 
t 
C
 
 
 
 
C
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
9
4
8
1
0
5 
G
 
 
 
 
 
 
 
G
 
 
g 
 
 
 
 
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L2
4
72
 
ty
rA
 
p
re
p
h
en
at
e 
d
eh
yd
ro
ge
n
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
A
rg
1
3
G
l
y 
3
2
7 
2
9
4
8
1
0
9 
G
 
 
 
 
 
 
 
 
 
g 
 
 
 
 
 
 
 
sy
n
. 
Lo
w
 
M
L2
4
72
 
ty
rA
 
p
re
p
h
en
at
e 
d
eh
yd
ro
ge
n
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
V
al
1
1
V
a
l 
3
2
7 
2
9
5
1
8
2
2 
T 
 
 
 
 
 
 
 
 
t 
 
 
 
 
T 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
9
5
1
8
2
3 
A
 
 
 
 
 
 
 
 
 
a 
 
 
 
 
A
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
9
6
1
7
8
5 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
C
 
 
 
G
 
G
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
9
6
4
9
9
9 
T 
 
 
 
C
 
 
C
 
C
 
C
 
C
 
C
 
 
 
C
 
C
 
C
 
C
 
sy
n
. 
Lo
w
 
M
L2
4
90
 
cl
p
B
 
en
d
o
p
ep
ti
d
as
e 
A
TP
 b
in
d
in
g 
p
ro
te
in
 
V
ir
u
le
e,
 
d
et
o
xi
fi
ca
ti
o
n
, 
ad
ap
ta
ti
o
n
 
G
lu
2
5
6
G
lu
 
8
4
8 
2
9
6
9
1
6
8 
C
 
 
 
 
 
 
C
 
C
 
 
G
 
C
 
 
 
C
 
C
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
9
7
1
0
5
5 
T 
 
 
C
 
 
 
T 
T 
T 
T 
T 
 
 
T 
T 
 
 
m
is
s.
 
M
o
d
er
. 
M
L2
4
95
 
gr
p
E 
gr
p
E 
p
ro
te
in
 
V
ir
u
le
e,
 
d
et
o
xi
fi
ca
ti
o
n
, 
ad
ap
ta
ti
o
n
 
H
is
1
7
2
A
rg
 
2
2
9 
2
9
7
8
0
2
3 
C
 
 
 
 
 
 
C
 
C
 
 
T 
C
 
 
 
C
 
C
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
9
7
8
3
7
4 
C
 
 
 
 
 
 
A
 
A
 
A
 
C
 
A
 
 
 
A
 
C
 
 
A
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
LXII
  
LXI 
2
9
9
0
1
5
0 
T 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
 
C
 
C
 
C
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
9
9
2
3
4
0 
T 
 
 
 
 
 
T 
T 
 
C
 
T 
 
 
T 
T 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
2
9
9
9
9
7
6 
C
 
 
 
 
 
 
T 
T 
T 
C
 
T 
 
 
T 
C
 
 
T 
m
is
s.
 
M
o
d
er
. 
M
L2
5
18
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
G
ly
7
8A
s
p
 
1
3
0 
3
0
1
6
1
7
5 
T 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
 
C
 
C
 
C
 
 
sy
n
. 
Lo
w
 
M
L2
5
34
 
P
E1
0 
P
E-
fa
m
ily
 p
ro
te
in
 
P
E/
P
P
E 
V
al
7
9
V
a
l 
1
0
2 
3
0
2
1
9
6
5 
C
 
 
 
 
 
 
 
C
 
C
 
T 
C
 
 
 
C
 
C
 
 
 
sy
n
. 
Lo
w
 
M
L2
5
36
 
ec
cB
3 
ES
X
 c
o
m
p
o
n
en
t 
p
ro
te
in
 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
V
al
4
2
V
a
l 
5
5
2 
3
0
3
1
6
3
6 
G
 
 
 
 
 
 
G
 
G
 
 
C
 
G
 
 
 
G
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
5
45
 
fa
d
E6
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
3
0
4
1
9
0
0 
T 
 
 
 
 
 
T 
T 
T 
C
 
T 
 
 
T 
T 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
5
52
 
n
ar
K3
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
3
0
4
7
6
4
4 
A
 
 
 
 
 
 
A
 
A
 
A
 
G
 
A
 
 
 
A
 
A
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
5
55
 
n
ir
B
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
3
0
5
7
1
2
4 
A
 
 
 
 
 
 
A
 
A
 
 
G
 
A
 
 
 
A
 
A
 
 
 
d
o
w
n
st
. 
6
0 
b
. 
M
o
d
i
f.
 
M
L2
5
63
 
fa
d
E5
 
ac
yl
-C
o
A
 d
eh
yd
ro
ge
n
as
e 
Li
p
id
 m
et
ab
o
lis
m
 
 
6
1
2 
3
0
5
7
1
2
4 
A
 
 
 
 
 
 
A
 
A
 
 
G
 
A
 
 
 
A
 
A
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L2
5
63
 
fa
d
E5
 
ac
yl
-C
o
A
 d
eh
yd
ro
ge
n
as
e 
Li
p
id
 m
et
ab
o
lis
m
 
Q
/R
 
6
1
2 
3
0
5
7
1
2
4 
A
 
 
 
 
 
 
A
 
A
 
 
G
 
A
 
 
 
A
 
A
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
3
0
7
6
1
1
0 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
 
G
 
A
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
5
75
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
3
0
7
8
0
3
7 
A
 
 
 
 
 
 
A
 
A
 
 
a 
A
 
 
 
A
 
A
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
5
78
 
fa
d
E4
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
3
0
7
8
0
3
9 
C
 
 
 
 
 
 
C
 
C
 
 
a 
 
 
 
C
 
C
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
5
78
 
fa
d
E4
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
3
0
8
1
0
2
1 
C
 
 
 
 
 
 
C
 
C
 
 
T 
C
 
 
 
C
 
C
 
 
 
sy
n
. 
Lo
w
 
M
L2
5
80
 
 
in
te
gr
al
 m
em
b
ra
n
e 
ac
yl
tr
an
sf
er
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
V
al
1
03
V
al
 
3
8
4 
3
0
8
7
9
1
6 
G
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
T 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
5
85
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
3
1
0
0
7
7
4 
G
 
 
 
 
 
 
 
 
 
g 
 
 
 
 
 
 
 
u
p
st
. 3
4
 b
. 
M
o
d
i
f.
 
M
L2
5
95
 
 
M
ce
-a
ss
o
ci
at
ed
 m
em
b
ra
n
e 
p
ro
te
in
 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
 
1
8
3 
3
1
0
0
7
7
4 
G
 
 
 
 
 
 
 
 
 
g 
 
 
 
 
 
 
 
d
o
w
n
st
. 
9
9 
b
. 
M
o
d
i
f.
 
M
L2
5
94
 
m
ce
1F
 
M
ce
-f
am
ily
 p
ro
te
in
 
V
ir
u
le
e,
 
d
et
o
xi
fi
ca
ti
o
n
, 
ad
ap
ta
ti
o
n
 
 
5
1
7 
3
1
0
0
7
7
4 
G
 
 
 
 
 
 
 
 
 
g 
 
 
 
 
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
3
1
0
2
7
7
8 
A
 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
 
C
 
C
 
C
 
C
 
m
is
s.
 
M
o
d
er
. 
M
L2
5
97
 
 
M
ce
-a
ss
o
ci
at
ed
 m
em
b
ra
n
e 
p
ro
te
in
 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
Ty
r1
5
1
S
er
 
1
8
4 
3
1
1
0
7
2
2 
G
 
 
 
 
 
 
G
 
G
 
A
 
G
 
G
 
 
 
G
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
6
06
 
b
gl
S 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
LXIII
  
LXII 
3
1
4
5
2
5
3 
G
 
 
 
 
 
 
G
 
G
 
 
A
 
G
 
 
 
G
 
G
 
 
 
sy
n
. 
Lo
w
 
M
L2
6
30
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
A
sn
1
15
A
sn
 
1
2
3 
3
1
4
8
0
9
2 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
A
 
 
 
G
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L2
6
31
 
 
o
xi
d
o
re
d
u
ct
as
e 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
A
la
3
1
8
V
al
 
4
4
9 
3
1
5
5
3
1
5 
G
 
 
 
 
 
 
G
 
G
 
 
C
 
G
 
 
 
G
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
6
37
 
fa
d
E2
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
3
1
5
9
4
0
8 
C
 
 
 
 
 
 
C
 
C
 
 
T 
C
 
 
 
C
 
C
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L2
6
40
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
A
la
1
9
4
T
h
r 
3
1
0 
3
1
5
9
7
3
2 
C
 
 
 
 
 
 
t 
T 
T 
C
 
C
 
 
 
T 
C
 
 
T 
m
is
s.
 
M
o
d
er
. 
M
L2
6
40
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
V
al
8
6
Ile
 
3
1
0 
3
1
6
5
2
5
4 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
A
 
 
 
G
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
6
45
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
3
1
7
5
2
9
6 
A
 
 
 
 
 
 
C
 
C
 
C
 
C
 
C
 
 
 
C
 
C
 
C
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
3
1
7
9
3
0
0 
C
 
 
 
 
 
 
C
 
C
 
C
 
T 
C
 
 
 
C
 
C
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
3
1
8
3
8
3
5 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
C
 
 
 
C
 
T 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
3
1
9
2
8
5
9 
C
 
 
 
 
 
 
C
 
C
 
 
T 
C
 
 
 
C
 
C
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
3
1
9
6
6
6
9 
A
 
 
 
 
 
 
g 
G
 
G
 
A
 
A
 
 
 
G
 
A
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
3
2
0
4
7
3
1 
G
 
 
 
 
 
 
G
 
G
 
 
A
 
G
 
 
 
G
 
G
 
G
 
 
m
is
s.
 
M
o
d
er
. 
M
L2
6
71
 
ct
p
I 
ca
ti
o
n
 t
ra
n
sp
o
rt
er
 A
TP
as
e 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
A
sp
8A
s
n
 
1
6
0
9 
3
2
1
2
3
5
3 
G
 
 
 
 
 
 
 
G
 
G
 
G
 
T 
 
 
G
 
G
 
G
 
 
sy
n
. 
Lo
w
 
M
L2
6
72
 
ic
d
2 
is
o
ci
tr
at
e 
d
eh
yd
ro
ge
n
as
e 
[N
A
D
P
] 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
A
rg
1
7
9
A
rg
 
7
4
6 
3
2
1
5
5
3
5 
G
 
 
 
 
 
 
G
 
G
 
 
A
 
G
 
 
 
G
 
G
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
3
2
2
4
9
1
5 
G
 
 
 
 
 
 
 
 
 
G
 
t 
 
 
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L2
6
78
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
Tr
p
8
3
8
C
ys
 
1
0
0
0 
3
2
2
4
9
1
9 
T 
 
 
 
 
 
 
t 
 
T 
G
 
 
 
 
T 
 
 
m
is
s.
 
M
o
d
er
. 
M
L2
6
78
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
Tr
p
8
4
0
G
ly
 
1
0
0
0 
3
2
3
4
6
4
4 
G
 
 
 
 
 
 
g 
G
 
 
G
 
G
 
 
 
G
 
G
 
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
6
86
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
3
2
3
7
1
5
9 
C
 
 
 
 
 
 
C
 
C
 
 
T 
C
 
 
 
C
 
C
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L2
6
88
 
p
o
n
A
 
p
en
ic
ill
in
-b
in
d
in
g 
p
ro
te
in
 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
V
al
5
43
Il
e 
7
0
8 
3
2
4
3
7
3
1 
A
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
A
 
A
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
6
94
 
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
3
2
4
6
7
2
8 
G
 
 
 
 
 
 
 
G
 
 
G
 
G
 
 
 
G
 
A
 
 
 
u
p
st
. 5
4
 b
. 
M
o
d
i
f.
 
M
L2
6
96
 
 
tr
an
sc
ri
p
ti
o
n
al
 r
eg
u
la
to
ry
 p
ro
te
in
 
R
eg
. p
ro
te
in
s 
 
2
4
4 
3
2
4
6
7
2
8 
G
 
 
 
 
 
 
 
G
 
 
G
 
G
 
 
 
G
 
A
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
LXIV
  
LXIII 
 32
5
6
6
7
7 
A
 
 
 
 
 
 
g 
G
 
G
 
A
 
A
 
 
 
G
 
A
 
 
G
 
SP
LI
C
E_
SI
TE
 
Lo
w
 
M
L2
7
00
 
 
tr
an
sm
em
b
ra
n
e 
p
ro
te
in
 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
Te
r1
2
0
7
Te
r 
1
2
0
6 
3
2
5
7
0
7
0 
G
 
 
 
 
 
 
G
 
G
 
 
G
 
G
 
 
 
G
 
A
 
A
 
 
in
tr
ag
. 
M
o
d
i
f.
 
M
L2
7
01
 
si
gM
 
p
se
u
d
o
ge
n
e 
P
se
u
d
o
ge
n
e 
 
 
3
2
5
8
1
2
6 
C
 
 
 
 
 
 
c 
C
 
C
 
C
 
C
 
 
 
C
 
C
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
3
2
5
9
7
7
6 
C
 
 
 
 
 
 
C
 
C
 
 
C
 
 
 
 
T 
C
 
C
 
 
sy
n
. 
Lo
w
 
M
L2
7
04
 
 
h
yd
ro
la
se
 
M
et
ab
o
lis
m
 
an
d
 
re
sp
ir
at
io
n
 
C
ys
6C
ys
 
4
0
6 
3
2
6
1
8
1
1 
G
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
A
 
 
u
p
st
. 5
6
 b
. 
M
o
d
i
f.
 
M
L2
7
05
 
 
h
yp
o
th
et
ic
al
 p
ro
te
in
 
U
n
kn
o
w
n
 
 
 
3
2
6
1
8
1
1 
G
 
 
 
 
 
 
G
 
G
 
G
 
G
 
G
 
 
 
G
 
G
 
A
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
3
2
6
1
8
7
7 
G
 
 
 
 
 
 
G
 
G
 
 
A
 
G
 
 
 
G
 
G
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
3
2
6
5
7
3
6 
G
 
 
 
 
 
 
G
 
G
 
G
 
A
 
G
 
 
 
G
 
G
 
 
 
m
is
s.
 
M
o
d
er
. 
M
L2
7
10
 
 
tr
an
sm
em
b
ra
n
e 
p
ro
te
in
 
C
el
l 
w
al
l 
an
d
 
ce
ll 
p
ro
ce
ss
es
 
P
ro
3
5
1
L
eu
 
3
8
0 
3
2
6
8
0
2
6 
G
 
 
 
 
 
 
G
 
G
 
 
A
 
G
 
 
 
G
 
G
 
 
 
in
te
rg
. 
M
o
d
i
f.
 
 
 
 
 
 
 
LXV
  
 
 
Supplementary Figure 6: M. leprae variants distribution 
A) SNP distribution per annotated effect, B) SNP distribution per impact, C) SNP distribution 
per product functional category. 
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12.3.7 Genotyping results 
Supplementary Table 15: SNP typing according to Singh et al, 2011 
The upper-case bases were obtained from the highest-quality list of SNPS available. The lower-
case bases were used when the base was not listed in the high-quality list of SNPs because it 
had been filtered out beforehand. 
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SJG 022 nc nc nc nd - - - - - - - - - - - - - - 
SJG 131 nc g nc 1 nc nc nc g - - - - - - - - - D 
SJG 149 nc nc nc nd - - - - - - - - - - - - - - 
SJG 189 C T nc Und. - - - - - - - - - - - - - - 
SJG 289 nc nc nc nd - - - - - - - - - - - - - - 
SJG 404 C T C 3 - - - - - - - - T T C G G I 
SJG 427 C T C 3 - - - - - - - - T T C G G I 
SJG 472 C T C 3 - - - - - - - - T T C G G I 
SJG 507 C T C 3 - - - - - - - - T G G G G K 
SJG 533 T C C Und. - - - - - - - - - - - - - - 
SJG 611 nc nc nc nd              - 
SJG 658 C g nc 1 nc nc G g - - - - - - - - - D 
SJG 722 C T C 3 - - - - - - - - T T C G G I 
SJG 749 C T A 2 - - - - C C A A - - - - - F 
SJG 978 C T A 2 - - - - C C nc A - - - - - F 
SJG 1137 nc T C 3 - - - - - - - - T T C G G I 
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Supplementary Table 16: SNP typing according to Monot et Al, 2009 
Out of the total 73 genotyping SNPs listed in the reference, the number of SNPs consistent 
with a type was calculated for each sample. In bracket is the total number of SNPs of the 
sample. 
 
Sa
m
p
le
 
G
0
2
2 
G
1
1
3
7 
G
1
3
1 
G
1
4
9 
G
1
8
9 
G
2
8
9 
G
4
0
4 
G
4
2
7 
G
4
7
2 
G
5
0
7 
G
5
3
3 
G
6
1
1 
G
6
5
8 
G
7
2
2 
G
7
4
9 
G
9
7
8 
Total SNPs 3 24 0 0 6 0 46 46 39 46 46 
 
13 46 46 31 
Ty
p
e 
1A 0 0 0 0 0 0 3 3 0 0 3 
 
0 3 10 2 
1B 2 13 0 0 4 0 24 24 18 21 24 
 
7 24 31 22 
1C 3 16 0 0 5 0 30 30 24 27 30 
 
9 30 37 25 
1D 3 17 0 0 5 0 31 31 25 28 31 
 
10 31 38 26 
2E 3 20 0 0 6 0 36 36 30 33 36 
 
12 36 43 30 
2F 3 22 0 0 6 0 38 38 32 35 38 
 
12 38 45 31 
2G 3 22 0 0 6 0 39 39 33 36 39 
 
12 39 44 31 
2H 3 22 0 0 6 0 40 40 34 37 40 
 
12 40 43 31 
3I 3 24 0 0 6 0 45 45 38 42 45 
 
13 45 38 30 
3J 3 24 0 0 6 0 43 43 38 44 43 
 
13 43 36 30 
3K 3 24 0 0 6 0 42 42 38 45 42 
 
13 42 35 29 
3L 3 24 0 0 6 0 42 42 38 45 42 
 
13 42 35 29 
4M 3 24 0 0 6 0 42 42 38 45 42 
 
13 42 35 29 
4N 3 24 0 0 6 0 42 42 38 45 42 
 
13 42 35 29 
4O 3 24 0 0 6 0 42 42 38 45 42 
 
13 42 35 29 
4P 3 24 0 0 6 0 42 42 38 45 42 
 
13 42 35 29 
Most likely 
type Und. Und. Und. Und. Und. Und 3I 3I Und. Und. 3I 
 
Und. 3I 2F Und. 
LXVIII
  
LXVII 
1
2
.3
.8
 I
n
-d
ep
th
 e
ff
ec
t 
p
re
d
ic
ti
o
n
 r
es
u
lt
s 
 
Su
p
p
le
m
en
ta
ry
 F
ig
u
re
 7
: H
yd
ro
p
h
ob
ic
it
y 
pr
of
ile
s 
of
 t
he
 p
ro
te
in
s 
Th
e 
p
ro
fi
le
s 
w
er
e 
co
m
p
u
te
d
 w
it
h
 P
ro
tS
ca
le
 f
ro
m
 t
h
e 
Ex
P
A
Sy
 p
la
tf
o
rm
 u
si
n
g
 d
ef
a
u
lt
 s
et
ti
n
g
s 
o
ve
r 
a
 2
1
b
p
 s
lid
in
g
 w
in
d
o
w
 t
o
 h
ig
h
lig
h
t 
ch
a
n
g
es
 a
t 
th
e 
ch
a
in
 s
ca
le
. 
Th
e 
a
m
in
o
 a
ci
d
 c
h
a
n
g
e 
lo
cu
s 
is
 in
d
ic
a
te
d
 b
y 
th
e 
ve
rt
ic
a
l b
a
rs
.T
h
e 
a
m
in
o
 a
ci
d
s 
a
re
 s
co
re
d
 u
si
n
g
 t
h
e 
K
yt
e 
&
 D
o
o
lit
tl
e 
h
yd
ro
p
h
o
b
ic
it
y 
sc
a
le
. 
LXIX
   
LXVIII 
 
Su
p
p
le
m
en
ta
ry
 F
ig
u
re
 8
: P
ol
a
ri
ty
 p
ro
fi
le
s 
of
 t
h
e 
pr
ot
ei
ns
 
Th
e 
p
ro
fi
le
s 
w
er
e 
co
m
p
u
te
d
 w
it
h
 P
ro
tS
ca
le
 f
ro
m
 t
h
e 
Ex
P
A
Sy
 p
la
tf
o
rm
 u
si
n
g
 d
ef
a
u
lt
 s
et
ti
n
g
s 
o
ve
r 
a
 2
1
b
p
 s
lid
in
g
 w
in
d
o
w
 t
o
 h
ig
h
lig
h
t 
ch
a
n
g
es
 a
t 
th
e 
ch
a
in
 s
ca
le
. 
Th
e 
a
m
in
o
 a
ci
d
 c
h
a
n
g
e 
lo
cu
s 
is
 in
d
ic
a
te
d
 b
y 
th
e 
ve
rt
ic
a
l b
a
rs
. T
h
e 
a
m
in
o
 a
ci
d
s 
a
re
 s
co
re
d
 u
si
n
g
 t
h
e 
G
ra
n
th
a
m
 p
o
la
ri
ty
 s
ca
le
. 
LXX
  
LXIX 
 
Su
p
p
le
m
en
ta
ry
 F
ig
u
re
 9
: B
u
ri
ed
 r
es
id
ue
s 
pr
of
ile
s 
of
 t
he
 p
ro
te
in
s 
Th
e 
p
ro
fi
le
s 
w
er
e 
co
m
p
u
te
d
 w
it
h
 P
ro
tS
ca
le
 f
ro
m
 t
h
e 
Ex
P
A
Sy
 p
la
tf
o
rm
 u
si
n
g
 d
ef
a
u
lt
 s
et
ti
n
g
s 
o
ve
r 
a
 2
1
b
p
 s
lid
in
g
 w
in
d
o
w
 t
o
 h
ig
h
lig
h
t 
ch
a
n
g
es
 a
t 
th
e 
ch
a
in
 s
ca
le
. 
Th
e 
a
m
in
o
 a
ci
d
 c
h
a
n
g
e 
lo
cu
s 
is
 in
d
ic
a
te
d
 b
y 
th
e 
ve
rt
ic
a
l b
a
rs
. T
h
e 
a
m
in
o
 a
ci
d
s 
a
re
 s
co
re
d
 u
si
n
g
 t
h
e 
Ja
n
in
 m
o
la
r 
fr
a
ct
io
n
 o
f 
p
o
la
r 
re
si
d
u
es
. 
LXXI
   
LLXXIIXX 
Su
p
p
le
m
en
ta
ry
 F
ig
u
re
 1
0:
 S
ec
on
da
ry
 s
tr
u
ct
u
re
 p
re
d
ic
ti
on
s 
cl
os
e-
up
 o
n
 t
h
e 
va
ri
a
n
t 
lo
ci
 
P
re
d
ic
ti
o
n
s 
fr
o
m
 t
h
e 
SO
P
M
A
 s
o
ft
w
a
re
 w
er
e 
p
er
fo
rm
ed
 u
si
n
g
 d
ef
a
u
lt
 s
et
ti
n
g
s.
 A
 s
ta
r 
m
a
rk
s 
ea
ch
 lo
cu
s 
p
o
si
ti
o
n
 o
n
 t
h
e 
se
q
u
en
ce
. 
Th
e 
va
ri
a
n
t 
se
q
u
en
ce
 is
 s
h
o
w
n
 
o
n
 t
h
e 
ri
g
h
t,
 w
it
h
 it
s 
co
rr
es
p
o
n
d
in
g
 s
ec
o
n
d
a
ry
 s
tr
u
ct
u
re
 p
re
d
ic
ti
o
n
. 
d
n
aA
 
 
(p
ar
ti
al
) 
  
 
Lo
cu
s 
1
 
     
 
Lo
cu
s2
 
gy
rA
 
 
(…
)
(p
ar
ti
al
) 
       
 
gl
cB
 
R
T 
 
(…
)
 
 
 
* 
* 
* 
*
 
LXXII
 LXXI 
 
12.3.9 Phylogenetic trees 
 
 
Supplementary Figure 11: Maximum-parsimony tree with the 6 high-coverage genomes 
UP: tree constructed from the MAFFT alignment,, DOWN: tree constructed from the MAUVE 
alignment. Nodes labels indicate the bootstrap values after 500 replications. Ancient genomes 
are shown in orange, modern ones in black. The mention “RefSeq” is used to identify the four 
modern reference sequences.The scale reprensents the average character-state changes. 
Sample s15 shows a different affilitation, with the MAUVE alignment placing it closer to 
strains 3K, while MAFFT places it closer to strain 3I/4. This has also been noticed when the 
strain was first published at attributed to an unusual number of genetic variations 
(Schuenemann et al. 2013). 
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Supplementary Figure 12: Neighbor-joining tree with the 6 high-coverage genomes 
UP: tree constructed from the MAFFT alignment,, DOWN: tree constructed from the MAUVE 
alignment. Nodes labels indicate the bootstrap values after 500 replications. Ancient genomes 
are shown in orange, modern ones in black. The mention “RefSeq” is used to identify the four 
modern reference sequences. 
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Supplementary Figure 13: Maximum-likelihood tree with the 6 high-coverage genomes 
Tree constructed from the MAUVE alignment. Nodes labels indicate the bootstrap values after 
500 replications. Ancient genomes are shown in orange, modern ones in black. The mention 
“RefSeq” is used to identify the four modern reference sequences. 
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